18264087	142	Sakai W	Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers.	Nature	2008	217
18264088	142	Edwards SL	Resistance to therapy caused by intragenic deletion in BRCA2.	Nature	2008	209
19648052	142	Broxterman HJ	Understanding the causes of multidrug resistance in cancer: a comparison of doxorubicin and sunitinib.	Drug resistance updates 	2009	55
20049735	142	Mendes-Pereira AM	Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors.	EMBO molecular medicine	2009	172
20142589	142	Zarghooni M	Whole-genome profiling of pediatric diffuse intrinsic pontine gliomas highlights platelet-derived growth factor receptor alpha and poly (ADP-ribose) polymerase as potential therapeutic targets.	Journal of clinical oncology 	2010	90
20406929	142	Fong PC	Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.	Journal of clinical oncology 	2010	202
20547991	142	Konstantinopoulos PA	Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer.	Journal of clinical oncology 	2010	102
20551068	142	Gottipati P	Poly(ADP-ribose) polymerase is hyperactivated in homologous recombination-defective cells.	Cancer research	2010	57
21205831	142	Yap TA	Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic.	CA	2011	51
21487248	142	Dedes KJ	Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations.	Cell cycle	2011	52
21521830	142	Jelovac D	Recent progress in the diagnosis and treatment of ovarian cancer.	CA	2011	103
21709188	142	Norquist B	Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas.	Journal of clinical oncology 	2011	85
21862407	142	Gelmon KA	Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.	The Lancet. Oncology	2011	225
22416035	142	Williamson CT	Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53.	EMBO molecular medicine	2012	40
22711857	142	Alsop K	BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.	Journal of clinical oncology 	2012	148
22753495	142	Mao Z	Sirtuin 6 (SIRT6) rescues the decline of homologous recombination repair during replicative senescence.	Proceedings of the National Academy of Sciences of the United States of America	2012	38
22912389	142	Wang ZC	Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome.	Clinical cancer research 	2012	37
23703322	142	Montero J	p53 regulates a non-apoptotic death induced by ROS.	Cell death and differentiation	2013	31
23744078	142	Young LC	Kdm4b histone demethylase is a DNA damage response protein and confers a survival advantage following Î³-irradiation.	The Journal of biological chemistry	2013	32
24037533	142	Michels J	Predictive biomarkers for cancer therapy with PARP inhibitors.	Oncogene	2014	21
24607283	142	Liu JF	PARP inhibitors in ovarian cancer: current status and future promise.	Gynecologic oncology	2014	22
24912431	142	Cao Y	The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom's Macroglobulinemia.	Leukemia	2015	15
25341009	142	Lord CJ	Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors.	Annual review of medicine	2015	54
25708226	142	Tangutoori S	PARP inhibitors: A new era of targeted therapy.	Maturitas	2015	26
25818403	142	Coleman RL	A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study.	Gynecologic oncology	2015	38
25869442	142	Ferguson LR	Genomic instability in human cancer: Molecular insights and opportunities for therapeutic attack and prevention through diet and nutrition.	Seminars in cancer biology	2015	22
25878361	142	Downward J	RAS Synthetic Lethal Screens Revisited: Still Seeking the Elusive Prize?	Clinical cancer research 	2015	21
26004083	142	Severson TM	BRCA1-like signature in triple negative breast cancer: Molecular and clinical characterization reveals subgroups with therapeutic potential.	Molecular oncology	2015	18
26590714	142	O'Connor MJ	Targeting the DNA Damage Response in Cancer.	Molecular cell	2015	62
27002934	142	Drew Y	Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer.	British journal of cancer	2016	15
27908594	142	Swisher EM	Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.	The Lancet. Oncology	2017	18
11357143	207	Blume-Jensen P	Oncogenic kinase signalling.	Nature	2001	728
12094235	207	Vivanco I	The phosphatidylinositol 3-Kinase AKT pathway in human cancer.	Nature reviews. Cancer	2002	1352
12938083	207	Eng C	PTEN: one gene, many syndromes.	Human mutation	2003	184
15342917	207	Roux PP	Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase.	Proceedings of the National Academy of Sciences of the United States of America	2004	221
16288292	207	Altomare DA	Perturbations of the AKT signaling pathway in human cancer.	Oncogene	2005	312
16341064	207	Hennessy BT	Exploiting the PI3K/AKT pathway for cancer drug discovery.	Nature reviews. Drug discovery	2005	511
16397263	207	Schittenhelm MM	Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies.	Cancer research	2006	92
16715125	207	Wang X	Overexpression of aurora kinase A in mouse mammary epithelium induces genetic instability preceding mammary tumor formation.	Oncogene	2006	71
17318262	207	Govindarajan B	Overexpression of Akt converts radial growth melanoma to vertical growth melanoma.	The Journal of clinical investigation	2007	86
17353198	207	Ji Z	Oncogenic KRAS activates hedgehog signaling pathway in pancreatic cancer cells.	The Journal of biological chemistry	2007	98
17404109	207	Puri N	c-Met is a potentially new therapeutic target for treatment of human melanoma.	Clinical cancer research 	2007	61
17611497	207	Carpten JD	A transforming mutation in the pleckstrin homology domain of AKT1 in cancer.	Nature	2007	373
17918180	207	Fraser M	Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function.	International journal of cancer	2008	50
18166498	207	LoPiccolo J	Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations.	Drug resistance updates 	2008	175
18256540	207	Malanga D	Activating E17K mutation in the gene encoding the protein kinase AKT1 in a subset of squamous cell carcinoma of the lung.	Cell cycle	2008	51
18337767	207	Steelman LS	Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia.	Leukemia	2008	94
18414037	207	Palomero T	The role of the PTEN/AKT Pathway in NOTCH1-induced leukemia.	Cell cycle	2008	65
18473732	207	Carnero A	The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications.	Current cancer drug targets	2008	139
18504432	207	Bleeker FE	AKT1(E17K) in human solid tumours.	Oncogene	2008	55
18676830	207	Stemke-Hale K	An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.	Cancer research	2008	299
18838554	207	Degtyarev M	Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents.	The Journal of cell biology	2008	147
19088048	207	Solit DB	Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma.	Clinical cancer research 	2008	68
19380449	207	Baselga J	Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.	Journal of clinical oncology 	2009	138
19411071	207	Junttila TT	Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.	Cancer cell	2009	221
19487299	207	Ricarte-Filho JC	Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1.	Cancer research	2009	123
19491896	207	Shoji K	The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas.	British journal of cancer	2009	51
19592505	207	Zong Y	ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells.	Proceedings of the National Academy of Sciences of the United States of America	2009	85
19996208	207	Davies MA	Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma.	Clinical cancer research 	2009	62
20101214	207	Gustafson WC	Myc proteins as therapeutic targets.	Oncogene	2010	55
20214616	207	Carnero A	The PKB/AKT pathway in cancer.	Current pharmaceutical design	2010	71
20622047	207	Zhang S	PI(3)king apart PTEN's role in cancer.	Clinical cancer research 	2010	73
21062993	207	Fan QW	Akt and autophagy cooperate to promote survival of drug-resistant glioma.	Science signaling	2010	103
21216929	207	Janku F	PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.	Molecular cancer therapeutics	2011	127
21302297	207	McCubrey JA	Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways.	Journal of cellular physiology	2011	52
21422497	207	Steelman LS	Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging.	Aging	2011	139
21464307	207	Xie X	IkappaB kinase epsilon and TANK-binding kinase 1 activate AKT by direct phosphorylation.	Proceedings of the National Academy of Sciences of the United States of America	2011	67
21788564	207	Oza AM	Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group.	Journal of clinical oncology 	2011	55
21793738	207	Lindhurst MJ	A mosaic activating mutation in AKT1 associated with the Proteus syndrome.	The New England journal of medicine	2011	154
21909130	207	Astle MV	AKT induces senescence in human cells via mTORC1 and p53 in the absence of DNA damage: implications for targeting mTOR during malignancy.	Oncogene	2012	40
22025163	207	Yap TA	First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors.	Journal of clinical oncology 	2011	160
22156546	207	Venkatesh HS	Reduced phosphocholine and hyperpolarized lactate provide magnetic resonance biomarkers of PI3K/Akt/mTOR inhibition in glioblastoma.	Neuro-oncology	2012	34
22194965	207	Atefi M	Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway.	PloS one	2011	63
22205714	207	Su F	Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation.	Cancer research	2012	51
22248929	207	Garrett JT	Will PI3K pathway inhibitors be effective as single agents in patients with cancer?	Oncotarget	2011	35
22261800	207	Shimizu T	The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer.	Clinical cancer research 	2012	110
22292935	207	Shi J	Highly frequent PIK3CA amplification is associated with poor prognosis in gastric cancer.	BMC cancer	2012	38
22422409	207	Meric-Bernstam F	PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors.	Clinical cancer research 	2012	61
22932669	207	Sangai T	Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.	Clinical cancer research 	2012	44
23444215	207	Catalanotti F	Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma.	Clinical cancer research 	2013	36
23897969	207	Iyer G	Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer.	Journal of clinical oncology 	2013	58
24055012	207	Heavey S	Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLC.	Cancer treatment reviews	2014	28
24242861	207	Rosenberg JE	A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma.	Investigational new drugs	2014	32
24265152	207	Shi H	A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.	Cancer discovery	2014	46
24440717	207	Janku F	Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors.	Cell reports	2014	50
24777052	207	Ocana A	Activation of the PI3K/mTOR/AKT pathway and survival in solid tumors: systematic review and meta-analysis.	PloS one	2014	30
24896186	207	Wang L	Novel somatic and germline mutations in intracranial germ cell tumours.	Nature	2014	26
25071141	207	Sabine VS	Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study.	Journal of clinical oncology 	2014	21
25146530	207	Lim HJ	Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer.	Journal of cancer research and clinical oncology	2015	21
25185240	207	RothÃ© F	Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer.	Annals of oncology 	2014	35
25284585	207	Dillon LM	P-REX1 creates a positive feedback loop to activate growth factor receptor, PI3K/AKT and MEK/ERK signaling in breast cancer.	Oncogene	2015	17
25541152	207	Musilova K	MicroRNAs in B-cell lymphomas: how a complex biology gets more complex.	Leukemia	2015	32
26014291	207	Meric-Bernstam F	Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials.	Journal of clinical oncology 	2015	51
26473415	207	Mayer IA	The PI3K/AKT Pathway as a Target for Cancer Treatment.	Annual review of medicine	2016	38
26826201	207	Abedalthagafi M	Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma.	Neuro-oncology	2016	16
26947078	207	Chen F	Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma.	Cell reports	2016	24
18451166	238	McDermott U	Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors.	Cancer research	2008	119
18990089	238	CarÃ©n H	High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours.	The Biochemical journal	2008	61
19671850	238	Rodig SJ	Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population.	Clinical cancer research 	2009	141
20418096	238	Sasaki T	The biology and treatment of EML4-ALK non-small cell lung cancer.	European journal of cancer	2010	101
20979469	238	Kwak EL	Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.	The New England journal of medicine	2010	1033
20979472	238	Butrynski JE	Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.	The New England journal of medicine	2010	140
20979473	238	Choi YL	EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.	The New England journal of medicine	2010	271
21030459	238	Sasaki T	The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers.	Cancer research	2010	98
21156280	238	Gerber DE	ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time.	Cancer cell	2010	65
21336183	238	Camidge DR	Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed.	Journal of thoracic oncology 	2011	61
21502504	238	Katayama R	Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK.	Proceedings of the National Academy of Sciences of the United States of America	2011	147
21575866	238	Sakamoto H	CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant.	Cancer cell	2011	114
21596819	238	Murugan AK	Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene.	Cancer research	2011	42
21623265	238	Ou SH	Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.	Journal of thoracic oncology 	2011	96
21642865	238	Lee JO	Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer.	Journal of thoracic oncology 	2011	38
21933749	238	Shaw AT	Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.	The Lancet. Oncology	2011	199
22034911	238	Zhang S	Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen.	Chemical biology and drug design	2011	41
22071784	238	McLeer-Florin A	Dual IHC and FISH testing for ALK gene rearrangement in lung adenocarcinomas in a routine practice: a French study.	Journal of thoracic oncology 	2012	40
22129856	238	Paik JH	Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: a proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma.	Lung cancer	2012	34
22184391	238	van Gaal JC	Anaplastic lymphoma kinase aberrations in rhabdomyosarcoma: clinical and prognostic implications.	Journal of clinical oncology 	2012	32
22589483	238	Matthay KK	Promising therapeutic targets in neuroblastoma.	Clinical cancer research 	2012	41
22735679	238	Ilie M	ALK-gene rearrangement: a comparative analysis on circulating tumour cells and tumour tissue from patients with lung adenocarcinoma.	Annals of oncology 	2012	37
23344087	238	Kim S	Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer.	Journal of thoracic oncology 	2013	38
23401436	238	Shaw AT	ALK in lung cancer: past, present, and future.	Journal of clinical oncology 	2013	77
23598171	238	MossÃ© YP	Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.	The Lancet. Oncology	2013	100
23724914	238	Awad MM	Acquired resistance to crizotinib from a mutation in CD74-ROS1.	The New England journal of medicine	2013	53
24060861	238	Hallberg B	Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology.	Nature reviews. Cancer	2013	82
24675041	238	Friboulet L	The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.	Cancer discovery	2014	128
24736079	238	Ignatius Ou SH	Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib.	Journal of thoracic oncology 	2014	33
24819116	238	Johnson TW	Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo4,3-h2,5,11-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations.	Journal of medicinal chemistry	2014	38
25228534	238	Katayama R	Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.	Clinical cancer research 	2014	45
25500544	238	Yoshihara K	The landscape and therapeutic relevance of cancer-associated transcript fusions.	Oncogene	2015	56
25724526	238	Gainor JF	Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib.	Clinical cancer research 	2015	25
26554404	238	Infarinato NR	The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma.	Cancer discovery	2016	14
26698910	238	Shaw AT	Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.	The New England journal of medicine	2016	42
1338904	324	Miyoshi Y	Somatic mutations of the APC gene in colorectal tumors: mutation cluster region in the APC gene.	Human molecular genetics	1992	175
1651174	324	Groden J	Identification and characterization of the familial adenomatous polyposis coli gene.	Cell	1991	447
10969779	324	Esteller M	Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer.	Cancer research	2000	106
15561772	324	Tighe A	Truncating APC mutations have dominant effects on proliferation, spindle checkpoint control, survival and chromosome stability.	Journal of cell science	2004	74
20144789	324	Quyn AJ	Spindle orientation bias in gut epithelial stem cell compartments is lost in precancerous tissue.	Cell stem cell	2010	81
21247378	324	Klampfer L	Cytokines, inflammation and colon cancer.	Current cancer drug targets	2011	44
2260966	367	Veldscholte J	A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens.	Biochemical and biophysical research communications	1990	150
7795646	367	Visakorpi T	In vivo amplification of the androgen receptor gene and progression of human prostate cancer.	Nature genetics	1995	280
9000575	367	Koivisto P	Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer.	Cancer research	1997	132
10363963	367	Taplin ME	Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist.	Cancer research	1999	113
12888829	367	Edwards J	Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer.	British journal of cancer	2003	78
15389811	367	Miyamoto H	Androgen deprivation therapy for prostate cancer: current status and future prospects.	The Prostate	2004	77
15833816	367	Bohl CE	Structural basis for antagonism and resistance of bicalutamide in prostate cancer.	Proceedings of the National Academy of Sciences of the United States of America	2005	70
16751763	367	Morfini G	JNK mediates pathogenic effects of polyglutamine-expanded androgen receptor on fast axonal transport.	Nature neuroscience	2006	76
17045208	367	Guo Z	Regulation of androgen receptor activity by tyrosine phosphorylation.	Cancer cell	2006	142
19111796	367	Yuan X	Mechanisms mediating androgen receptor reactivation after castration.	Urologic oncology	2009	82
19345326	367	Xu K	Regulation of androgen receptor transcriptional activity and specificity by RNF6-induced ubiquitination.	Cancer cell	2009	69
19366804	367	Steinkamp MP	Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy.	Cancer research	2009	60
22266865	367	Li Y	AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression.	Oncogene	2012	67
22334387	367	Gottlieb B	The androgen receptor gene mutations database: 2012 update.	Human mutation	2012	64
23580326	367	Balbas MD	Overcoming mutation-based resistance to antiandrogens with rational drug design.	eLife	2013	81
23779130	367	Joseph JD	A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509.	Cancer discovery	2013	104
23842682	367	Korpal M	An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide).	Cancer discovery	2013	103
23859952	367	Shafi AA	Androgen receptors in hormone-dependent and castration-resistant prostate cancer.	Pharmacology and therapeutics	2013	42
24508459	367	An J	Destruction of full-length androgen receptor by wild-type SPOP, but not prostate-cancer-associated mutants.	Cell reports	2014	42
25232177	367	Carreira S	Tumor clone dynamics in lethal prostate cancer.	Science translational medicine	2014	68
25274033	367	Geng C	Androgen receptor is the key transcriptional mediator of the tumor suppressor SPOP in prostate cancer.	Cancer research	2014	23
25712683	367	Azad AA	Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer.	Clinical cancer research 	2015	51
26160840	367	Zhang G	Androgen receptor splice variants circumvent AR blockade by microtubule-targeting agents.	Oncotarget	2015	18
27184417	367	Bianchini G	Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.	Nature reviews. Clinical oncology	2016	42
7792600	472	Savitsky K	A single ataxia telangiectasia gene with a product similar to PI-3 kinase.	Science	1995	475
15928302	472	Thompson D	Cancer risks and mortality in heterozygous ATM mutation carriers.	Journal of the National Cancer Institute	2005	85
17968022	472	Austen B	Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion.	Journal of clinical oncology 	2007	59
18794134	472	Rainey MD	Transient inhibition of ATM kinase is sufficient to enhance cellular sensitivity to ionizing radiation.	Cancer research	2008	57
20580718	472	Derheimer FA	Multiple roles of ATM in monitoring and maintaining DNA integrity.	FEBS letters	2010	80
21139141	472	Bensimon A	ATM-dependent and -independent dynamics of the nuclear phosphoproteome after DNA damage.	Science signaling	2010	87
22585167	472	Roberts NJ	ATM mutations in patients with hereditary pancreatic cancer.	Cancer discovery	2012	93
23091097	472	Skowronska A	Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial.	Journal of clinical oncology 	2012	32
23620409	472	Biddlestone-Thorpe L	ATM kinase inhibition preferentially sensitizes p53-mutant glioma to ionizing radiation.	Clinical cancer research 	2013	32
28096526	472	Maciejowski J	Telomeres in cancer: tumour suppression and genome instability.	Nature reviews. Molecular cell biology	2017	9
7907678	672	Ford D	Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.	Lancet	1994	261
9145676	672	Struewing JP	The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews.	The New England journal of medicine	1997	316
9443863	672	Parmigiani G	Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2.	American journal of human genetics	1998	141
9701363	672	Lakhani SR	Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations.	Journal of the National Cancer Institute	1998	119
10359546	672	Peto J	Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer.	Journal of the National Cancer Institute	1999	148
10883018	672	Holschneider CH	Ovarian cancer: epidemiology, biology, and prognostic factors.	Seminars in surgical oncology	2000	105
11179017	672	Risch HA	Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer.	American journal of human genetics	2001	166
11207349	672	Hedenfalk I	Gene-expression profiles in hereditary breast cancer.	The New England journal of medicine	2001	260
11257103	672	Welcsh PL	BRCA1 and BRCA2 and the genetics of breast and ovarian cancer.	Human molecular genetics	2001	114
11320250	672	Ruffner H	Cancer-predisposing mutations within the RING domain of BRCA1: loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity.	Proceedings of the National Academy of Sciences of the United States of America	2001	96
11463009	672	Meijers-Heijboer H	Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation.	The New England journal of medicine	2001	91
11710890	672	King MC	Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial.	JAMA	2001	91
11857015	672	Antoniou AC	A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes.	British journal of cancer	2002	106
12023992	672	Kauff ND	Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.	The New England journal of medicine	2002	167
12023993	672	Rebbeck TR	Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.	The New England journal of medicine	2002	204
12162889	672	Radmacher MD	A paradigm for class prediction using gene expression profiles.	Journal of computational biology 	2002	82
12237281	672	Thompson D	Cancer Incidence in BRCA1 mutation carriers.	Journal of the National Cancer Institute	2002	206
12483514	672	Jasin M	Homologous repair of DNA damage and tumorigenesis: the BRCA connection.	Oncogene	2002	94
12677558	672	Antoniou A	Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.	American journal of human genetics	2003	579
14576434	672	King MC	Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2.	Science	2003	394
14981104	672	Rebbeck TR	Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.	Journal of clinical oncology 	2004	146
15041722	672	Foulkes WD	Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type.	Clinical cancer research 	2004	76
15197194	672	Metcalfe K	Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.	Journal of clinical oncology 	2004	111
15367553	672	Warner E	Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination.	JAMA	2004	146
15547178	672	Kennedy RD	The role of BRCA1 in the cellular response to chemotherapy.	Journal of the National Cancer Institute	2004	85
15784178	672	Dumitrescu RG	Understanding breast cancer risk -- where do we stand in 2005?	Journal of cellular and molecular medicine	2005	81
15910949	672	Leach MO	Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS).	Lancet	2005	156
16014699	672	Tavtigian SV	Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral.	Journal of medical genetics	2006	168
16137750	672	Finch A	Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers.	Gynecologic oncology	2006	73
16144895	672	Nelson HD	Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services Task Force.	Annals of internal medicine	2005	84
16234515	672	Eisen A	Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study.	Journal of clinical oncology 	2005	79
16284991	672	Pal T	BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.	Cancer	2005	156
16293877	672	Kuhl CK	Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer.	Journal of clinical oncology 	2005	116
16357213	672	Kennedy RD	The Fanconi Anemia/BRCA pathway: new faces in the crowd.	Genes and development	2005	154
16397213	672	Elstrodt F	BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants.	Cancer research	2006	68
16484695	672	Chen S	Characterization of BRCA1 and BRCA2 mutations in a large United States sample.	Journal of clinical oncology 	2006	70
16522644	672	Mathe E	Computational approaches for predicting the biological effect of p53 missense mutations: a comparison of three sequence analysis based methods.	Nucleic acids research	2006	81
16522651	672	Deng CX	BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution.	Nucleic acids research	2006	120
16835424	672	Finch A	Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation.	JAMA	2006	93
16912212	672	Malone KE	Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years.	Cancer research	2006	64
17117391	672	Lee Y	A candidate precursor to serous carcinoma that originates in the distal fallopian tube.	The Journal of pathology	2007	198
17148771	672	Risch HA	Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada.	Journal of the National Cancer Institute	2006	127
17416853	672	Chen S	Meta-analysis of BRCA1 and BRCA2 penetrance.	Journal of clinical oncology 	2007	280
17456833	672	Crum CP	Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer.	Clinical medicine and research	2007	64
17761984	672	Callahan MJ	Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction.	Journal of clinical oncology 	2007	100
17924331	672	Easton DF	A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes.	American journal of human genetics	2007	131
18034184	672	Fackenthal JD	Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations.	Nature reviews. Cancer	2007	108
18159056	672	John EM	Prevalence of pathogenic BRCA1 mutation carriers in 5 US racial/ethnic groups.	JAMA	2007	104
18165636	672	Chetrit A	Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer.	Journal of clinical oncology 	2008	79
18182601	672	Begg CB	Variation of breast cancer risk among BRCA1/2 carriers.	JAMA	2008	82
18268356	672	Kauff ND	Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study.	Journal of clinical oncology 	2008	92
18342932	672	Folkins AK	A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations.	Gynecologic oncology	2008	62
18349832	672	Antoniou AC	The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions.	British journal of cancer	2008	99
18458280	672	Warner E	Systematic review: using magnetic resonance imaging to screen women at high risk for breast cancer.	Annals of internal medicine	2008	79
18649131	672	Byrski T	Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients.	Breast cancer research and treatment	2009	72
18779615	672	Atchley DP	Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer.	Journal of clinical oncology 	2008	107
18955455	672	Tan DS	"BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations.	Journal of clinical oncology 	2008	101
19060844	672	Clarke B	Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss.	Modern pathology 	2009	60
19141781	672	Rebbeck TR	Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers.	Journal of the National Cancer Institute	2009	128
19241424	672	Hall MJ	BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer.	Cancer	2009	70
19298662	672	Young SR	The prevalence of BRCA1 mutations among young women with triple-negative breast cancer.	BMC cancer	2009	55
19491823	672	Poley JW	The yield of first-time endoscopic ultrasonography in screening individuals at a high risk of developing pancreatic cancer.	The American journal of gastroenterology	2009	64
19553641	672	Fong PC	Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.	The New England journal of medicine	2009	840
19636370	672	Brown PO	The preclinical natural history of serous ovarian cancer: defining the target for early detection.	PLoS medicine	2009	57
19648928	672	Lim E	Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers.	Nature medicine	2009	454
19841585	672	Kurian AW	BRCA1 and BRCA2 mutations across race and ethnicity: distribution and clinical implications.	Current opinion in obstetrics and gynecology	2010	41
19858402	672	Graeser MK	Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers.	Journal of clinical oncology 	2009	52
19996028	672	Oktay K	Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks.	Journal of clinical oncology 	2010	57
20008645	672	Byrski T	Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy.	Journal of clinical oncology 	2010	108
20177395	672	Moynahan ME	Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis.	Nature reviews. Molecular cell biology	2010	267
20368571	672	Malone KE	Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2.	Journal of clinical oncology 	2010	46
20400477	672	O'Donovan PJ	BRCA1 and BRCA2: breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair.	Carcinogenesis	2010	70
20427433	672	Amir E	Assessing women at high risk of breast cancer: a review of risk assessment models.	Journal of the National Cancer Institute	2010	89
20516115	672	Lee MS	Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.	Cancer research	2010	40
20606085	672	Hennessy BT	Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer.	Journal of clinical oncology 	2010	67
20609467	672	Tutt A	Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.	Lancet	2010	389
20609468	672	Audeh MW	Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.	Lancet	2010	309
20616022	672	Walsh T	Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing.	Proceedings of the National Academy of Sciences of the United States of America	2010	126
20810374	672	Domchek SM	Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.	JAMA	2010	187
21135251	672	Villarroel MC	Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer.	Molecular cancer therapeutics	2011	65
21233401	672	Gonzalez-Angulo AM	Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer.	Clinical cancer research 	2011	109
21324516	672	Zhang S	Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer.	Gynecologic oncology	2011	52
21358336	672	Levy DE	Underutilization of BRCA1/2 testing to guide breast cancer treatment: black and Hispanic women particularly at risk.	Genetics in medicine 	2011	55
21505135	672	Link DC	Identification of a novel TP53 cancer susceptibility mutation through whole-genome sequencing of a patient with therapy-related AML.	JAMA	2011	59
21717445	672	Schwartz MD	Long-term outcomes of BRCA1/BRCA2 testing: risk reduction and surveillance.	Cancer	2012	31
21987798	672	Konishi H	Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells.	Proceedings of the National Academy of Sciences of the United States of America	2011	47
21990146	672	Spurdle AB	ENIGMA--evidence-based network for the interpretation of germline mutant alleles: an international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes.	Human mutation	2012	45
21990299	672	Yang D	Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer.	JAMA	2011	104
22193408	672	Roy R	BRCA1 and BRCA2: different roles in a common pathway of genome protection.	Nature reviews. Cancer	2011	216
22203755	672	Kaye SB	Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer.	Journal of clinical oncology 	2012	94
22314128	672	Krepischi AC	Germline DNA copy number variation in familial and early-onset breast cancer.	Breast cancer research 	2012	31
22452356	672	Ledermann J	Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.	The New England journal of medicine	2012	200
22516946	672	Leongamornlert D	Germline BRCA1 mutations increase prostate cancer risk.	British journal of cancer	2012	30
22576213	672	Birkbak NJ	Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents.	Cancer discovery	2012	44
22614657	672	Hartman AR	Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer.	Cancer	2012	37
22933060	672	Popova T	Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation.	Cancer research	2012	57
23099806	672	Iqbal J	The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers.	British journal of cancer	2012	33
23233716	672	Weitzel JN	Prevalence and type of BRCA mutations in Hispanics undergoing genetic cancer risk assessment in the southwestern United States: a report from the Clinical Cancer Genetics Community Research Network.	Journal of clinical oncology 	2013	33
23257159	672	McLaughlin JR	Long-term ovarian cancer survival associated with mutation in BRCA1 or BRCA2.	Journal of the National Cancer Institute	2013	26
23257362	672	Verhaak RG	Prognostically relevant gene signatures of high-grade serous ovarian carcinoma.	The Journal of clinical investigation	2013	106
23269703	672	Domchek SM	Biallelic deleterious BRCA1 mutations in a woman with early-onset ovarian cancer.	Cancer discovery	2013	29
23377543	672	Tang J	Acetylation limits 53BP1 association with damaged chromatin to promote homologous recombination.	Nature structural and molecular biology	2013	123
23558900	672	Lips EH	Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers.	British journal of cancer	2013	33
23569316	672	Castro E	Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.	Journal of clinical oncology 	2013	59
23628597	672	Mavaddat N	Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE.	Journal of the National Cancer Institute	2013	94
23810788	672	Sandhu SK	The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.	The Lancet. Oncology	2013	84
23918944	672	Phillips KA	Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.	Journal of clinical oncology 	2013	27
23942203	672	Tarabeux J	Streamlined ion torrent PGM-based diagnostics: BRCA1 and BRCA2 genes as a model.	European journal of human genetics 	2014	21
24042365	672	Rosenberg SM	Perceptions, knowledge, and satisfaction with contralateral prophylactic mastectomy among young women with breast cancer: a cross-sectional survey.	Annals of internal medicine	2013	27
24140203	672	Widschwendter M	The sex hormone system in carriers of BRCA1/2 mutations: a case-control study.	The Lancet. Oncology	2013	25
24218601	672	Etemadmoghadam D	Synthetic lethality between CCNE1 amplification and loss of BRCA1.	Proceedings of the National Academy of Sciences of the United States of America	2013	31
24225019	672	Lee JM	PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies.	Annals of oncology 	2014	55
24292448	672	Phelan CM	Incidence of colorectal cancer in BRCA1 and BRCA2 mutation carriers: results from a follow-up study.	British journal of cancer	2014	23
24346285	672	Lee AJ	BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface.	British journal of cancer	2014	21
24366376	672	Moyer VA	Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement.	Annals of internal medicine	2014	57
24366442	672	Nelson HD	Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: a systematic review to update the U.S. Preventive Services Task Force recommendation.	Annals of internal medicine	2014	33
24449235	672	Schwartz MD	Randomized noninferiority trial of telephone versus in-person genetic counseling for hereditary breast and ovarian cancer.	Journal of clinical oncology 	2014	24
24478461	672	Laddha SV	Mutational landscape of the essential autophagy gene BECN1 in human cancers.	Molecular cancer research 	2014	37
24519767	672	Metcalfe K	Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis.	BMJ	2014	23
24567435	672	Finch AP	Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation.	Journal of clinical oncology 	2014	57
24618965	672	Dewey FE	Clinical interpretation and implications of whole-genome sequencing.	JAMA	2014	118
24675953	672	Couch FJ	Two decades after BRCA: setting paradigms in personalized cancer care and prevention.	Science	2014	57
24675954	672	Venkitaraman AR	Cancer suppression by the chromosome custodians, BRCA1 and BRCA2.	Science	2014	31
24824314	672	Friebel TM	Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: systematic review and meta-analysis.	Journal of the National Cancer Institute	2014	23
24947112	672	Heemskerk-Gerritsen BA	Improved overall survival after contralateral risk-reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer: a prospective analysis.	International journal of cancer	2015	16
25072261	672	Golan T	Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers.	British journal of cancer	2014	24
25224030	672	Mersch J	Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian.	Cancer	2015	25
25348513	672	Zhong Q	Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis.	Clinical cancer research 	2015	19
25366685	672	Kaufman B	Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.	Journal of clinical oncology 	2015	144
25398451	672	Candido-dos-Reis FJ	Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer.	Clinical cancer research 	2015	16
25454609	672	Castro E	Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer.	European urology	2015	16
25481791	672	Oza AM	Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.	The Lancet. Oncology	2015	70
25673085	672	Dietze EC	Triple-negative breast cancer in African-American women: disparities versus biology.	Nature reviews. Cancer	2015	28
26187614	672	Kim G	FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy.	Clinical cancer research 	2015	35
26426480	672	Armstrong J	Utilization and Outcomes of BRCA Genetic Testing and Counseling in a National Commercially Insured Population: The ABOUT Study.	JAMA oncology	2015	15
26757170	672	Siu AL	Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement.	Annals of internal medicine	2016	42
12198537	673	Rajagopalan H	Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status.	Nature	2002	276
12460918	673	Brose MS	BRAF and RAS mutations in human lung cancer and melanoma.	Cancer research	2002	256
12697856	673	Cohen Y	BRAF mutation in papillary thyroid carcinoma.	Journal of the National Cancer Institute	2003	149
12970315	673	Namba H	Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers.	The Journal of clinical endocrinology and metabolism	2003	78
14500344	673	Hingorani SR	Suppression of BRAF(V599E) in human melanoma abrogates transformation.	Cancer research	2003	105
14679157	673	Maldonado JL	Determinants of BRAF mutations in primary melanomas.	Journal of the National Cancer Institute	2003	104
15488754	673	Garnett MJ	Guilty as charged: B-RAF is a human oncogene.	Cancer cell	2004	156
16174717	673	Xing M	BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer.	The Journal of clinical endocrinology and metabolism	2005	147
16804544	673	Weisenberger DJ	CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer.	Nature genetics	2006	534
17148775	673	Samowitz WS	Association of smoking, CpG island methylator phenotype, and V600E BRAF mutations in colon cancer.	Journal of the National Cancer Institute	2006	105
17717450	673	Kebebew E	The prevalence and prognostic value of BRAF mutation in thyroid cancer.	Annals of surgery	2007	69
17724477	673	Michaloglou C	BRAF(E600) in benign and malignant human tumours.	Oncogene	2008	71
17785355	673	Lupi C	Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma.	The Journal of clinical endocrinology and metabolism	2007	60
17940185	673	Xing M	BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications.	Endocrine reviews	2007	186
18287029	673	Tsai J	Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity.	Proceedings of the National Academy of Sciences of the United States of America	2008	331
18310287	673	Frasca F	BRAF(V600E) mutation and the biology of papillary thyroid cancer.	Endocrine-related cancer	2008	54
18398503	673	Pfister S	BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas.	The Journal of clinical investigation	2008	112
18519771	673	French AJ	Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer.	Clinical cancer research 	2008	71
18532874	673	Viros A	Improving melanoma classification by integrating genetic and morphologic features.	PLoS medicine	2008	59
18682506	673	Elisei R	BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study.	The Journal of clinical endocrinology and metabolism	2008	92
18832519	673	Ogino S	CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer.	Gut	2009	259
19255327	673	Kloos RT	Phase II trial of sorafenib in metastatic thyroid cancer.	Journal of clinical oncology 	2009	123
19276360	673	Hoeflich KP	Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.	Cancer research	2009	50
19414674	673	Xing M	BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer.	Journal of clinical oncology 	2009	47
19861538	673	Riesco-Eizaguirre G	The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer.	Cancer research	2009	48
19883729	673	Xing M	Prognostic utility of BRAF mutation in papillary thyroid cancer.	Molecular and cellular endocrinology	2010	41
19924296	673	MacConaill LE	Profiling critical cancer gene mutations in clinical tumor samples.	PloS one	2009	145
20519626	673	Badalian-Very G	Recurrent BRAF mutations in Langerhans cell histiocytosis.	Blood	2010	108
20551065	673	Yang H	RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models.	Cancer research	2010	102
20587792	673	Limsui D	Cigarette smoking and colorectal cancer risk by molecularly defined subtypes.	Journal of the National Cancer Institute	2010	88
20630094	673	Rubinstein JC	Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032.	Journal of translational medicine	2010	60
20635392	673	Tie J	Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation.	International journal of cancer	2011	39
20818844	673	Flaherty KT	Inhibition of mutated, activated BRAF in metastatic melanoma.	The New England journal of medicine	2010	938
20823850	673	Bollag G	Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.	Nature	2010	428
20959481	673	Gopal YN	Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells.	Cancer research	2010	96
21139585	673	Arkenau HT	Targeting BRAF for patients with melanoma.	British journal of cancer	2011	36
21274720	673	Schindler G	Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma.	Acta neuropathologica	2011	134
21285991	673	Yokota T	BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer.	British journal of cancer	2011	79
21343559	673	Long GV	Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.	Journal of clinical oncology 	2011	163
21430775	673	Chapman MA	Initial genome sequencing and analysis of multiple myeloma.	Nature	2011	414
21456008	673	Tran B	Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer.	Cancer	2011	92
21479234	673	Dias-Santagata D	BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications.	PloS one	2011	57
21639808	673	Chapman PB	Improved survival with vemurafenib in melanoma with BRAF V600E mutation.	The New England journal of medicine	2011	1498
21663470	673	Tiacci E	BRAF mutations in hairy-cell leukemia.	The New England journal of medicine	2011	157
21768580	673	Ladabaum U	Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis.	Annals of internal medicine	2011	71
21882184	673	Kim TH	The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis.	Cancer	2012	60
22012135	673	Capper D	Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases.	Acta neuropathologica	2012	40
22038996	673	Nicolaides TP	Targeted therapy for BRAFV600E malignant astrocytoma.	Clinical cancer research 	2011	51
22105174	673	Chakravarty D	Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation.	The Journal of clinical investigation	2011	59
22147942	673	Ogino S	Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803.	Clinical cancer research 	2012	80
22180495	673	Yang H	Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.	Cancer research	2012	54
22228154	673	Kalady MF	BRAF mutations in colorectal cancer are associated with distinct clinical characteristics and worse prognosis.	Diseases of the colon and rectum	2012	38
22235286	673	Yancovitz M	Intra- and inter-tumor heterogeneity of BRAF(V600E))mutations in primary and metastatic melanoma.	PloS one	2012	59
22306669	673	Halait H	Analytical performance of a real-time PCR-based assay for V600 mutations in the BRAF gene, used as the companion diagnostic test for the novel BRAF inhibitor vemurafenib in metastatic melanoma.	Diagnostic molecular pathology 	2012	35
22332713	673	Anderson S	Multisite analytic performance studies of a real-time polymerase chain reaction assay for the detection of BRAF V600E mutations in formalin-fixed, paraffin-embedded tissue specimens of malignant melanoma.	Archives of pathology and laboratory medicine	2012	37
22355009	673	Hong DS	BRAF(V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency.	Clinical cancer research 	2012	36
22356324	673	Sosman JA	Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.	The New England journal of medicine	2012	474
22393095	673	Popovici V	Identification of a poor-prognosis BRAF-mutant-like population of patients with colon cancer.	Journal of clinical oncology 	2012	47
22395615	673	Shi H	Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance.	Nature communications	2012	160
22454415	673	McArthur GA	Marked, homogeneous, and early 18Ffluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma.	Journal of clinical oncology 	2012	33
22508706	673	Guerra A	A high percentage of BRAFV600E alleles in papillary thyroid carcinoma predicts a poorer outcome.	The Journal of clinical endocrinology and metabolism	2012	30
22535154	673	Menzies AM	Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma.	Clinical cancer research 	2012	64
22608338	673	Falchook GS	Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.	Lancet	2012	179
22640478	673	Ascierto PA	Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use.	Journal of translational medicine	2012	30
22649091	673	Sen B	Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib.	Science translational medicine	2012	34
22743296	673	Gautschi O	A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib.	Journal of thoracic oncology 	2012	37
22798288	673	Dahlman KB	BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors.	Cancer discovery	2012	49
22899730	673	Phipps AI	BRAF mutation status and survival after colorectal cancer diagnosis according to patient and tumor characteristics.	Cancer epidemiology, biomarkers and prevention 	2012	40
22930283	673	Grisham RN	BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer.	Cancer	2013	27
22932786	673	Tufano RP	BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis.	Medicine	2012	46
22941165	673	Howell GM	BRAF V600E mutation independently predicts central compartment lymph node metastasis in patients with papillary thyroid cancer.	Annals of surgical oncology	2013	27
22972589	673	Patel SP	Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma.	Cancer	2013	28
23026937	673	Long GV	Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma.	The American journal of surgical pathology	2013	46
23055546	673	Li C	BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis.	The Journal of clinical endocrinology and metabolism	2012	36
23056577	673	Safaee Ardekani G	The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis.	PloS one	2012	34
23066120	673	Elisei R	The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study.	The Journal of clinical endocrinology and metabolism	2012	34
23273605	673	Greaves WO	Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma.	The Journal of molecular diagnostics 	2013	37
23290787	673	Sullivan RJ	Resistance to BRAF-targeted therapy in melanoma.	European journal of cancer	2013	74
23352452	673	Freeman AK	Effects of Raf dimerization and its inhibition on normal and disease-associated Raf signaling.	Molecular cell	2013	39
23416974	673	Kwong LN	Targeted therapy for melanoma: rational combinatorial approaches.	Oncogene	2014	23
23442159	673	ChappÃ© C	Dysembryoplastic neuroepithelial tumors share with pleomorphic xanthoastrocytomas and gangliogliomas BRAF(V600E) mutation and expression.	Brain pathology	2013	26
23533272	673	Sievert AJ	Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas.	Proceedings of the National Academy of Sciences of the United States of America	2013	52
23569304	673	Trunzer K	Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.	Journal of clinical oncology 	2013	83
23571588	673	Xing M	Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer.	JAMA	2013	123
23612012	673	Andrulis M	Targeting the BRAF V600E mutation in multiple myeloma.	Cancer discovery	2013	35
23735514	673	Robert C	Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.	The Lancet. Oncology	2013	36
23800934	673	Nishihara R	Aspirin use and risk of colorectal cancer according to BRAF mutation status.	JAMA	2013	48
23833299	673	Nathanson KL	Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436).	Clinical cancer research 	2013	36
23852808	673	Roepman P	Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition.	International journal of cancer	2014	47
23856246	673	Abaan OD	The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology.	Cancer research	2013	80
23878352	673	Lochhead P	Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication.	Journal of the National Cancer Institute	2013	81
23903755	673	Corcoran RB	TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma.	Science translational medicine	2013	49
23918947	673	Ascierto PA	Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma.	Journal of clinical oncology 	2013	60
24291778	673	Bucheit AD	Emerging insights into resistance to BRAF inhibitors in melanoma.	Biochemical pharmacology	2014	29
24295639	673	Dummer R	Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study.	European journal of cancer	2014	36
24345920	673	Hutchinson KE	BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition.	Clinical cancer research 	2013	33
24410877	673	Ihle MA	Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations.	BMC cancer	2014	46
24463458	673	Rizos H	BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact.	Clinical cancer research 	2014	63
24508103	673	McArthur GA	Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.	The Lancet. Oncology	2014	119
24582505	673	Larkin J	Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.	The Lancet. Oncology	2014	28
24617711	673	Liu X	TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer.	The Journal of clinical endocrinology and metabolism	2014	41
24638167	673	Berres ML	BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups.	The Journal of experimental medicine	2014	42
24725538	673	Robinson GW	Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy.	BMC cancer	2014	24
24737664	673	Yaeger R	BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer.	Cancer	2014	29
24768112	673	Brose MS	Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial.	Lancet	2014	112
24958825	673	Hu-Lieskovan S	Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges.	Journal of clinical oncology 	2014	41
25024077	673	Xing M	BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence.	Journal of clinical oncology 	2014	57
25139339	673	Venderbosch S	Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies.	Clinical cancer research 	2014	23
25202140	673	Chakraborty R	Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis.	Blood	2014	35
25332244	673	Xing M	Association between BRAF V600E mutation and recurrence of papillary thyroid cancer.	Journal of clinical oncology 	2015	48
25344914	673	Spagnolo F	Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma.	Oncotarget	2014	28
25353071	673	Dadu R	Efficacy and tolerability of vemurafenib in patients with BRAF(V600E) -positive papillary thyroid cancer: M.D. Anderson Cancer Center off label experience.	The Journal of clinical endocrinology and metabolism	2015	17
25411185	673	Sanmamed MF	Quantitative cell-free circulating BRAFV600E mutation analysis by use of droplet digital PCR in the follow-up of patients with melanoma being treated with BRAF inhibitors.	Clinical chemistry	2015	23
25891304	673	Postow MA	Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.	The New England journal of medicine	2015	330
25918280	673	Fakih MG	Metastatic colorectal cancer: current state and future directions.	Journal of clinical oncology 	2015	33
26037941	673	Long GV	Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial.	Lancet	2015	84
26038390	673	Campbell PT	Association between body mass index and mortality for colorectal cancer survivors: overall and by tumor molecular phenotype.	Cancer epidemiology, biomarkers and prevention 	2015	16
26287849	673	Hyman DM	Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.	The New England journal of medicine	2015	128
26338525	673	Cremolini C	FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.	The Lancet. Oncology	2015	39
26527776	673	AndrÃ© T	Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.	Journal of clinical oncology 	2015	20
26715644	673	Girotti MR	Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma.	Cancer discovery	2016	16
26733501	673	Liu R	TERT promoter mutations in thyroid cancer.	Endocrine-related cancer	2016	13
26811525	673	Long GV	Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib.	Journal of clinical oncology 	2016	21
27022117	673	Stadler ZK	Reliable Detection of Mismatch Repair Deficiency in Colorectal Cancers Using Mutational Load in Next-Generation Sequencing Panels.	Journal of clinical oncology 	2016	18
27080216	673	Planchard D	Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial.	The Lancet. Oncology	2016	18
8524414	675	Wooster R	Identification of the breast cancer susceptibility gene BRCA2.	Nature	1995	496
8589730	675	Tavtigian SV	The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds.	Nature genetics	1996	133
8968085	675	Goggins M	Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas.	Cancer research	1996	133
10433620	675	Breast Cancer Linkage Consortium.	Cancer risks in BRCA2 mutation carriers.	Journal of the National Cancer Institute	1999	251
12065746	675	Howlett NG	Biallelic inactivation of BRCA2 in Fanconi anemia.	Science	2002	276
16141007	675	van Asperen CJ	Cancer risks in BRCA2 families: estimates for sites other than breast and ovary.	Journal of medical genetics	2005	70
16793542	675	Xia B	Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2.	Molecular cell	2006	233
21952622	675	Kote-Jarai Z	BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients.	British journal of cancer	2011	43
22274685	675	Bolton KL	Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer.	JAMA	2012	99
23165508	675	Barber LJ	Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor.	The Journal of pathology	2013	40
23544012	675	Gaudet MM	Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk.	PLoS genetics	2013	45
1720541	861	Miyoshi H	t(8;21) breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene, AML1.	Proceedings of the National Academy of Sciences of the United States of America	1991	163
19808697	861	Tang JL	AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations.	Blood	2009	60
21343560	861	Gaidzik VI	RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group.	Journal of clinical oncology 	2011	53
22201794	861	Lam K	RUNX1 and RUNX1-ETO: roles in hematopoiesis and leukemogenesis.	Frontiers in bioscience	2012	33
22753902	861	Mendler JH	RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.	Journal of clinical oncology 	2012	46
23352661	861	Wilkinson AC	RUNX1 is a key target in t(4;11) leukemias that contributes to gene activation through an AF4-MLL complex interaction.	Cell reports	2013	35
24055056	861	Ben-Ami O	Addiction of t(8;21) and inv(16) acute myeloid leukemia to native RUNX1.	Cell reports	2013	26
8033105	999	Becker KF	E-cadherin gene mutations provide clues to diffuse type gastric carcinomas.	Cancer research	1994	139
8557030	999	Berx G	E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers.	The EMBO journal	1995	152
11597316	999	Berx G	The E-cadherin/catenin complex: an important gatekeeper in breast cancer tumorigenesis and malignant progression.	Breast cancer research 	2001	92
16495925	999	Lombaerts M	E-cadherin transcriptional downregulation by promoter methylation but not mutation is related to epithelial-to-mesenchymal transition in breast cancer cell lines.	British journal of cancer	2006	104
17545690	999	Kaurah P	Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer.	JAMA	2007	66
19011757	999	Vandewalle C	The role of the ZEB family of transcription factors in development and disease.	Cellular and molecular life sciences 	2009	121
20591882	999	Fitzgerald RC	Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research.	Journal of medical genetics	2010	71
23341533	999	Corso G	Somatic mutations and deletions of the E-cadherin gene predict poor survival of patients with gastric cancer.	Journal of clinical oncology 	2013	28
25979631	999	van der Post RS	Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers.	Journal of medical genetics	2015	26
1833068	1017	Koff A	Human cyclin E, a new cyclin that interacts with two members of the CDC2 gene family.	Cell	1991	148
8266103	1017	van den Heuvel S	Distinct roles for cyclin-dependent kinases in cell cycle control.	Science	1993	305
9192874	1017	Lukas J	Cyclin E-induced S phase without activation of the pRb/E2F pathway.	Genes and development	1997	105
10499591	1017	Spruck CH	Deregulated cyclin E induces chromosome instability.	Nature	1999	188
10648628	1017	Dickson MA	Human keratinocytes that express hTERT and also bypass a p16(INK4a)-enforced mechanism that limits life span become immortal yet retain normal growth and differentiation characteristics.	Molecular and cellular biology	2000	241
12124352	1017	Yakes FM	Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action.	Cancer research	2002	158
21321214	1017	Scaltriti M	Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients.	Proceedings of the National Academy of Sciences of the United States of America	2011	79
7652577	1019	WÃ¶lfel T	A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma.	Science	1995	179
7777060	1019	Lukas J	Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16.	Nature	1995	182
8152487	1019	Nobori T	Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers.	Nature	1994	206
9242437	1019	Schutte M	Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas.	Cancer research	1997	136
17047042	1019	Goldstein AM	High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL.	Cancer research	2006	74
18790768	1019	Smalley KS	Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas.	Molecular cancer therapeutics	2008	64
19415697	1019	Kim JK	Nuclear cyclin D1: an oncogenic driver in human cancer.	Journal of cellular physiology	2009	108
19609742	1019	Rao SK	A survey of glioblastoma genomic amplifications and deletions.	Journal of neuro-oncology	2010	46
21412932	1019	Birnbaum DJ	Genome profiling of pancreatic adenocarcinoma.	Genes, chromosomes and cancer	2011	43
22711607	1019	Cen L	p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells.	Neuro-oncology	2012	34
24495407	1019	Young RJ	Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.	Pigment cell and melanoma research	2014	25
25002028	1019	Vora SR	CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors.	Cancer cell	2014	50
25082755	1019	Chiron D	Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.	Cancer discovery	2014	33
25498841	1019	Carneiro BA	Emerging therapeutic targets in bladder cancer.	Cancer treatment reviews	2015	16
25609060	1019	Di Stefano AL	Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type Glioma.	Clinical cancer research 	2015	19
26833129	1019	Bouillez A	Inhibition of MUC1-C Suppresses MYC Expression and Attenuates Malignant Growth in KRAS Mutant Lung Adenocarcinomas.	Cancer research	2016	14
26947331	1019	Cristofanilli M	Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.	The Lancet. Oncology	2016	40
7958916	1026	Di Leonardo A	DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts.	Genes and development	1994	207
8118801	1026	el-Deiry WS	WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis.	Cancer research	1994	376
8843196	1026	Chen X	p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells.	Genes and development	1996	154
9296497	1026	Somasundaram K	Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiP1.	Nature	1997	106
10430607	1026	Bunz F	Disruption of p53 in human cancer cells alters the responses to therapeutic agents.	The Journal of clinical investigation	1999	247
11309634	1026	Watanabe T	Molecular predictors of survival after adjuvant chemotherapy for colon cancer.	The New England journal of medicine	2001	174
11745677	1026	Piek JM	Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer.	The Journal of pathology	2001	132
12773551	1026	Zhu WG	Methylation of adjacent CpG sites affects Sp1/Sp3 binding and activity in the p21(Cip1) promoter.	Molecular and cellular biology	2003	77
16854453	1026	McCubrey JA	Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.	Advances in enzyme regulation	2006	155
19141585	1026	Agarwal SK	Rare germline mutations in cyclin-dependent kinase inhibitor genes in multiple endocrine neoplasia type 1 and related states.	The Journal of clinical endocrinology and metabolism	2009	48
19861444	1026	Chung CH	Human papillomavirus in head and neck cancer: its role in pathogenesis and clinical implications.	Clinical cancer research 	2009	92
20507599	1026	Baba Y	Epigenomic diversity of colorectal cancer indicated by LINE-1 methylation in a database of 869 tumors.	Molecular cancer	2010	50
21331045	1026	Elyada E	CKIÎ± ablation highlights a critical role for p53 in invasiveness control.	Nature	2011	56
22580610	1026	Yin D	miR-34a functions as a tumor suppressor modulating EGFR in glioblastoma multiforme.	Oncogene	2013	27
24100703	1026	Sanli T	AMP-activated protein kinase (AMPK) beyond metabolism: a novel genomic stress sensor participating in the DNA damage response pathway.	Cancer biology and therapy	2014	37
27323328	1026	Galanos P	Chronic p53-independent p21 expression causes genomic instability by deregulating replication licensing.	Nature cell biology	2016	18
9018243	1027	Porter PL	Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients.	Nature medicine	1997	135
17030811	1027	Pellegata NS	Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans.	Proceedings of the National Academy of Sciences of the United States of America	2006	91
18559508	1027	Wei D	Kruppel-like factor 4 induces p27Kip1 expression in and suppresses the growth and metastasis of human pancreatic cancer cells.	Cancer research	2008	54
18691549	1027	Majumder PK	A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression.	Cancer cell	2008	67
21750219	1027	Yuan J	PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity.	Molecular cancer therapeutics	2011	46
26551667	1027	da Silva Almeida AC	The mutational landscape of cutaneous T cell lymphoma and SÃ©zary syndrome.	Nature genetics	2015	27
7553621	1029	Herman JG	Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers.	Cancer research	1995	241
7585152	1029	Merlo A	5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers.	Nature medicine	1995	274
8153634	1029	Kamb A	A cell cycle regulator potentially involved in genesis of many tumor types.	Science	1994	337
9135016	1029	Rozenblum E	Tumor-suppressive pathways in pancreatic carcinoma.	Cancer research	1997	154
9776413	1029	Cairncross JG	Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas.	Journal of the National Cancer Institute	1998	181
10072356	1029	Sharpless NE	The INK4A/ARF locus and its two gene products.	Current opinion in genetics and development	1999	107
10319873	1029	Barrett MT	Evolution of neoplastic cell lineages in Barrett oesophagus.	Nature genetics	1999	97
10416987	1029	Ishii N	Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines.	Brain pathology	1999	155
10541553	1029	Schmitt CA	INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53.	Genes and development	1999	135
10811111	1029	Esteller M	Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis.	Cancer research	2000	93
11196170	1029	ZÃ¶chbauer-MÃ¼ller S	Aberrant promoter methylation of multiple genes in non-small cell lung cancers.	Cancer research	2001	104
11544531	1029	Sharpless NE	Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis.	Nature	2001	231
12692724	1029	Sipos B	A comprehensive characterization of pancreatic ductal carcinoma cell lines: towards the establishment of an in vitro research platform.	Virchows Archiv 	2003	84
12789288	1029	Wu H	PTEN signaling pathways in melanoma.	Oncogene	2003	86
14722605	1029	Sharpless NE	Telomeres, stem cells, senescence, and cancer.	The Journal of clinical investigation	2004	112
15466178	1029	Ohgaki H	Genetic pathways to glioblastoma: a population-based study.	Cancer research	2004	282
15608680	1029	Tagawa H	Genome-wide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene BIM.	Oncogene	2005	85
15899794	1029	Rich JN	Gene expression profiling and genetic markers in glioblastoma survival.	Cancer research	2005	78
15977639	1029	Ohgaki H	Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas.	Journal of neuropathology and experimental neurology	2005	237
16799619	1029	Laurent-Puig P	Genetics of hepatocellular tumors.	Oncogene	2006	82
16905682	1029	Goldstein AM	Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents.	Journal of medical genetics	2007	75
16964246	1029	Denoyelle C	Anti-oncogenic role of the endoplasmic reticulum differentially activated by mutations in the MAPK pathway.	Nature cell biology	2006	97
17088437	1029	Ikediobi ON	Mutation analysis of 24 known cancer genes in the NCI-60 cell line set.	Molecular cancer therapeutics	2006	152
17326708	1029	Galipeau PC	NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma.	PLoS medicine	2007	87
17334996	1029	JÃ¶nsson G	High-resolution genomic profiles of breast cancer cell lines assessed by tiling BAC array comparative genomic hybridization.	Genes, chromosomes and cancer	2007	64
17456751	1029	Ohgaki H	Genetic pathways to primary and secondary glioblastoma.	The American journal of pathology	2007	299
17890455	1029	Kawamata N	Molecular allelokaryotyping of pediatric acute lymphoblastic leukemias by high-resolution single nucleotide polymorphism oligonucleotide genomic microarray.	Blood	2008	57
18305067	1029	Leedham SJ	Individual crypt genetic heterogeneity and the origin of metaplastic glandular epithelium in human Barrett's oesophagus.	Gut	2008	56
18394558	1029	Wiedemeyer R	Feedback circuit among INK4 tumor suppressors constrains human glioblastoma development.	Cancer cell	2008	59
18474878	1029	Kumar B	EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer.	Journal of clinical oncology 	2008	169
18688285	1029	Hacein-Bey-Abina S	Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1.	The Journal of clinical investigation	2008	456
18688286	1029	Howe SJ	Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients.	The Journal of clinical investigation	2008	321
18922929	1029	Barault L	Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases.	Cancer research	2008	106
19074898	1029	Solomon DA	Mutational inactivation of PTPRD in glioblastoma multiforme and malignant melanoma.	Cancer research	2008	50
19593635	1029	Hollestelle A	Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines.	Breast cancer research and treatment	2010	83
19718709	1029	Mohseny AB	Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2.	The Journal of pathology	2009	71
19825961	1029	Ogino S	Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype.	Clinical cancer research 	2009	92
20068183	1029	Schiffman JD	Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas.	Cancer research	2010	86
20451455	1029	Marur S	HPV-associated head and neck cancer: a virus-related cancer epidemic.	The Lancet. Oncology	2010	283
20460471	1029	JÃ¶nsson G	Gene expression profiling-based identification of molecular subtypes in stage IV melanomas with different clinical outcome.	Clinical cancer research 	2010	58
20522802	1029	Kajstura J	Cardiomyogenesis in the adult human heart.	Circulation research	2010	101
21129377	1029	Vasen HF	Magnetic resonance imaging surveillance detects early-stage pancreatic cancer in carriers of a p16-Leiden mutation.	Gastroenterology	2011	39
21248843	1029	Notta F	Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells.	Nature	2011	154
21509761	1029	Ahn JB	DNA methylation predicts recurrence from resected stage III proximal colon cancer.	Cancer	2011	47
21619050	1029	Li J	Regulatory mechanisms of tumor suppressor P16(INK4A) and their relevance to cancer.	Biochemistry	2011	38
21636552	1029	Raabe EH	BRAF activation induces transformation and then senescence in human neural stem cells: a pilocytic astrocytoma model.	Clinical cancer research 	2011	42
22065079	1029	Carbone M	Molecular pathways: targeting mechanisms of asbestos and erionite carcinogenesis in mesothelioma.	Clinical cancer research 	2012	46
22067401	1029	Oberholzer PA	RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors.	Journal of clinical oncology 	2012	79
22084097	1029	Nagai H	Diameter and rigidity of multiwalled carbon nanotubes are critical factors in mesothelial injury and carcinogenesis.	Proceedings of the National Academy of Sciences of the United States of America	2011	89
22256804	1029	Su F	RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.	The New England journal of medicine	2012	200
22833868	1029	Rothenberg SM	The molecular pathogenesis of head and neck squamous cell carcinoma.	The Journal of clinical investigation	2012	72
22975375	1029	Navas C	EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma.	Cancer cell	2012	91
23135763	1029	Canto MI	International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer.	Gut	2013	87
23412337	1029	Sottoriva A	Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics.	Proceedings of the National Academy of Sciences of the United States of America	2013	266
23470568	1029	Oshima M	Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer.	Annals of surgery	2013	42
23601657	1029	Riaz M	miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs.	Breast cancer research 	2013	38
23663786	1029	Yang L	Diverse mechanisms of somatic structural variations in human cancer genomes.	Cell	2013	74
23677068	1029	Sekido Y	Molecular pathogenesis of malignant mesothelioma.	Carcinogenesis	2013	32
23887298	1029	Ross JS	Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy.	Modern pathology 	2014	36
23907151	1029	Kanagal-Shamanna R	Next-generation sequencing-based multi-gene mutation profiling of solid tumors using fine needle aspiration samples: promises and challenges for routine clinical diagnostics.	Modern pathology 	2014	32
24127483	1029	Fabbri G	Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome.	The Journal of experimental medicine	2013	26
24425785	1029	Li H	Genomic analysis of head and neck squamous cell carcinoma cell lines and human tumors: a rational approach to preclinical model selection.	Molecular cancer research 	2014	21
24733792	1029	Kurian AW	Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment.	Journal of clinical oncology 	2014	68
24957142	1029	Moorman AV	A novel integrated cytogenetic and genomic classification refines risk stratification in pediatric acute lymphoblastic leukemia.	Blood	2014	24
25009010	1029	De Mattos-Arruda L	Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle.	Annals of oncology 	2014	47
25010205	1029	Brohl AS	The genomic landscape of the Ewing Sarcoma family of tumors reveals recurrent STAG2 mutation.	PLoS genetics	2014	53
25092538	1029	Kim PH	Genomic predictors of survival in patients with high-grade urothelial carcinoma of the bladder.	European urology	2015	19
25117714	1029	Ozawa T	Most human non-GCIMP glioblastoma subtypes evolve from a common proneural-like precursor glioma.	Cancer cell	2014	54
25223734	1029	Tirode F	Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations.	Cancer discovery	2014	57
25479140	1029	Grant RC	Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer.	Gastroenterology	2015	23
25503501	1029	Maxwell KN	Prevalence of mutations in a panel of breast cancer susceptibility genes in BRCA1/2-negative patients with early-onset breast cancer.	Genetics in medicine 	2015	24
25536104	1029	Churi CR	Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications.	PloS one	2014	40
25584893	1029	Damsky W	mTORC1 activation blocks BrafV600E-induced growth arrest but is insufficient for melanoma formation.	Cancer cell	2015	15
25589618	1029	Li YY	Genomic analysis of metastatic cutaneous squamous cell carcinoma.	Clinical cancer research 	2015	17
25712460	1029	Chung CH	Genomic alterations in head and neck squamous cell carcinoma determined by cancer gene-targeted sequencing.	Annals of oncology 	2015	17
25822088	1029	Schulze K	Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets.	Nature genetics	2015	104
26099527	1029	Zucman-Rossi J	Genetic Landscape and Biomarkers of Hepatocellular Carcinoma.	Gastroenterology	2015	47
26192918	1029	Stachler MD	Paired exome analysis of Barrett's esophagus and adenocarcinoma.	Nature genetics	2015	30
26536169	1029	Cancer Genome Atlas Research Network.	Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma.	The New England journal of medicine	2016	69
26551670	1029	Wang L	Genomic profiling of SÃ©zary syndrome identifies alterations of key T cell signaling and differentiation genes.	Nature genetics	2015	24
26658419	1029	Roberts NJ	Whole Genome Sequencing Defines the Genetic Heterogeneity of Familial Pancreatic Cancer.	Cancer discovery	2016	14
26830752	1029	Kamisawa T	Pancreatic cancer.	Lancet	2016	47
26873401	1029	Sawada G	Genomic Landscape of Esophageal Squamous Cell Carcinoma inÂ a Japanese Population.	Gastroenterology	2016	17
26912361	1029	Mavrakis KJ	Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5.	Science	2016	19
27114589	1029	Vasen H	Benefit of Surveillance for Pancreatic Cancer in High-Risk Individuals: Outcome of Long-Term Prospective Follow-Up Studies From Three European Expert Centers.	Journal of clinical oncology 	2016	16
27213815	1029	Dauch D	A MYC-aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer.	Nature medicine	2016	15
11242107	1050	Pabst T	Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia.	Nature genetics	2001	172
11283671	1050	Pabst T	AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia.	Nature medicine	2001	99
14726504	1050	FrÃ¶hling S	CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations.	Journal of clinical oncology 	2004	80
15084694	1050	Valk PJ	Prognostically useful gene-expression profiles in acute myeloid leukemia.	The New England journal of medicine	2004	309
16051734	1050	DÃ¶hner K	Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations.	Blood	2005	140
16076867	1050	Schnittger S	Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype.	Blood	2005	106
16109776	1050	Verhaak RG	Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance.	Blood	2005	94
16446383	1050	Radomska HS	Block of C/EBP alpha function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations.	The Journal of experimental medicine	2006	63
16960150	1050	MrÃ³zek K	Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?	Blood	2007	122
17925434	1050	Kendall J	Oncogenic cooperation and coamplification of developmental transcription factor genes in lung cancer.	Proceedings of the National Academy of Sciences of the United States of America	2007	91
18288131	1050	Renneville A	Cooperating gene mutations in acute myeloid leukemia: a review of the literature.	Leukemia	2008	62
18450602	1050	Schlenk RF	Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.	The New England journal of medicine	2008	304
18559874	1050	Paschka P	Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.	Journal of clinical oncology 	2008	60
18809607	1050	Marcucci G	Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study.	Journal of clinical oncology 	2008	108
19075268	1050	Koschmieder S	Dysregulation of the C/EBPalpha differentiation pathway in human cancer.	Journal of clinical oncology 	2009	45
20038735	1050	Dufour A	Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome.	Journal of clinical oncology 	2010	45
20368538	1050	Wagner K	Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor.	Journal of clinical oncology 	2010	55
20889924	1050	Pulikkan JA	C/EBPÎ± regulated microRNA-34a targets E2F3 during granulopoiesis and is down-regulated in AML with CEBPA mutations.	Blood	2010	45
21038412	1050	Zeng C	A novel GSK-3 beta-C/EBP alpha-miR-122-insulin-like growth factor 1 receptor regulatory circuitry in human hepatocellular carcinoma.	Hepatology	2010	41
21177436	1050	Taskesen E	Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity.	Blood	2011	47
21881046	1050	Shen Y	Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia.	Blood	2011	63
22180162	1050	Estey EH	Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management.	American journal of hematology	2012	36
22417203	1050	Patel JP	Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.	The New England journal of medicine	2012	352
23526416	1050	Estey EH	Acute myeloid leukemia: 2013 update on risk-stratification and management.	American journal of hematology	2013	65
24183681	1050	Zhang H	Sox4 is a key oncogenic target in C/EBPÎ± mutant acute myeloid leukemia.	Cancer cell	2013	31
24487413	1050	Kihara R	Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients.	Leukemia	2014	34
25079101	1050	Meyer SC	Translational implications of somatic genomics in acute myeloid leukaemia.	The Lancet. Oncology	2014	21
25303533	1050	Chen JC	Identification of causal genetic drivers of human disease through systems-level analysis of regulatory networks.	Cell	2014	42
25512507	1050	Garzon R	Expression and prognostic impact of lncRNAs in acute myeloid leukemia.	Proceedings of the National Academy of Sciences of the United States of America	2014	35
11333986	1111	Bulavin DV	Initiation of a G2/M checkpoint after ultraviolet radiation requires p38 kinase.	Nature	2001	124
12781359	1111	Bartek J	Chk1 and Chk2 kinases in checkpoint control and cancer.	Cancer cell	2003	347
15159417	1111	Melixetian M	Loss of Geminin induces rereplication in the presence of functional p53.	The Journal of cell biology	2004	101
15189136	1111	Sancar A	Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints.	Annual review of biochemistry	2004	775
17485253	1111	Kaina B	MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents.	DNA repair	2007	131
18790776	1111	Zabludoff SD	AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies.	Molecular cancer therapeutics	2008	129
19091954	1111	Wilsker D	Essential function of Chk1 can be uncoupled from DNA damage checkpoint and replication control.	Proceedings of the National Academy of Sciences of the United States of America	2008	53
19808869	1111	Bolderson E	Recent advances in cancer therapy targeting proteins involved in DNA double-strand break repair.	Clinical cancer research 	2009	64
20371347	1111	Davoli T	Persistent telomere damage induces bypass of mitosis and tetraploidy.	Cell	2010	92
20581868	1111	Bartkova J	Replication stress and oxidative damage contribute to aberrant constitutive activation of DNA damage signalling in human gliomas.	Oncogene	2010	53
23242585	1111	Ma CX	A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer.	Breast cancer research and treatment	2013	27
25931285	1111	Khanna A	DNA damage in cancer therapeutics: a boon or a curse?	Cancer research	2015	17
17908689	1387	Evans PM	Kruppel-like factor 4 is acetylated by p300 and regulates gene transcription via modulation of histone acetylation.	The Journal of biological chemistry	2007	73
17942008	1387	Roelfsema JH	Rubinstein-Taybi syndrome: clinical and molecular overview.	Expert reviews in molecular medicine	2007	62
19648934	1387	Dansen TB	Redox-sensitive cysteines bridge p300/CBP-mediated acetylation and FoxO4 activity.	Nature chemical biology	2009	58
21390130	1387	Mullighan CG	CREBBP mutations in relapsed acute lymphoblastic leukaemia.	Nature	2011	162
22941188	1387	Peifer M	Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer.	Nature genetics	2012	215
23685749	1387	Ho AS	The mutational landscape of adenoid cystic carcinoma.	Nature genetics	2013	75
24662245	1387	Mar BG	Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia.	Nature communications	2014	35
25713363	1387	Green MR	Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation.	Proceedings of the National Academy of Sciences of the United States of America	2015	33
22554099	1493	Ascierto PA	The role of BRAF V600 mutation in melanoma.	Journal of translational medicine	2012	56
24054424	1493	Eggermont AM	Cutaneous melanoma.	Lancet	2014	64
24782321	1493	Brown SD	Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival.	Genome research	2014	85
25213377	1493	Kuehn HS	Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4.	Science	2014	83
25409260	1493	Snyder A	Genetic basis for clinical response to CTLA-4 blockade in melanoma.	The New England journal of medicine	2014	455
25795410	1493	Weber JS	Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.	The Lancet. Oncology	2015	227
26258847	1493	Ungewickell A	Genomic analysis of mycosis fungoides and SÃ©zary syndrome identifies recurrent alterations in TNFR2.	Nature genetics	2015	27
26359337	1493	Van Allen EM	Genomic correlates of response to CTLA-4 blockade in metastatic melanoma.	Science	2015	151
26420858	1493	Mak MP	A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition.	Clinical cancer research 	2016	24
26940869	1493	McGranahan N	Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade.	Science	2016	126
27622997	1493	Hodi FS	Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.	The Lancet. Oncology	2016	31
9065403	1499	Rubinfeld B	Stabilization of beta-catenin by genetic defects in melanoma cell lines.	Science	1997	285
9294210	1499	Ilyas M	Beta-catenin mutations in cell lines established from human colorectal cancers.	Proceedings of the National Academy of Sciences of the United States of America	1997	118
10092233	1499	Seeling JM	Regulation of beta-catenin signaling by the B56 subunit of protein phosphatase 2A.	Science	1999	108
10192393	1499	Chan EF	A common human skin tumour is caused by activating mutations in beta-catenin.	Nature genetics	1999	126
10630639	1499	Miller JR	Mechanism and function of signal transduction by the Wnt/beta-catenin and Wnt/Ca2+ pathways.	Oncogene	1999	124
10987273	1499	Truica CI	Beta-catenin affects androgen receptor transcriptional activity and ligand specificity.	Cancer research	2000	102
11381089	1499	Gottardi CJ	E-cadherin suppresses cellular transformation by inhibiting beta-catenin signaling in an adhesion-independent manner.	The Journal of cell biology	2001	150
11940574	1499	Leung JY	Activation of AXIN2 expression by beta-catenin-T cell factor. A feedback repressor pathway regulating Wnt signaling.	The Journal of biological chemistry	2002	119
12045208	1499	Albuquerque C	The 'just-right' signaling model: APC somatic mutations are selected based on a specific level of activation of the beta-catenin signaling cascade.	Human molecular genetics	2002	98
15480989	1499	Merle P	Functional consequences of frizzled-7 receptor overexpression in human hepatocellular carcinoma.	Gastroenterology	2004	72
15761464	1499	Bell DA	Origins and molecular pathology of ovarian cancer.	Modern pathology 	2005	100
15973414	1499	Batlle E	EphB receptor activity suppresses colorectal cancer progression.	Nature	2005	110
16023783	1499	Verras M	Roles and regulation of Wnt signaling and beta-catenin in prostate cancer.	Cancer letters	2006	72
16258095	1499	Ellison DW	beta-Catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children's Cancer Study Group Brain Tumour Committee.	Journal of clinical oncology 	2005	68
16288032	1499	Huang L	MUC1 oncoprotein blocks glycogen synthase kinase 3beta-mediated phosphorylation and degradation of beta-catenin.	Cancer research	2005	99
16964294	1499	Zucman-Rossi J	Differential effects of inactivated Axin1 and activated beta-catenin mutations in human hepatocellular carcinomas.	Oncogene	2007	59
17187432	1499	Boyault S	Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets.	Hepatology	2007	191
17208432	1499	Polakis P	The many ways of Wnt in cancer.	Current opinion in genetics and development	2007	269
17295177	1499	Villanueva A	Genomics and signaling pathways in hepatocellular carcinoma.	Seminars in liver disease	2007	150
17785413	1499	Tward AD	Distinct pathways of genomic progression to benign and malignant tumors of the liver.	Proceedings of the National Academy of Sciences of the United States of America	2007	64
18832571	1499	Lazar AJ	Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors.	The American journal of pathology	2008	55
19078924	1499	Bansal N	The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies.	Cancer control 	2009	64
19197950	1499	Fattet S	Beta-catenin status in paediatric medulloblastomas: correlation of immunohistochemical expression with mutational status, genetic profiles, and clinical characteristics.	The Journal of pathology	2009	50
19703993	1499	Saydam O	Downregulated microRNA-200a in meningiomas promotes tumor growth by reducing E-cadherin and activating the Wnt/beta-catenin signaling pathway.	Molecular and cellular biology	2009	83
19723656	1499	Hoshida Y	Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma.	Cancer research	2009	176
20227366	1499	Tauriello DV	Loss of the tumor suppressor CYLD enhances Wnt/beta-catenin signaling through K63-linked ubiquitination of Dvl.	Molecular cell	2010	46
20921458	1499	Ellison DW	Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables.	Journal of clinical oncology 	2011	63
21076461	1499	Geyer FC	Î²-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation.	Modern pathology 	2011	81
21245303	1499	Fiedler M	Dishevelled interacts with the DIX domain polymerization interface of Axin to interfere with its function in down-regulating Î²-catenin.	Proceedings of the National Academy of Sciences of the United States of America	2011	48
21324318	1499	Toffanin S	MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a.	Gastroenterology	2011	53
21521850	1499	Morikawa T	Association of CTNNB1 (beta-catenin) alterations, body mass index, and physical activity with survival in patients with colorectal cancer.	JAMA	2011	78
21531761	1499	Osada T	Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutations.	Cancer research	2011	54
21966251	1499	Nishida N	Genetic and epigenetic signatures in human hepatocellular carcinoma: a systematic review.	Current genomics	2011	40
22071650	1499	Sequist LV	Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice.	Annals of oncology 	2011	92
22080605	1499	SÃ¡nchez-TillÃ³ E	Î²-catenin/TCF4 complex induces the epithelial-to-mesenchymal transition (EMT)-activator ZEB1 to regulate tumor invasiveness.	Proceedings of the National Academy of Sciences of the United States of America	2011	96
22142829	1499	Shukla N	Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways.	Clinical cancer research 	2012	62
22158988	1499	Wu J	Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways.	Proceedings of the National Academy of Sciences of the United States of America	2011	120
22234612	1499	Biechele TL	Wnt/Î²-catenin signaling and AXIN1 regulate apoptosis triggered by inhibition of the mutant kinase BRAFV600E in human melanoma.	Science signaling	2012	50
22494971	1499	Jeong WJ	Ras stabilization through aberrant activation of Wnt/Î²-catenin signaling promotes intestinal tumorigenesis.	Science signaling	2012	32
22536370	1499	Lovly CM	Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials.	PloS one	2012	49
22538770	1499	Santarpia L	Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers.	Breast cancer research and treatment	2012	35
22653804	1499	McConechy MK	Use of mutation profiles to refine the classification of endometrial carcinomas.	The Journal of pathology	2012	45
22820256	1499	Pugh TJ	Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations.	Nature	2012	203
22975805	1499	Seo JS	The transcriptional landscape and mutational profile of lung adenocarcinoma.	Genome research	2012	139
23325582	1499	Peeters M	Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer.	Clinical cancer research 	2013	56
23337059	1499	Wangefjord S	Associations of beta-catenin alterations and MSI screening status with expression of key cell cycle regulating proteins and survival from colorectal cancer.	Diagnostic pathology	2013	27
23463346	1499	BeyoÄlu D	Tissue metabolomics of hepatocellular carcinoma: tumor energy metabolism and the role of transcriptomic classification.	Hepatology	2013	37
23636398	1499	Cancer Genome Atlas Research Network.	Integrated genomic characterization of endometrial carcinoma.	Nature	2013	552
23765252	1499	McConechy MK	Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles.	Modern pathology 	2014	25
23780408	1499	Bashashati A	Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling.	The Journal of pathology	2013	80
23788652	1499	Kan Z	Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma.	Genome research	2013	95
23887712	1499	Nault JC	High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions.	Nature communications	2013	82
23979959	1499	Nikiforova MN	Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer.	The Journal of clinical endocrinology and metabolism	2013	52
24413733	1499	Brastianos PK	Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas.	Nature genetics	2014	36
24429522	1499	Kode A	Leukaemogenesis induced by an activating Î²-catenin mutation in osteoblasts.	Nature	2014	80
24436047	1499	Shern JF	Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors.	Cancer discovery	2014	82
25248380	1499	Friemel J	Intratumor heterogeneity in hepatocellular carcinoma.	Clinical cancer research 	2015	28
25490274	1499	Juhlin CC	Whole-exome sequencing characterizes the landscape of somatic mutations and copy number alterations in adrenocortical carcinoma.	The Journal of clinical endocrinology and metabolism	2015	17
25720322	1499	Stelloo E	Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative.	Modern pathology 	2015	16
25901018	1499	Madan B	Targeting Wnts at the source--new mechanisms, new biomarkers, new drugs.	Molecular cancer therapeutics	2015	18
21067377	1788	Ley TJ	DNMT3A mutations in acute myeloid leukemia.	The New England journal of medicine	2010	433
21415852	1788	Walter MJ	Recurrent DNMT3A mutations in patients with myelodysplastic syndromes.	Leukemia	2011	136
21670448	1788	Thol F	Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia.	Journal of clinical oncology 	2011	77
21828135	1788	Jankowska AM	Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A.	Blood	2011	80
22077061	1788	Hou HA	DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications.	Blood	2012	42
22216861	1788	CouronnÃ© L	TET2 and DNMT3A mutations in human T-cell lymphoma.	The New England journal of medicine	2012	60
22291079	1788	Marcucci G	Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia.	Journal of clinical oncology 	2012	65
22490330	1788	Ribeiro AF	Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia.	Blood	2012	62
23341344	1788	Grossmann V	The molecular profile of adult T-cell acute lymphoblastic leukemia: mutations in RUNX1 and DNMT3A are associated with poor prognosis in T-ALL.	Genes, chromosomes and cancer	2013	31
23603912	1788	Neumann M	Whole-exome sequencing in adult ETP-ALL reveals a high rate of DNMT3A mutations.	Blood	2013	45
23632886	1788	Gaidzik VI	Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG).	Blood	2013	31
23704090	1788	KrÃ¶nke J	Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia.	Blood	2013	42
24142997	1788	Luthra R	Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring.	Haematologica	2014	30
24522528	1788	Shlush LI	Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia.	Nature	2014	220
24614070	1788	Tatton-Brown K	Mutations in the DNA methyltransferase gene DNMT3A cause an overgrowth syndrome with intellectual disability.	Nature genetics	2014	36
24699305	1788	Im AP	DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies.	Leukemia	2014	37
25092778	1788	Bejar R	Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation.	Journal of clinical oncology 	2014	40
25693834	1788	Yang L	DNMT3A in haematological malignancies.	Nature reviews. Cancer	2015	43
1557402	1956	Wong AJ	Structural alterations of the epidermal growth factor receptor gene in human gliomas.	Proceedings of the National Academy of Sciences of the United States of America	1992	188
2981413	1956	Libermann TA	Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin.	Nature	1985	263
3477813	1956	Wong AJ	Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification.	Proceedings of the National Academy of Sciences of the United States of America	1987	173
3798106	1956	Slamon DJ	Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.	Science	1987	1881
6328312	1956	Ullrich A	Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells.	Nature	1984	491
9006938	1956	Huang HS	The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling.	The Journal of biological chemistry	1997	162
10728703	1956	Frederick L	Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas.	Cancer research	2000	153
11504770	1956	Smith JS	PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme.	Journal of the National Cancer Institute	2001	100
14583498	1956	Shinojima N	Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme.	Cancer research	2003	158
14744244	1956	Holbro T	ErbB receptors: directing key signaling networks throughout life.	Annual review of pharmacology and toxicology	2004	147
15057284	1956	Qian X	E-cadherin-mediated adhesion inhibits ligand-dependent activation of diverse receptor tyrosine kinases.	The EMBO journal	2004	106
15118073	1956	Lynch TJ	Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.	The New England journal of medicine	2004	2246
15118125	1956	Paez JG	EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.	Science	2004	1965
15158434	1956	Roskoski R Jr	The ErbB/HER receptor protein-tyrosine kinases and cancer.	Biochemical and biophysical research communications	2004	70
15329413	1956	Pao W	EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.	Proceedings of the National Academy of Sciences of the United States of America	2004	999
15604253	1956	Kosaka T	Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.	Cancer research	2004	233
15623594	1956	Huang SF	High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan.	Clinical cancer research 	2004	78
15665299	1956	Amann J	Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer.	Cancer research	2005	98
15681531	1956	Marchetti A	EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment.	Journal of clinical oncology 	2005	149
15709185	1956	Tokumo M	The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers.	Clinical cancer research 	2005	94
15710947	1956	Han SW	Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib.	Journal of clinical oncology 	2005	135
15728811	1956	Kobayashi S	EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.	The New England journal of medicine	2005	832
15735034	1956	Stabile LP	Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects.	Cancer research	2005	82
15737014	1956	Pao W	Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.	PLoS medicine	2005	871
15738541	1956	Mitsudomi T	Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence.	Journal of clinical oncology 	2005	175
15741570	1956	Shigematsu H	Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers.	Journal of the National Cancer Institute	2005	439
15753357	1956	Shigematsu H	Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.	Cancer research	2005	142
15767641	1956	Pao W	Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions.	Journal of clinical oncology 	2005	94
15831234	1956	Giannini C	Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme.	Neuro-oncology	2005	158
15863375	1956	Moroni M	Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study.	The Lancet. Oncology	2005	197
15870435	1956	Cappuzzo F	Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.	Journal of the National Cancer Institute	2005	311
15886310	1956	JÃ¤nne PA	Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology.	Journal of clinical oncology 	2005	82
15920544	1956	Bhargava R	EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations.	Modern pathology 	2005	76
15956649	1956	Haas-Kogan DA	Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib.	Journal of the National Cancer Institute	2005	132
15994928	1956	Zhao X	Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis.	Cancer research	2005	120
15998907	1956	Takano T	Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer.	Journal of clinical oncology 	2005	139
16014883	1956	Tsao MS	Erlotinib in lung cancer - molecular and clinical predictors of outcome.	The New England journal of medicine	2005	312
16033833	1956	Lakhani SR	Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype.	Clinical cancer research 	2005	149
16049312	1956	Pan Q	Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas.	The Journal of molecular diagnostics 	2005	74
16061871	1956	Schilder RJ	Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study.	Clinical cancer research 	2005	66
16105816	1956	Nagai Y	Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp.	Cancer research	2005	91
16161046	1956	Hanawa M	EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus.	International journal of cancer	2006	67
16204011	1956	Bell DW	Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials.	Journal of clinical oncology 	2005	119
16230383	1956	Baird K	Gene expression profiling of human sarcomas: insights into sarcoma biology.	Cancer research	2005	85
16231326	1956	Shigematsu H	Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers.	International journal of cancer	2006	139
16282176	1956	Mellinghoff IK	Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.	The New England journal of medicine	2005	399
16322287	1956	Haura EB	Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer.	Clinical cancer research 	2005	70
16361555	1956	Yauch RL	Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients.	Clinical cancer research 	2005	161
16377102	1956	Normanno N	Epidermal growth factor receptor (EGFR) signaling in cancer.	Gene	2006	350
16467097	1956	Riely GJ	Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib.	Clinical cancer research 	2006	173
16533793	1956	Tam IY	Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features.	Clinical cancer research 	2006	112
16540667	1956	Alvarez JV	Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor.	Cancer research	2006	61
16549822	1956	Takeuchi T	Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors.	Journal of clinical oncology 	2006	64
16730237	1956	Ji H	The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies.	Cancer cell	2006	125
16740687	1956	Song L	Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival.	Cancer research	2006	73
16757721	1956	Carey LA	Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.	JAMA	2006	957
16785471	1956	Inoue A	Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations.	Journal of clinical oncology 	2006	116
16818686	1956	Jackman DM	Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.	Clinical cancer research 	2006	120
16818687	1956	Kimura H	Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer.	Clinical cancer research 	2006	67
16837691	1956	Zakowski MF	EGFR mutations in small-cell lung cancers in patients who have never smoked.	The New England journal of medicine	2006	65
16890793	1956	Mendelsohn J	Epidermal growth factor receptor targeting in cancer.	Seminars in oncology	2006	150
17020982	1956	Kosaka T	Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib.	Clinical cancer research 	2006	131
17047648	1956	Asahina H	A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations.	British journal of cancer	2006	67
17075123	1956	Hirsch FR	Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer.	Journal of clinical oncology 	2006	145
17085664	1956	Balak MN	Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.	Clinical cancer research 	2006	195
17126425	1956	McCubrey JA	Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance.	Biochimica et biophysica acta	2007	423
17189394	1956	Riely GJ	Update on epidermal growth factor receptor mutations in non-small cell lung cancer.	Clinical cancer research 	2006	99
17189395	1956	Ono M	Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs.	Clinical cancer research 	2006	79
17218988	1956	Kenny PA	Targeting TACE-dependent EGFR ligand shedding in breast cancer.	The Journal of clinical investigation	2007	72
17228019	1956	Jackman DM	Phase II clinical trial of chemotherapy-naive patients &amp;gt; or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer.	Journal of clinical oncology 	2007	82
17283074	1956	Hsu SC	Characterization of a novel tripartite nuclear localization sequence in the EGFR family.	The Journal of biological chemistry	2007	83
17290066	1956	Subramanian J	Lung cancer in never smokers: a review.	Journal of clinical oncology 	2007	141
17290067	1956	Sequist LV	Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer.	Journal of clinical oncology 	2007	144
17308052	1956	Buck E	Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition.	Molecular cancer therapeutics	2007	70
17317677	1956	Hirsch FR	Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib.	Annals of oncology 	2007	69
17332364	1956	Mulloy R	Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib.	Cancer research	2007	62
17404082	1956	Shaffer DR	Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer.	Clinical cancer research 	2007	98
17473659	1956	Wu YL	Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China.	Journal of thoracic oncology 	2007	58
17504988	1956	Massarelli E	KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.	Clinical cancer research 	2007	154
17538160	1956	Temam S	Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer.	Journal of clinical oncology 	2007	89
17664471	1956	Khambata-Ford S	Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.	Journal of clinical oncology 	2007	291
17785346	1956	Krex D	Long-term survival with glioblastoma multiforme.	Brain 	2007	171
17888036	1956	Mitsudomi T	Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer.	Cancer science	2007	121
17974918	1956	Okawa T	The functional interplay between EGFR overexpression, hTERT activation, and p53 mutation in esophageal epithelial cells with activation of stromal fibroblasts induces tumor development, invasion, and differentiation.	Genes and development	2007	65
18060032	1956	Gao SP	Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas.	The Journal of clinical investigation	2007	193
18093943	1956	Bean J	MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib.	Proceedings of the National Academy of Sciences of the United States of America	2007	446
18281673	1956	Eberhard DA	Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting.	Journal of clinical oncology 	2008	67
18283321	1956	Tamura K	Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403).	British journal of cancer	2008	54
18303429	1956	Marks JL	Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma.	Journal of thoracic oncology 	2008	71
18304967	1956	Weiss GJ	EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines.	Annals of oncology 	2008	74
18325048	1956	Taniguchi K	Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib.	Cancer science	2008	61
18339877	1956	Jhawer M	PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab.	Cancer research	2008	130
18349398	1956	Miller VA	Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib.	Journal of clinical oncology 	2008	66
18375904	1956	Kumar A	Structure and clinical relevance of the epidermal growth factor receptor in human cancer.	Journal of clinical oncology 	2008	58
18391747	1956	Motoi N	Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis.	The American journal of surgical pathology	2008	77
18408761	1956	Li D	BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models.	Oncogene	2008	267
18413800	1956	Godin-Heymann N	The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor.	Molecular cancer therapeutics	2008	58
18437168	1956	Ladanyi M	Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond.	Modern pathology 	2008	71
18458038	1956	Sequist LV	First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.	Journal of clinical oncology 	2008	233
18483355	1956	Engelman JA	Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.	Clinical cancer research 	2008	188
18509184	1956	Yang CH	Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy.	Journal of clinical oncology 	2008	56
18596266	1956	Maheswaran S	Detection of mutations in EGFR in circulating lung-cancer cells.	The New England journal of medicine	2008	402
18626007	1956	Zhu CQ	Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.	Journal of clinical oncology 	2008	160
18676761	1956	Wu JY	Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response.	Clinical cancer research 	2008	71
18794099	1956	Personeni N	Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study.	Clinical cancer research 	2008	51
18802721	1956	van Krieken JH	KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program.	Virchows Archiv 	2008	73
18927285	1956	Fichtner I	Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers.	Clinical cancer research 	2008	85
18948947	1956	Ding L	Somatic mutations affect key pathways in lung adenocarcinoma.	Nature	2008	865
18981003	1956	Costa DB	Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.	Clinical cancer research 	2008	54
19010870	1956	Bean J	Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma.	Clinical cancer research 	2008	77
19010912	1956	Pratilas CA	Genetic predictors of MEK dependence in non-small cell lung cancer.	Cancer research	2008	83
19010923	1956	Yano S	Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations.	Cancer research	2008	169
19088172	1956	Gow CH	Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer.	Annals of oncology 	2009	47
19096300	1956	Onozato R	Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers.	Journal of thoracic oncology 	2009	61
19170230	1956	Wong DW	The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS.	Cancer	2009	157
19188670	1956	Allegra CJ	American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy.	Journal of clinical oncology 	2009	311
19224850	1956	Inoue A	First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy.	Journal of clinical oncology 	2009	84
19234440	1956	Inamura K	EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset.	Modern pathology 	2009	103
19238632	1956	Tang Z	Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer.	British journal of cancer	2008	57
19252415	1956	Golding SE	Pro-survival AKT and ERK signaling from EGFR and mutant EGFRvIII enhances DNA double-strand break repair in human glioma cells.	Cancer biology and therapy	2009	49
19255323	1956	Cappuzzo F	Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients.	Journal of clinical oncology 	2009	114
19276259	1956	Yung TK	Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients.	Clinical cancer research 	2009	99
19351754	1956	Kuang Y	Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer.	Clinical cancer research 	2009	65
19366827	1956	Yu J	Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer.	Clinical cancer research 	2009	54
19412429	1956	Pillay V	The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases.	Neoplasia	2009	48
19414683	1956	Bai H	Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer.	Journal of clinical oncology 	2009	84
19447865	1956	Naumov GN	Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.	Clinical cancer research 	2009	55
19483740	1956	Linardou H	Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC.	Nature reviews. Clinical oncology	2009	57
19536109	1956	Walther A	Genetic prognostic and predictive markers in colorectal cancer.	Nature reviews. Cancer	2009	170
19549916	1956	Di Vizio D	Oncosome formation in prostate cancer: association with a region of frequent chromosomal deletion in metastatic disease.	Cancer research	2009	77
19584155	1956	Schmid K	EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases.	Clinical cancer research 	2009	66
19596646	1956	Anders CK	Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer.	Clinical breast cancer	2009	104
19632948	1956	Nguyen KS	Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.	Clinical lung cancer	2009	108
19636327	1956	Normanno N	Implications for KRAS status and EGFR-targeted therapies in metastatic CRC.	Nature reviews. Clinical oncology	2009	107
19667264	1956	Shaw AT	Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.	Journal of clinical oncology 	2009	383
19671762	1956	Liu TJ	NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas.	Molecular cancer therapeutics	2009	89
19671843	1956	Jackman DM	Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials.	Clinical cancer research 	2009	111
19680293	1956	Gazdar AF	Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors.	Oncogene	2009	163
19690143	1956	Lu KV	Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients.	Cancer research	2009	55
19692680	1956	Mok TS	Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.	The New England journal of medicine	2009	1545
19692684	1956	Rosell R	Screening for epidermal growth factor receptor mutations in lung cancer.	The New England journal of medicine	2009	452
19723643	1956	Krishnaswamy S	Ethnic differences and functional analysis of MET mutations in lung cancer.	Clinical cancer research 	2009	55
19738166	1956	Siena S	Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer.	Journal of the National Cancer Institute	2009	144
19806185	1956	Sartore-Bianchi A	Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer.	PloS one	2009	85
19825799	1956	Sampson JH	An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme.	Molecular cancer therapeutics	2009	75
19826477	1956	Soh J	Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells.	PloS one	2009	66
19884556	1956	Laurent-Puig P	Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.	Journal of clinical oncology 	2009	189
19917871	1956	Azzoli CG	American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer.	Journal of clinical oncology 	2009	139
19920198	1956	Gravendeel LA	Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology.	Cancer research	2009	128
19942479	1956	Folprecht G	Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.	The Lancet. Oncology	2010	131
19949011	1956	Jackman D	Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.	Journal of clinical oncology 	2010	156
20022809	1956	Mitsudomi T	Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.	The Lancet. Oncology	2010	783
20028749	1956	Dahabreh IJ	Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer.	Clinical cancer research 	2010	44
20038723	1956	Douillard JY	Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial.	Journal of clinical oncology 	2010	141
20065189	1956	Wells SA Jr	Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.	Journal of clinical oncology 	2010	95
20100958	1956	Khambata-Ford S	Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer.	Journal of clinical oncology 	2010	63
20100961	1956	Bardelli A	Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer.	Journal of clinical oncology 	2010	160
20103678	1956	Baldus SE	Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases.	Clinical cancer research 	2010	109
20108024	1956	Suda K	Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation.	Cancer metastasis reviews	2010	44
20118985	1956	Ercan D	Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor.	Oncogene	2010	63
20124471	1956	McDermott U	Acquired resistance of non-small cell lung cancer cells to MET kinase inhibition is mediated by a switch to epidermal growth factor receptor dependency.	Cancer research	2010	51
20129249	1956	Turke AB	Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.	Cancer cell	2010	279
20146086	1956	Clarke JL	High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer.	Journal of neuro-oncology	2010	50
20183914	1956	Takahashi T	Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene.	Annals of surgical oncology	2010	80
20351699	1956	Harris TJ	The molecular pathology of cancer.	Nature reviews. Clinical oncology	2010	57
20399983	1956	Tol J	Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.	Clinical therapeutics	2010	50
20431034	1956	Tsiatis AC	Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications.	The Journal of molecular diagnostics 	2010	105
20479403	1956	Sequist LV	Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer.	Journal of clinical oncology 	2010	96
20493771	1956	Cappuzzo F	Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.	The Lancet. Oncology	2010	278
20495549	1956	Singh M	Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models.	Nature biotechnology	2010	91
20530271	1956	Lubner SJ	Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study.	Journal of clinical oncology 	2010	55
20551945	1956	Janku F	Targeted therapy in non-small-cell lung cancer--is it becoming a reality?	Nature reviews. Clinical oncology	2010	61
20573926	1956	Maemondo M	Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.	The New England journal of medicine	2010	979
20595147	1956	Porta R	Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation.	The European respiratory journal	2011	60
20624322	1956	Zhang X	Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression.	Molecular cancer	2010	79
20627894	1956	Eichler AF	EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer.	Neuro-oncology	2010	48
20679611	1956	Yap TA	Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors.	Journal of clinical oncology 	2010	77
20824720	1956	da Cunha Santos G	Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3.	Cancer	2010	42
20838621	1956	Punnoose EA	Molecular biomarker analyses using circulating tumor cells.	PloS one	2010	78
20855820	1956	Johnson FM	Phase II study of dasatinib in patients with advanced non-small-cell lung cancer.	Journal of clinical oncology 	2010	53
20855837	1956	Sun Y	Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.	Journal of clinical oncology 	2010	93
20864632	1956	Attolini CS	A mathematical framework to determine the temporal sequence of somatic genetic events in cancer.	Proceedings of the National Academy of Sciences of the United States of America	2010	47
20871269	1956	Pirker R	Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop.	Journal of thoracic oncology 	2010	57
20887192	1956	da Cunha Santos G	EGFR mutations and lung cancer.	Annual review of pathology	2011	65
20921459	1956	Sampson JH	Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.	Journal of clinical oncology 	2010	184
20921461	1956	Roberts PJ	Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?	Journal of clinical oncology 	2010	77
20921462	1956	Peeters M	Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.	Journal of clinical oncology 	2010	181
20921465	1956	Douillard JY	Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.	Journal of clinical oncology 	2010	342
20940188	1956	Sequist LV	Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer.	Journal of clinical oncology 	2010	100
20966921	1956	Pao W	Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer.	Nature reviews. Cancer	2010	237
21030498	1956	Heon S	Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib.	Clinical cancer research 	2010	44
21062932	1956	Camidge DR	Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment.	Clinical cancer research 	2010	75
21062933	1956	Suda K	Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer.	Clinical cancer research 	2010	47
21081655	1956	John T	The ability to form primary tumor xenografts is predictive of increased risk of disease recurrence in early-stage non-small cell lung cancer.	Clinical cancer research 	2011	38
21135146	1956	Oxnard GR	Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation.	Clinical cancer research 	2011	102
21163703	1956	De Roock W	KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer.	The Lancet. Oncology	2011	125
21168239	1956	Chung JH	Clinical and molecular evidences of epithelial to mesenchymal transition in acquired resistance to EGFR-TKIs.	Lung cancer	2011	39
21200037	1956	Dahabreh IJ	Systematic review: Anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer.	Annals of internal medicine	2011	47
21220471	1956	JÃ¤nne PA	Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors.	Clinical cancer research 	2011	39
21220474	1956	Donev IS	Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer.	Clinical cancer research 	2011	37
21233402	1956	Rosell R	Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations.	Clinical cancer research 	2011	78
21248300	1956	Arcila ME	Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay.	Clinical cancer research 	2011	120
21248303	1956	Janjigian YY	Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib.	Clinical cancer research 	2011	45
21258250	1956	Ludovini V	Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.	Journal of thoracic oncology 	2011	44
21258415	1956	Normant E	The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models.	Oncogene	2011	46
21266349	1956	Liccardi G	EGFR nuclear translocation modulates DNA repair following cisplatin and ionizing radiation treatment.	Cancer research	2011	65
21266357	1956	Qi J	Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors.	Cancer research	2011	49
21277552	1956	Pao W	New driver mutations in non-small-cell lung cancer.	The Lancet. Oncology	2011	244
21289483	1956	Cho WC	MiR-145 inhibits cell proliferation of human lung adenocarcinoma by targeting EGFR and NUDT1.	RNA biology	2011	53
21303969	1956	Ramalingam SS	Lung cancer: New biological insights and recent therapeutic advances.	CA	2011	87
21408138	1956	van Eijk R	Rapid KRAS, EGFR, BRAF and PIK3CA mutation analysis of fine needle aspirates from non-small-cell lung cancer using allele-specific qPCR.	PloS one	2011	43
21422426	1956	Zander T	Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using (18)Ffluorodeoxyglucose and (18)Ffluorothymidine positron emission tomography.	Journal of clinical oncology 	2011	37
21430269	1956	Sequist LV	Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.	Science translational medicine	2011	619
21430781	1956	Bivona TG	FAS and NF-ÎºB signalling modulate dependence of lung cancers on mutant EGFR.	Nature	2011	99
21482987	1956	D'Angelo SP	Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas.	Journal of clinical oncology 	2011	59
21482992	1956	Keedy VL	American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy.	Journal of clinical oncology 	2011	117
21483012	1956	Paik PK	Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations.	Journal of clinical oncology 	2011	115
21502544	1956	Van Cutsem E	Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.	Journal of clinical oncology 	2011	350
21531810	1956	Wu JY	Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer.	Clinical cancer research 	2011	85
21597390	1956	Suda K	Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib.	Journal of thoracic oncology 	2011	69
21641636	1956	Maughan TS	Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.	Lancet	2011	199
21646616	1956	Price TJ	Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer.	Journal of clinical oncology 	2011	58
21670455	1956	Fukuoka M	Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).	Journal of clinical oncology 	2011	294
21687663	1956	Li N	Inhibition of cell proliferation by an anti-EGFR aptamer.	PloS one	2011	41
21720997	1956	Kim HR	Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.	Cancer	2012	33
21730270	1956	Yatabe Y	Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma.	Journal of clinical oncology 	2011	46
21734175	1956	Chmielecki J	Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling.	Science translational medicine	2011	156
21764376	1956	Yasuda H	EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications.	The Lancet. Oncology	2012	79
21768463	1956	Sequist LV	Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer.	Journal of clinical oncology 	2011	120
21775534	1956	Oxnard GR	New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer.	Clinical cancer research 	2011	83
21783417	1956	Zhou C	Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.	The Lancet. Oncology	2011	709
21788562	1956	Zhou Q	Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer.	Journal of clinical oncology 	2011	61
21791641	1956	Sasaki T	A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors.	Cancer research	2011	157
21856766	1956	Chaft JE	Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design.	Clinical cancer research 	2011	90
21865399	1956	Grommes C	"Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer.	Neuro-oncology	2011	57
21900837	1956	Goto K	Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer.	Journal of thoracic oncology 	2012	51
21969500	1956	Brugger W	Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.	Journal of clinical oncology 	2011	68
21976538	1956	Taniguchi K	Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas.	Clinical cancer research 	2011	75
22025148	1956	Lai A	Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin.	Journal of clinical oncology 	2011	91
22025157	1956	Ramalingam SS	Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer.	Journal of clinical oncology 	2011	59
22042947	1956	Lennerz JK	MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib.	Journal of clinical oncology 	2011	116
22052230	1956	Yano S	Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort.	Journal of thoracic oncology 	2011	47
22054879	1956	Travis WD	Pathology of lung cancer.	Clinics in chest medicine	2011	59
22119437	1956	Soria JC	EGFR-mutated oncogene-addicted non-small cell lung cancer: current trends and future prospects.	Cancer treatment reviews	2012	35
22135231	1956	Chaft JE	Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling.	Molecular cancer therapeutics	2012	55
22137795	1956	Snuderl M	Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma.	Cancer cell	2011	184
22139077	1956	Bonavia R	EGFRvIII promotes glioma angiogenesis and growth through the NF-ÎºB, interleukin-8 pathway.	Oncogene	2012	52
22140546	1956	Li C	Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers.	PloS one	2011	54
22144946	1956	Karar J	PI3K/AKT/mTOR Pathway in Angiogenesis.	Frontiers in molecular neuroscience	2011	107
22178589	1956	Andersen JB	Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors.	Gastroenterology	2012	76
22186794	1956	Parato KA	The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers.	Molecular therapy 	2012	47
22189713	1956	Deng XS	Metformin targets Stat3 to inhibit cell growth and induce apoptosis in triple-negative breast cancers.	Cell cycle	2012	48
22194472	1956	Ju YS	A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing.	Genome research	2012	122
22209049	1956	O'Flaherty JD	Circulating tumour cells, their role in metastasis and their clinical utility in lung cancer.	Lung cancer	2012	44
22215752	1956	Su KY	Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer.	Journal of clinical oncology 	2012	111
22228640	1956	Rekhtman N	Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations.	Clinical cancer research 	2012	73
22228822	1956	Kim Y	The EGFR T790M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor.	Molecular cancer therapeutics	2012	34
22235099	1956	Doebele RC	Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.	Clinical cancer research 	2012	213
22237264	1956	Sun PL	High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features.	Journal of thoracic oncology 	2012	34
22270724	1956	Montagut C	Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer.	Nature medicine	2012	100
22277784	1956	Katayama R	Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.	Science translational medicine	2012	268
22282022	1956	Doebele RC	Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer.	Cancer	2012	48
22282308	1956	Cheng L	Molecular pathology of lung cancer: key to personalized medicine.	Modern pathology 	2012	41
22285168	1956	Rosell R	Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.	The Lancet. Oncology	2012	876
22315472	1956	Deng N	A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets.	Gut	2012	127
22317764	1956	Zhang Y	Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis.	Clinical cancer research 	2012	46
22407829	1956	Perez-Moreno P	Squamous cell carcinoma of the lung: molecular subtypes and therapeutic opportunities.	Clinical cancer research 	2012	48
22440336	1956	Scagliotti GV	Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer.	Clinical lung cancer	2012	44
22448344	1956	Corcoran RB	EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.	Cancer discovery	2012	179
22452803	1956	Fokas E	NVP-BEZ235 and NVP-BGT226, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors, enhance tumor and endothelial cell radiosensitivity.	Radiation oncology	2012	30
22452895	1956	Yang JC	Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial.	The Lancet. Oncology	2012	76
22464348	1956	Couraud S	Lung cancer in never smokers--a review.	European journal of cancer	2012	51
22492982	1956	Punnoose EA	Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib.	Clinical cancer research 	2012	75
22505743	1956	Navani N	Suitability of endobronchial ultrasound-guided transbronchial needle aspiration specimens for subtyping and genotyping of non-small cell lung cancer: a multicenter study of 774 patients.	American journal of respiratory and critical care medicine	2012	53
22547605	1956	JÃ¤nne PA	Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial.	Journal of clinical oncology 	2012	75
22552284	1956	Turke AB	MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors.	Cancer research	2012	72
22588883	1956	Vivanco I	Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors.	Cancer discovery	2012	73
22590557	1956	Wilkerson MD	Differential pathogenesis of lung adenocarcinoma subtypes involving sequence mutations, copy number, chromosomal instability, and methylation.	PloS one	2012	45
22649089	1956	Forshew T	Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA.	Science translational medicine	2012	209
22673630	1956	Chen ZY	EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomas.	The oncologist	2012	36
22677429	1956	Park SJ	Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation.	Lung cancer	2012	50
22722830	1956	Misale S	Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer.	Nature	2012	333
22722843	1956	Diaz LA Jr	The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers.	Nature	2012	379
22751098	1956	Zhang Z	Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer.	Nature genetics	2012	263
22768234	1956	An SJ	Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status.	PloS one	2012	50
22773810	1956	Ohashi K	Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1.	Proceedings of the National Academy of Sciences of the United States of America	2012	121
22778317	1956	Gridelli C	First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial.	Journal of clinical oncology 	2012	54
22797485	1956	Zhao X	Comparison of epidermal growth factor receptor mutation statuses in tissue and plasma in stage I-IV non-small cell lung cancer patients.	Respiration; international review of thoracic diseases	2013	30
22806307	1956	Togashi Y	Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer.	Cancer chemotherapy and pharmacology	2012	34
22810899	1956	Johnson ML	Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas.	Cancer	2013	32
22826274	1956	Bai H	Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer.	Journal of clinical oncology 	2012	60
22891331	1956	Fenton TR	Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240.	Proceedings of the National Academy of Sciences of the United States of America	2012	32
22956860	1956	Creighton CJ	The molecular profile of luminal B breast cancer.	Biologics 	2012	45
22961667	1956	Ercan D	Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.	Cancer discovery	2012	77
22964225	1956	Johnson H	Molecular characterization of EGFR and EGFRvIII signaling networks in human glioblastoma tumor xenografts.	Molecular and cellular proteomics 	2012	30
22967997	1956	Inoue A	Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naÃ¯ve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002).	Annals of oncology 	2013	73
23000897	1956	Cancer Genome Atlas Network.	Comprehensive molecular portraits of human breast tumours.	Nature	2012	2327
23012302	1956	AndrÃ© F	Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents.	Annals of oncology 	2012	58
23014527	1956	Dogan S	Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers.	Clinical cancer research 	2012	74
23021375	1956	Berg M	EGFR and downstream genetic alterations in KRAS/BRAF and PI3K/AKT pathways in colorectal cancer: implications for targeted therapy.	Discovery medicine	2012	32
23079155	1956	Yang JJ	Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer.	Lung cancer	2013	33
23091115	1956	Byers LA	An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance.	Clinical cancer research 	2013	176
23103856	1956	Young A	Oncogenic and wild-type Ras play divergent roles in the regulation of mitogen-activated protein kinase signaling.	Cancer discovery	2013	48
23123196	1956	Yang W	EGFR-induced and PKCÎµ monoubiquitylation-dependent NF-ÎºB activation upregulates PKM2 expression and promotes tumorigenesis.	Molecular cell	2012	55
23129122	1956	Wu YL	Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803).	Annals of oncology 	2013	36
23136247	1956	Gasch C	Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer.	Clinical chemistry	2013	55
23154552	1956	Weickhardt AJ	Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer.	Journal of thoracic oncology 	2012	80
23154553	1956	D'Angelo SP	Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib.	Journal of thoracic oncology 	2012	36
23172555	1956	Ellison G	EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples.	Journal of clinical pathology	2013	49
23233388	1956	Mostert B	KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue.	International journal of cancer	2013	30
23242438	1956	Yoshizawa A	Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients.	Journal of thoracic oncology 	2013	67
23242808	1956	Girotti MR	Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma.	Cancer discovery	2013	99
23265711	1956	Licitra L	Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies.	European journal of cancer	2013	27
23332287	1956	Gadgeel SM	Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer.	Clinical lung cancer	2013	29
23341526	1956	Welsh JW	Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer.	Journal of clinical oncology 	2013	71
23341890	1956	Li Y	Clinical significance of EML4-ALK fusion gene and association with EGFR and KRAS gene mutations in 208 Chinese patients with non-small cell lung cancer.	PloS one	2013	41
23344264	1956	Yeh P	DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): a catalog of clinically relevant cancer mutations to enable genome-directed anticancer therapy.	Clinical cancer research 	2013	35
23362162	1956	Tuononen K	Comparison of targeted next-generation sequencing (NGS) and real-time PCR in the detection of EGFR, KRAS, and BRAF mutations on formalin-fixed, paraffin-embedded tumor material of non-small cell lung carcinoma-superiority of NGS.	Genes, chromosomes and cancer	2013	34
23370315	1956	Hirsch FR	Epidermal growth factor receptor inhibition in lung cancer: status 2012.	Journal of thoracic oncology 	2013	26
23391413	1956	Voss JS	Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions.	Human pathology	2013	38
23401440	1956	Roberts PJ	KRAS mutation: should we test for it, and does it matter?	Journal of clinical oncology 	2013	54
23401448	1956	Mok T	Treating patients with EGFR-sensitizing mutations: first line or second line--is there a difference?	Journal of clinical oncology 	2013	27
23401451	1956	Ohashi K	Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease.	Journal of clinical oncology 	2013	103
23401452	1956	Laurie SA	Role of epidermal growth factor receptor inhibitors in epidermal growth factor receptor wild-type non-small-cell lung cancer.	Journal of clinical oncology 	2013	29
23404247	1956	Valtorta E	KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy.	International journal of cancer	2013	34
23407558	1956	Yu HA	Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors.	Journal of thoracic oncology 	2013	48
23470965	1956	Yu HA	Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.	Clinical cancer research 	2013	251
23486266	1956	Russell PA	Correlation of mutation status and survival with predominant histologic subtype according to the new IASLC/ATS/ERS lung adenocarcinoma classification in stage III (N2) patients.	Journal of thoracic oncology 	2013	29
23552377	1956	Lindeman NI	Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.	Journal of thoracic oncology 	2013	124
23553849	1956	Socinski MA	A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer.	Clinical cancer research 	2013	70
23562183	1956	Lindeman NI	Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.	The Journal of molecular diagnostics 	2013	60
23563269	1956	Murtaza M	Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA.	Nature	2013	259
23584090	1956	De Sousa E Melo F	Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions.	Nature medicine	2013	132
23589544	1956	Buettner R	Lessons learned from lung cancer genomics: the emerging concept of individualized diagnostics and treatment.	Journal of clinical oncology 	2013	33
23594426	1956	Lee CK	Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis.	Journal of the National Cancer Institute	2013	98
23676460	1956	Banck MS	The genomic landscape of small intestine neuroendocrine tumors.	The Journal of clinical investigation	2013	36
23707073	1956	Babic I	EGFR mutation-induced alternative splicing of Max contributes to growth of glycolytic tumors in brain cancer.	Cell metabolism	2013	30
23723294	1956	Dearden S	Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap).	Annals of oncology 	2013	58
23729361	1956	Gainor JF	ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer.	Clinical cancer research 	2013	85
23768755	1956	Roengvoraphoj M	Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients.	Cancer treatment reviews	2013	25
23777544	1956	Gan HK	The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered.	The FEBS journal	2013	46
23814043	1956	Gainor JF	Novel targets in non-small cell lung cancer: ROS1 and RET fusions.	The oncologist	2013	35
23816960	1956	Sequist LV	Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.	Journal of clinical oncology 	2013	383
23816963	1956	Katakami N	LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both.	Journal of clinical oncology 	2013	63
23816967	1956	Yang JC	Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations.	Journal of clinical oncology 	2013	49
23829935	1956	Remon J	Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: a new era begins.	Cancer treatment reviews	2014	22
23833300	1956	Cardarella S	Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer.	Clinical cancer research 	2013	34
23852704	1956	Duffy MJ	Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update.	International journal of cancer	2014	26
23883922	1956	Garassino MC	Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.	The Lancet. Oncology	2013	116
23888061	1956	Liu X	The diagnostic accuracy of pleural effusion and plasma samples versus tumour tissue for detection of EGFR mutation in patients with advanced non-small cell lung cancer: comparison of methodologies.	Journal of clinical pathology	2013	29
23891509	1956	Tsuta K	The utility of the proposed IASLC/ATS/ERS lung adenocarcinoma subtypes for disease prognosis and correlation of driver gene alterations.	Lung cancer	2013	35
23894143	1956	Li R	Niclosamide overcomes acquired resistance to erlotinib through suppression of STAT3 in non-small cell lung cancer.	Molecular cancer therapeutics	2013	32
23931927	1956	Gridelli C	ALK inhibitors in the treatment of advanced NSCLC.	Cancer treatment reviews	2014	34
23948351	1956	Shi Y	Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial.	The Lancet. Oncology	2013	73
23953842	1956	Yewale C	Epidermal growth factor receptor targeting in cancer: a review of trends and strategies.	Biomaterials	2013	44
23972815	1956	Rosell R	Genetics and biomarkers in personalisation of lung cancer treatment.	Lancet	2013	60
23980091	1956	Goss GD	Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study.	Journal of clinical oncology 	2013	40
24021541	1956	Iuchi T	Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma.	Lung cancer	2013	31
24034250	1956	Wei Y	EGFR-mediated Beclin 1 phosphorylation in autophagy suppression, tumor progression, and tumor chemoresistance.	Cell	2013	104
24065147	1956	Niederst MJ	Bypass mechanisms of resistance to receptor tyrosine kinase inhibition in lung cancer.	Science signaling	2013	53
24065731	1956	Walter AO	Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.	Cancer discovery	2013	122
24072220	1956	Goldberg SB	Chemotherapy with Erlotinib or chemotherapy alone in advanced non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitors.	The oncologist	2013	37
24098024	1956	Pichler M	miR-181a is associated with poor clinical outcome in patients with colorectal cancer treated with EGFR inhibitor.	Journal of clinical pathology	2014	26
24105277	1956	Hata A	Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor: Comparison between T790M mutation-positive and mutation-negative populations.	Cancer	2013	38
24135280	1956	Fan QW	EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma.	Cancer cell	2013	50
24141978	1956	Zhang L	A subset of gastric cancers with EGFR amplification and overexpression respond to cetuximab therapy.	Scientific reports	2013	28
24199682	1956	Yamaguchi N	Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer.	Lung cancer	2014	23
24202392	1956	Chong CR	The quest to overcome resistance to EGFR-targeted therapies in cancer.	Nature medicine	2013	168
24236184	1956	Scarpa A	Molecular typing of lung adenocarcinoma on cytological samples using a multigene next generation sequencing panel.	PloS one	2013	28
24263064	1956	Douillard JY	First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study.	British journal of cancer	2014	33
24269963	1956	Roskoski R Jr	The ErbB/HER family of protein-tyrosine kinases and cancer.	Pharmacological research	2014	122
24310612	1956	Nathanson DA	Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA.	Science	2014	70
24353160	1956	Yasuda H	Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.	Science translational medicine	2013	45
24366937	1956	Vergote IB	Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study.	Journal of clinical oncology 	2014	23
24378644	1956	Siegelin MD	Epidermal growth factor receptor mutations in lung adenocarcinoma.	Laboratory investigation; a journal of technical methods and pathology	2014	40
24384534	1956	Maroun CR	The Met receptor tyrosine kinase: a key player in oncogenesis and drug resistance.	Pharmacology and therapeutics	2014	31
24406864	1956	Park HS	High EGFR gene copy number predicts poor outcome in triple-negative breast cancer.	Modern pathology 	2014	33
24419411	1956	Shi Y	A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER).	Journal of thoracic oncology 	2014	113
24429876	1956	Oxnard GR	Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA.	Clinical cancer research 	2014	111
24439929	1956	Wu YL	Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.	The Lancet. Oncology	2014	223
24443522	1956	Yang JJ	Lung cancers with concomitant EGFR mutations and ALK rearrangements: diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylation.	Clinical cancer research 	2014	29
24458568	1956	Suda K	The insulin-like growth factor 1 receptor causes acquired resistance to erlotinib in lung cancer cells with the wild-type epidermal growth factor receptor.	International journal of cancer	2014	22
24478319	1956	Yu HA	Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing.	Annals of oncology 	2014	23
24501009	1956	Reckamp KL	A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib.	Cancer	2014	23
24513263	1956	Vanderlaan PA	Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer.	Lung cancer	2014	20
24533047	1956	Liang W	Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations.	PloS one	2014	21
24550739	1956	Borad MJ	Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma.	PLoS genetics	2014	55
24656976	1956	Yan M	HER2 aberrations in cancer: implications for therapy.	Cancer treatment reviews	2014	40
24666267	1956	Therkildsen C	The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.	Acta oncologica	2014	56
24670642	1956	Sun C	Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.	Nature	2014	139
24685132	1956	Sun C	Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3.	Cell reports	2014	43
24687833	1956	Schwartzberg LS	PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer.	Journal of clinical oncology 	2014	99
24687921	1956	Koeppen H	Biomarker analyses from a placebo-controlled phase II study evaluating erlotinibÂ±onartuzumab in advanced non-small cell lung cancer: MET expression levels are predictive of patient benefit.	Clinical cancer research 	2014	26
24715074	1956	Lee JK	Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis.	JAMA	2014	27
24743704	1956	Li S	Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts.	British journal of cancer	2014	25
24773774	1956	Weber B	Detection of EGFR mutations in plasma and biopsies from non-small cell lung cancer patients by allele-specific PCR assays.	BMC cancer	2014	25
24841974	1956	Kawaguchi T	Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA).	Journal of clinical oncology 	2014	53
24846037	1956	Kris MG	Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.	JAMA	2014	182
24857124	1956	Gerber DE	Management and future directions in non-small cell lung cancer with known activating mutations.	American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Meeting	2014	23
24868098	1956	Khozin S	U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations.	The oncologist	2014	20
24893891	1956	Cross DA	AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.	Cancer discovery	2014	170
24919569	1956	Van Cutsem E	Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer.	Clinical cancer research 	2014	22
24919575	1956	Yoshida T	Tyrosine phosphoproteomics identifies both codrivers and cotargeting strategies for T790M-related EGFR-TKI resistance in non-small cell lung cancer.	Clinical cancer research 	2014	20
24939055	1956	Qu Y	Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models.	Journal of experimental and clinical cancer research 	2014	22
25009014	1956	Azuma K	Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer.	Annals of oncology 	2014	66
25013125	1956	Couraud S	Noninvasive diagnosis of actionable mutations by deep sequencing of circulating free DNA in lung cancer from never-smokers: a proof-of-concept study from BioCAST/IFCT-1002.	Clinical cancer research 	2014	40
25031274	1956	Lee SM	Randomized trial of erlotinib plus whole-brain radiotherapy for NSCLC patients with multiple brain metastases.	Journal of the National Cancer Institute	2014	22
25057166	1956	Missiaglia E	Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features.	Annals of oncology 	2014	38
25074459	1956	Janjigian YY	Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations.	Cancer discovery	2014	69
25079552	1956	Cancer Genome Atlas Research Network.	Comprehensive molecular profiling of lung adenocarcinoma.	Nature	2014	567
25080476	1956	MÃ¼ller C	Hematogenous dissemination of glioblastoma multiforme.	Science translational medicine	2014	27
25103305	1956	Sorensen BS	Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib.	Cancer	2014	32
25115304	1956	Sorich MJ	Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials.	Annals of oncology 	2015	68
25122430	1956	Douillard JY	Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status.	Journal of thoracic oncology 	2014	62
25137181	1956	Marchetti A	Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: toward a real-time liquid biopsy for treatment.	PloS one	2014	33
25150284	1956	LabussiÃ¨re M	Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes.	Neurology	2014	29
25164765	1956	Brannon AR	Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions.	Genome biology	2014	54
25175099	1956	Seto T	Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.	The Lancet. Oncology	2014	67
25193862	1956	Wilson C	Overcoming EMT-associated resistance to anti-cancer drugs via Src/FAK pathway inhibition.	Oncotarget	2014	28
25222496	1956	Zhang Y	Patients with exon 19 deletion were associated with longer progression-free survival compared to those with L858R mutation after first-line EGFR-TKIs for advanced non-small cell lung cancer: a meta-analysis.	PloS one	2014	27
25247337	1956	Hoffknecht P	Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease.	Journal of thoracic oncology 	2015	25
25248381	1956	Laurent-Puig P	Clinical relevance of KRAS-mutated subclones detected with picodroplet digital PCR in advanced colorectal cancer treated with anti-EGFR therapy.	Clinical cancer research 	2015	30
25271963	1956	Finlay MR	Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor.	Journal of medicinal chemistry	2014	27
25311215	1956	Leighl NB	Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cancer/association for molecular pathology guideline.	Journal of clinical oncology 	2014	42
25339418	1956	Qiu M	Circulating tumor DNA is effective for the detection of EGFR mutation in non-small cell lung cancer: a meta-analysis.	Cancer epidemiology, biomarkers and prevention 	2015	30
25345567	1956	Hagemann IS	Clinical next-generation sequencing in patients with non-small cell lung cancer.	Cancer	2015	29
25349291	1956	Iyengar P	Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer.	Journal of clinical oncology 	2014	23
25394791	1956	Crystal AS	Patient-derived models of acquired resistance can identify effective drug combinations for cancer.	Science	2014	120
25405807	1956	Wang Z	Quantification and dynamic monitoring of EGFR T790M in plasma cell-free DNA by digital PCR for prognosis of EGFR-TKI treatment in advanced NSCLC.	PloS one	2014	31
25444907	1956	Hao C	Gene mutations in primary tumors and corresponding patient-derived xenografts derived from non-small cell lung cancer.	Cancer letters	2015	18
25468223	1956	Cohen AL	Glioma biology and molecular markers.	Cancer treatment and research	2015	26
25567908	1956	Drilon A	Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches.	Clinical cancer research 	2015	30
25586468	1956	Schuster J	A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study.	Neuro-oncology	2015	54
25589191	1956	Yang JC	Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.	The Lancet. Oncology	2015	173
25593032	1956	Linnekamp JF	Colorectal cancer heterogeneity and targeted therapy: a case for molecular disease subtypes.	Cancer research	2015	21
25593300	1956	Cani AK	Next-Gen Sequencing Exposes Frequent MED12 Mutations and Actionable Therapeutic Targets in Phyllodes Tumors.	Molecular cancer research 	2015	18
25605843	1956	Van Cutsem E	Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer.	Journal of clinical oncology 	2015	74
25623215	1956	Arena S	Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer.	Clinical cancer research 	2015	24
25628445	1956	Morelli MP	Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment.	Annals of oncology 	2015	22
25629635	1956	Wu C	High Discrepancy of Driver Mutations in Patients with NSCLC and Synchronous Multiple Lung Ground-Glass Nodules.	Journal of thoracic oncology 	2015	16
25639985	1956	Mao C	Concordant analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression between primary colorectal cancer and matched metastases.	Scientific reports	2015	19
25649416	1956	Stahl P	Heterogeneity of amplification of HER2, EGFR, CCND1 and MYC in gastric cancer.	BMC gastroenterology	2015	17
25667274	1956	Lopez-Chavez A	Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial.	Journal of clinical oncology 	2015	33
25673558	1956	Pietrantonio F	Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis.	European journal of cancer	2015	37
25673644	1956	Ahronian LG	Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.	Cancer discovery	2015	46
25689095	1956	Kumarakulasinghe NB	Molecular targeted therapy in the treatment of advanced stage non-small cell lung cancer (NSCLC).	Respirology	2015	16
25738220	1956	Sholl LM	Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience.	Journal of thoracic oncology 	2015	37
25758528	1956	Niederst MJ	RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer.	Nature communications	2015	45
25769900	1956	Zhu G	Highly Sensitive Droplet Digital PCR Method for Detection of EGFR-Activating Mutations in Plasma Cell-Free DNA from Patients with Advanced Non-Small Cell Lung Cancer.	The Journal of molecular diagnostics 	2015	22
25807554	1956	Tang MC	Chloroquine enhances gefitinib cytotoxicity in gefitinib-resistant nonsmall cell lung cancer cells.	PloS one	2015	15
25829397	1956	Mok T	Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy.	Clinical cancer research 	2015	43
25870145	1956	Eberlein CA	Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.	Cancer research	2015	30
25882755	1956	Watanabe M	Ultra-Sensitive Detection of the Pretreatment EGFR T790M Mutation in Non-Small Cell Lung Cancer Patients with an EGFR-Activating Mutation Using Droplet Digital PCR.	Clinical cancer research 	2015	37
25895031	1956	Tang Y	The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs.	Oncotarget	2015	32
25897154	1956	Lee CK	Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis.	Journal of clinical oncology 	2015	32
25923549	1956	JÃ¤nne PA	AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.	The New England journal of medicine	2015	228
25923550	1956	Sequist LV	Rociletinib in EGFR-mutated non-small-cell lung cancer.	The New England journal of medicine	2015	125
25934077	1956	Piotrowska Z	Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor.	Cancer discovery	2015	55
25943888	1956	Aldape K	Glioblastoma: pathology, molecular mechanisms and markers.	Acta neuropathologica	2015	25
25956936	1956	Rizzo S	CT Radiogenomic Characterization of EGFR, K-RAS, and ALK Mutations in Non-Small Cell Lung Cancer.	European radiology	2016	12
25964297	1956	Niederst MJ	The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.	Clinical cancer research 	2015	41
25989278	1956	Rowland A	Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer.	British journal of cancer	2015	21
26014294	1956	Zhou C	BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer.	Journal of clinical oncology 	2015	26
26024796	1956	Cooper WA	PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma.	Lung cancer	2015	29
26030179	1956	Siravegna G	Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.	Nature medicine	2015	58
26036643	1956	Tricker EM	Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer.	Cancer discovery	2015	28
26051236	1956	Yang JC	Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.	The Lancet. Oncology	2015	39
26105600	1956	Wu YL	First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study.	Annals of oncology 	2015	30
26124204	1956	Della Corte CM	SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer.	Clinical cancer research 	2015	18
26141208	1956	Zhou C	Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802).	Annals of oncology 	2015	39
26159065	1956	Soria JC	Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.	The Lancet. Oncology	2015	49
26206882	1956	Uchida J	Diagnostic Accuracy of Noninvasive Genotyping of EGFR in Lung Cancer Patients by Deep Sequencing of Plasma Cell-Free DNA.	Clinical chemistry	2015	25
26227959	1956	Sun W	Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer.	Journal of hematology and oncology	2015	25
26243863	1956	Kavuri SM	HER2 activating mutations are targets for colorectal cancer treatment.	Cancer discovery	2015	18
26269204	1956	Planchard D	EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients.	Annals of oncology 	2015	26
26295376	1956	Marchetti A	Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC Patients.	Journal of thoracic oncology 	2015	25
26308162	1956	Russo A	A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives.	Oncotarget	2015	30
26318427	1956	Bronte G	New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?	Oncotarget	2015	16
26324367	1956	Masters GA	Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.	Journal of clinical oncology 	2015	47
26354927	1956	Dubbink HJ	Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial.	Neuro-oncology	2016	14
26358176	1956	Dietel M	A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.	Cancer gene therapy	2015	25
26392535	1956	Kamburov A	Comprehensive assessment of cancer missense mutation clustering in protein structures.	Proceedings of the National Academy of Sciences of the United States of America	2015	26
26410082	1956	Brastianos PK	Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets.	Cancer discovery	2015	51
26416997	1956	Cai W	Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma.	Journal of clinical oncology 	2015	21
26434585	1956	Schneider MR	The EGFR-HER2 module: a stem cell approach to understanding a prime target and driver of solid tumors.	Oncogene	2016	12
26438111	1956	Allegra CJ	Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015.	Journal of clinical oncology 	2016	31
26446944	1956	Sundaresan TK	Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses.	Clinical cancer research 	2016	45
26460303	1956	Kopetz S	Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer.	Journal of clinical oncology 	2015	41
26477306	1956	Schabath MB	Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma.	Oncogene	2016	11
26494259	1956	Thress KS	EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291.	Lung cancer	2015	39
26525104	1956	Best MG	RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics.	Cancer cell	2015	34
26537995	1956	Minguet J	Targeted therapies for treatment of non-small cell lung cancer--Recent advances and future perspectives.	International journal of cancer	2016	19
26577492	1956	Sueoka-Aragane N	Monitoring EGFR T790M with plasma DNA from lung cancer patients in a prospective observational study.	Cancer science	2016	13
26582655	1956	Xu S	Circulating tumor DNA identified by targeted sequencing in advanced-stage non-small cell lung cancer patients.	Cancer letters	2016	12
26625312	1956	PÃ©cuchet N	Different prognostic impact of STK11 mutations in non-squamous non-small-cell lung cancer.	Oncotarget	2017	5
26644315	1956	Russo M	Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer.	Cancer discovery	2016	23
26690310	1956	Richman SD	HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials.	The Journal of pathology	2016	11
26724471	1956	Lin JJ	Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs.	Journal of thoracic oncology 	2016	12
26727163	1956	Quoix E	TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial.	The Lancet. Oncology	2016	17
26729443	1956	Awad MM	MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.	Journal of clinical oncology 	2016	33
26735353	1956	Bournet B	Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities.	European journal of cancer	2016	16
26755650	1956	Lee JY	Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02).	Oncotarget	2016	16
26777916	1956	Barlesi F	Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT).	Lancet	2016	43
26789630	1956	Yoshida T	ZEB1 Mediates Acquired Resistance to the Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.	PloS one	2016	13
26799287	1956	Del Re M	Contribution of KRAS mutations and c.2369C &amp;gt; T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA.	Oncotarget	2017	9
26823294	1956	Schuler M	First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases.	Journal of thoracic oncology 	2016	12
26828195	1956	Hata AN	Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition.	Nature medicine	2016	57
26843189	1956	Arena S	MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.	Science translational medicine	2016	11
26844548	1956	Hedner C	Expression and Prognostic Significance of Human Epidermal Growth Factor Receptors 1 and 3 in Gastric and Esophageal Adenocarcinoma.	PloS one	2016	11
26867973	1956	Zheng D	Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance.	Scientific reports	2016	29
26898616	1956	Tan CS	Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.	Lung cancer	2016	17
26926684	1956	Desmedt C	Genomic Characterization of Primary Invasive Lobular Breast Cancer.	Journal of clinical oncology 	2016	12
26942675	1956	Li X	Mitochondria-Translocated PGK1 Functions as a Protein Kinase to Coordinate Glycolysis and the TCA Cycle in Tumorigenesis.	Molecular cell	2016	14
27060149	1956	Lai Z	VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research.	Nucleic acids research	2016	12
27071706	1956	Wang S	Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer.	Journal of hematology and oncology	2016	29
27083334	1956	Park K	Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.	The Lancet. Oncology	2016	46
27354477	1956	Oxnard GR	Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer.	Journal of clinical oncology 	2016	31
27688480	1956	Yip SS	Associations Between Somatic Mutations and Metabolic Imaging Phenotypes in Non-Small Cell Lung Cancer.	Journal of nuclear medicine 	2017	7
27718847	1956	Reck M	Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.	The New England journal of medicine	2016	147
27922044	1956	Punt CJ	From tumour heterogeneity to advances in precision treatment of colorectal cancer.	Nature reviews. Clinical oncology	2017	5
27959700	1956	Mok TS	Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.	The New England journal of medicine	2017	42
2470152	2064	Slamon DJ	Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.	Science	1989	1073
3003577	2064	Yamamoto T	Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor.	Nature	1986	184
7657393	2064	Bellacosa A	Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas.	International journal of cancer	1995	174
10029066	2064	Bubendorf L	Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays.	Cancer research	1999	105
10223227	2064	Nakajima M	The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas.	Cancer	1999	113
11694782	2064	Yarden Y	Biology of HER2 and its importance in breast cancer.	Oncology	2001	104
12761490	2064	Knuefermann C	HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells.	Oncogene	2003	102
15194824	2064	Meng S	HER-2 gene amplification can be acquired as breast cancer progresses.	Proceedings of the National Academy of Sciences of the United States of America	2004	119
15457249	2064	Stephens P	Lung cancer: intragenic ERBB2 kinase mutations in tumours.	Nature	2004	166
16707747	2064	Pritchard KI	HER2 and responsiveness of breast cancer to adjuvant chemotherapy.	The New England journal of medicine	2006	100
16846532	2064	Calza S	Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients.	Breast cancer research 	2006	81
16868827	2064	Park DI	HER-2/neu amplification is an independent prognostic factor in gastric cancer.	Digestive diseases and sciences	2006	70
17157792	2064	Chin K	Genomic and transcriptional aberrations linked to breast cancer pathophysiologies.	Cancer cell	2006	472
17377838	2064	Soerjomataram I	An overview of prognostic factors for long-term survivors of breast cancer.	Breast cancer research and treatment	2008	84
17440164	2064	Scaltriti M	Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.	Journal of the National Cancer Institute	2007	170
17471238	2064	Moasser MM	The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis.	Oncogene	2007	133
17606733	2064	Marangoni E	A new model of patient tumor-derived breast cancer xenografts for preclinical assays.	Clinical cancer research 	2007	106
17675364	2064	Bignell GR	Architectures of somatic genomic rearrangement in human cancer amplicons at sequence-level resolution.	Genome research	2007	77
17686164	2064	Viani GA	Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials.	BMC cancer	2007	74
18171422	2064	Reis-Filho JS	Triple negative tumours: a critical review.	Histopathology	2008	212
18223211	2064	Allred DC	Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution.	Clinical cancer research 	2008	91
18339869	2064	Yamaguchi N	NOTCH3 signaling pathway plays crucial roles in the proliferation of ErbB2-negative human breast cancer cells.	Cancer research	2008	54
18434311	2064	Najy AJ	The ectodomain shedding of E-cadherin by ADAM15 supports ErbB receptor activation.	The Journal of biological chemistry	2008	61
18487574	2064	Rakha EA	Basal-like breast cancer: a critical review.	Journal of clinical oncology 	2008	213
18625725	2064	Wang SE	Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab.	Molecular and cellular biology	2008	61
18772890	2064	Cancer Genome Atlas Research Network.	Comprehensive genomic characterization defines human glioblastoma genes and core pathways.	Nature	2008	2168
18829560	2064	Serra V	NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.	Cancer research	2008	251
19008097	2064	Irvin WJ Jr	What is triple-negative breast cancer?	European journal of cancer	2008	77
19010894	2064	Eichhorn PJ	Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.	Cancer research	2008	140
19156142	2064	Barros-Silva JD	Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients.	British journal of cancer	2009	50
19204209	2064	Sauter G	Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations.	Journal of clinical oncology 	2009	106
19318578	2064	Neal CL	14-3-3zeta overexpression defines high risk for breast cancer recurrence and promotes cancer cell survival.	Cancer research	2009	55
19597704	2064	Pestrin M	Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients.	Breast cancer research and treatment	2009	56
19633047	2064	Kataoka Y	Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines.	Annals of oncology 	2010	56
19766563	2064	Cicalese A	The tumor suppressor p53 regulates polarity of self-renewing divisions in mammary stem cells.	Cell	2009	231
20100965	2064	Silver DP	Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer.	Journal of clinical oncology 	2010	209
20231686	2064	Staaf J	Identification of subtypes in human epidermal growth factor receptor 2--positive breast cancer reveals a gene signature prognostic of outcome.	Journal of clinical oncology 	2010	54
20453058	2064	O'Brien C	Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models.	Clinical cancer research 	2010	82
20576095	2064	JÃ¶nsson G	Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics.	Breast cancer research 	2010	65
20581867	2064	Chakrabarty A	H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3.	Oncogene	2010	43
20877296	2064	Carey L	Triple-negative breast cancer: disease entity or title of convenience?	Nature reviews. Clinical oncology	2010	180
20920229	2064	Bediaga NG	DNA methylation epigenotypes in breast cancer molecular subtypes.	Breast cancer research 	2010	47
21050424	2064	ChacÃ³n RD	Triple-negative breast cancer.	Breast cancer research 	2010	57
21115860	2064	Valero V	Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens.	Journal of clinical oncology 	2011	43
21135276	2064	Dave B	Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers.	Journal of clinical oncology 	2011	77
21373875	2064	GlÃ¼ck S	TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine Â± trastuzumab.	Breast cancer research and treatment	2012	58
21965336	2064	Higgins MJ	Targeted therapies for breast cancer.	The Journal of clinical investigation	2011	89
22114931	2064	Miller TW	Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer.	Breast cancer research 	2011	84
22124364	2064	Arteaga CL	Treatment of HER2-positive breast cancer: current status and future perspectives.	Nature reviews. Clinical oncology	2011	196
22172323	2064	Jensen JD	PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab.	Annals of oncology 	2012	36
22198468	2064	Esserman LJ	Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).	Breast cancer research and treatment	2012	88
22325357	2064	De GrÃ¨ve J	Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu.	Lung cancer	2012	47
22331459	2064	Stevens KN	19p13.1 is a triple-negative-specific breast cancer susceptibility locus.	Cancer research	2012	44
22373922	2064	Whale AS	Comparison of microfluidic digital PCR and conventional quantitative PCR for measuring copy number variation.	Nucleic acids research	2012	57
22388760	2064	Seol H	Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance.	Modern pathology 	2012	36
22471661	2064	Rexer BN	Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications.	Critical reviews in oncogenesis	2012	67
22495314	2064	Shah SP	The clonal and mutational evolution spectrum of primary triple-negative breast cancers.	Nature	2012	499
22761469	2064	Arcila ME	Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas.	Clinical cancer research 	2012	53
22817698	2064	Byrski T	Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer.	Breast cancer research 	2012	36
22899400	2064	Anglesio MS	Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas.	The Journal of pathology	2013	31
22956644	2064	Takezawa K	HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation.	Cancer discovery	2012	134
23159108	2064	Colomba E	Detection of BRAF p.V600E mutations in melanomas: comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing.	The Journal of molecular diagnostics 	2013	36
23220880	2064	Bose R	Activating HER2 mutations in HER2 gene amplification negative breast cancer.	Cancer discovery	2013	135
23442322	2064	Ithimakin S	HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab.	Cancer research	2013	55
23589555	2064	Sleijfer S	Designing transformative clinical trials in the cancer genome era.	Journal of clinical oncology 	2013	35
23610105	2064	MaziÃ¨res J	Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives.	Journal of clinical oncology 	2013	82
23807776	2064	Hanna WM	HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity.	Modern pathology 	2014	31
23852170	2064	Roberts SA	An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers.	Nature genetics	2013	205
24127447	2064	Gomez-Martin C	Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab.	Journal of clinical oncology 	2013	32
24323026	2064	Gandhi L	Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors.	Journal of clinical oncology 	2014	37
24739973	2064	Godinho SA	Oncogene-like induction of cellular invasion from centrosome amplification.	Nature	2014	60
24829859	2064	Yadav BS	Systemic treatment strategies for triple-negative breast cancer.	World journal of clinical oncology	2014	24
24960601	2064	Choi W	Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer.	Nature reviews. Urology	2014	30
24970867	2064	Wilkerson MD	Integrated RNA and DNA sequencing improves mutation detection in low purity tumors.	Nucleic acids research	2014	21
25129345	2064	Byrski T	Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients.	Breast cancer research and treatment	2014	31
25332247	2064	Baselga J	Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer.	Journal of clinical oncology 	2014	42
25559818	2064	Majewski IJ	PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer.	Journal of clinical oncology 	2015	38
25636205	2064	Groenendijk FH	ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy.	European urology	2016	15
25682074	2064	Wong-Brown MW	Prevalence of BRCA1 and BRCA2 germline mutations in patients with triple-negative breast cancer.	Breast cancer research and treatment	2015	17
25713166	2064	Ng CK	Breast cancer genomics from microarrays to massively parallel sequencing: paradigms and new insights.	Journal of the National Cancer Institute	2015	20
25805799	2064	Basu B	First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014.	Clinical cancer research 	2015	21
25847929	2064	Telli ML	Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105.	Journal of clinical oncology 	2015	27
25896973	2064	Chantrill LA	Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial.	Clinical cancer research 	2015	25
25902832	2064	Toss A	Molecular characterization and targeted therapeutic approaches in breast cancer.	Breast cancer research 	2015	19
26387133	2064	Palma G	Triple negative breast cancer: looking for the missing link between biology and treatments.	Oncotarget	2015	25
26527775	2064	Carey LA	Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib.	Journal of clinical oncology 	2016	16
26530965	2064	Murtaza M	Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer.	Nature communications	2015	33
26628478	2064	Hecht JR	Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial.	Journal of clinical oncology 	2016	58
26995633	2064	Yang SX	New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer.	Cancer treatment reviews	2016	15
27269946	2064	Fribbens C	Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.	Journal of clinical oncology 	2016	25
18510925	2068	Liu H	Structure of the DNA repair helicase XPD.	Cell	2008	84
25096233	2068	Van Allen EM	Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma.	Cancer discovery	2014	47
17334343	2078	Mehra R	Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer.	Modern pathology 	2007	85
18483239	2078	Mehra R	Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer.	Cancer research	2008	78
19190343	2078	Gopalan A	TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy.	Cancer research	2009	81
19407851	2078	Han B	Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression.	Modern pathology 	2009	60
19657377	2078	Clark JP	ETS gene fusions in prostate cancer.	Nature reviews. Urology	2009	84
19933109	2078	Mani RS	Induced chromosomal proximity and gene fusions in prostate cancer.	Science	2009	130
20651988	2078	Park K	Antibody-based detection of ERG rearrangement-positive prostate cancer.	Neoplasia	2010	104
21307934	2078	Berger MF	The genomic complexity of primary human prostate cancer.	Nature	2011	439
25730763	2078	Cooper CS	Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue.	Nature genetics	2015	51
7641693	2099	CavaillÃ¨s V	Nuclear factor RIP140 modulates transcriptional activation by the estrogen receptor.	The EMBO journal	1995	165
9524123	2099	Migliaccio A	Activation of the Src/p21ras/Erk pathway by progesterone receptor via cross-talk with estrogen receptor.	The EMBO journal	1998	119
15583021	2099	Herynk MH	Estrogen receptor mutations in human disease.	Endocrine reviews	2004	78
17113977	2099	Russo J	The role of estrogen in the initiation of breast cancer.	The Journal of steroid biochemistry and molecular biology	2006	72
17417639	2099	Holst F	Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer.	Nature genetics	2007	75
18574464	2099	Ramsay RG	MYB function in normal and cancer cells.	Nature reviews. Cancer	2008	146
20180843	2099	Xiong J	An estrogen receptor alpha suppressor, microRNA-22, is downregulated in estrogen receptor alpha-positive human breast cancer cell lines and clinical samples.	The FEBS journal	2010	45
20427689	2099	Barone I	Estrogen receptor mutations and changes in downstream gene expression and signaling.	Clinical cancer research 	2010	42
20547749	2099	Stender JD	Genome-wide analysis of estrogen receptor alpha DNA binding and tethering mechanisms identifies Runx1 as a novel tethering factor in receptor-mediated transcriptional activation.	Molecular and cellular biology	2010	63
21362200	2099	Sanchez CG	Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.	Breast cancer research 	2011	46
24055055	2099	Li S	Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts.	Cell reports	2013	117
24185510	2099	Robinson DR	Activating ESR1 mutations in hormone-resistant metastatic breast cancer.	Nature genetics	2013	157
24217577	2099	Merenbakh-Lamin K	D538G mutation in estrogen receptor-Î±: A novel mechanism for acquired endocrine resistance in breast cancer.	Cancer research	2013	56
24398047	2099	Jeselsohn R	Emergence of constitutively active estrogen receptor-Î± mutations in pretreated advanced estrogen receptor-positive breast cancer.	Clinical cancer research 	2014	76
24663045	2099	Mayer IA	Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.	Journal of clinical oncology 	2014	41
24858917	2099	Ohba K	In vivo and in vitro studies suggest a possible involvement of HPV infection in the early stage of breast carcinogenesis via APOBEC3B induction.	PloS one	2014	23
25013076	2099	Yu M	Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility.	Science	2014	133
25877889	2099	Bosch A	PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer.	Science translational medicine	2015	28
25979954	2099	Guttery DS	Noninvasive detection of activating estrogen receptor 1 (ESR1) mutations in estrogen receptor-positive metastatic breast cancer.	Clinical chemistry	2015	22
26261103	2099	Chu D	ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients.	Clinical cancer research 	2016	22
26317216	2099	Butler TM	Exome Sequencing of Cell-Free DNA from Metastatic Cancer Patients Identifies Clinically Actionable Mutations Distinct from Primary Disease.	PloS one	2015	17
26500237	2099	Wang P	Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients.	Clinical cancer research 	2016	22
26560360	2099	Schiavon G	Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer.	Science translational medicine	2015	41
26563128	2099	Ma CX	A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer.	Clinical cancer research 	2016	13
27532364	2099	Chandarlapaty S	Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial.	JAMA oncology	2016	18
9360930	2120	Lacronique V	A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia.	Science	1997	164
10602411	2120	van Dongen JJ	Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia.	Leukemia	1999	111
12048236	2120	Mori H	Chromosome translocations and covert leukemic clones are generated during normal fetal development.	Proceedings of the National Academy of Sciences of the United States of America	2002	93
15908956	2120	Castor A	Distinct patterns of hematopoietic stem cell involvement in acute lymphoblastic leukemia.	Nature medicine	2005	67
18202291	2120	Hong D	Initiating and cancer-propagating cells in TEL-AML1-associated childhood leukemia.	Science	2008	94
20409752	2120	Moorman AV	Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial.	The Lancet. Oncology	2010	58
20410810	2120	SkÃ¡lovÃ¡ A	Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity.	The American journal of surgical pathology	2010	69
22162831	2120	Van Vlierberghe P	ETV6 mutations in early immature human T cell leukemias.	The Journal of experimental medicine	2011	49
22578774	2120	De Braekeleer E	ETV6 fusion genes in hematological malignancies: a review.	Leukemia research	2012	38
24327398	2120	Leeman-Neill RJ	ETV6-NTRK3 is a common chromosomal rearrangement in radiation-associated thyroid cancer.	Cancer	2014	25
12086853	2130	Lessnick SL	The Ewing's sarcoma oncoprotein EWS/FLI induces a p53-dependent growth arrest in primary human fibroblasts.	Cancer cell	2002	86
17250957	2130	Riggi N	The Biology of Ewing sarcoma.	Cancer letters	2007	59
20543858	2130	Toomey EC	Recent advances in the molecular pathogenesis of Ewing's sarcoma.	Oncogene	2010	51
21872822	2130	Sankar S	Promiscuous partnerships in Ewing's sarcoma.	Cancer genetics	2011	35
23568838	2130	Piganeau M	Cancer translocations in human cells induced by zinc finger and TALE nucleases.	Genome research	2013	42
26810070	2130	Qaddoumi I	Genetic alterations in uncommon low-grade neuroepithelial tumors: BRAF, FGFR1, and MYB mutations occur at high frequency and align with morphology.	Acta neuropathologica	2016	15
14532106	2146	Bracken AP	EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer.	The EMBO journal	2003	331
21078963	2146	Sneeringer CJ	Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas.	Proceedings of the National Academy of Sciences of the United States of America	2010	139
21367748	2146	Chase A	Aberrations of EZH2 in cancer.	Clinical cancer research 	2011	141
21659531	2146	Wu SC	Cyclin-dependent kinase 1 (CDK1)-mediated phosphorylation of enhancer of zeste 2 (Ezh2) regulates its stability.	The Journal of biological chemistry	2011	44
21921040	2146	Guglielmelli P	EZH2 mutational status predicts poor survival in myelofibrosis.	Blood	2011	41
22053108	2146	Score J	Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms.	Blood	2012	40
22323599	2146	McCabe MT	Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27).	Proceedings of the National Academy of Sciences of the United States of America	2012	101
23568486	2146	Ronan JL	From neural development to cognition: unexpected roles for chromatin.	Nature reviews. Genetics	2013	122
24052547	2146	BÃ¶dÃ¶r C	EZH2 mutations are frequent and represent an early event in follicular lymphoma.	Blood	2013	30
24097870	2146	Behrens C	EZH2 protein expression associates with the early pathogenesis, tumor progression, and prognosis of non-small cell lung carcinoma.	Clinical cancer research 	2013	33
25457180	2146	Bradley WD	EZH2 inhibitor efficacy in non-Hodgkin's lymphoma does not require suppression of H3K27 monomethylation.	Chemistry and biology	2014	31
25965569	2146	Kim E	SRSF2 Mutations Contribute to Myelodysplasia by Mutant-Specific Effects on Exon Recognition.	Cancer cell	2015	49
26501191	2146	Huang L	Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell- and patient-derived tumor organoids.	Nature medicine	2015	19
26552009	2146	Kim KH	SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2.	Nature medicine	2015	30
18245465	2260	Lin WM	Modeling genomic diversity and tumor dependency in malignant melanoma.	Cancer research	2008	104
21119661	2260	Lamont FR	Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo.	British journal of cancer	2011	42
21666749	2260	Dutt A	Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer.	PloS one	2011	112
22684217	2260	Schildhaus HU	Definition of a fluorescence in-situ hybridization score identifies high- and low-level FGFR1 amplification types in squamous cell lung cancer.	Modern pathology 	2012	32
23002168	2260	Guagnano V	FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor.	Cancer discovery	2012	59
23026827	2260	Drilon A	Squamous-cell carcinomas of the lung: emerging biology, controversies, and the promise of targeted therapy.	The Lancet. Oncology	2012	47
23082000	2260	Zhang J	Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models.	Clinical cancer research 	2012	47
23154548	2260	Heist RS	FGFR1 amplification in squamous cell carcinoma of the lung.	Journal of thoracic oncology 	2012	37
23182986	2260	Kim HR	Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer.	Journal of clinical oncology 	2013	45
24302556	2260	Malchers F	Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancer.	Cancer discovery	2014	22
26373574	2260	Helsten T	The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing.	Clinical cancer research 	2016	21
10471491	2261	Cappellen D	Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas.	Nature genetics	1999	156
17668422	2261	Tomlinson DC	FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer.	The Journal of pathology	2007	63
19381019	2261	Qing J	Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice.	The Journal of clinical investigation	2009	62
19843843	2261	Catto JW	Distinct microRNA alterations characterize high- and low-grade bladder cancer.	Cancer research	2009	89
21072204	2261	Kompier LC	FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy.	PloS one	2010	63
22045636	2261	Foldynova-Trantirkova S	Sixteen years and counting: the current understanding of fibroblast growth factor receptor 3 (FGFR3) signaling in skeletal dysplasias.	Human mutation	2012	41
22325359	2261	Goriely A	Paternal age effect mutations and selfish spermatogonial selection: causes and consequences for human disease.	American journal of human genetics	2012	50
22493262	2261	Chen CH	Aristolochic acid-associated urothelial cancer in Taiwan.	Proceedings of the National Academy of Sciences of the United States of America	2012	55
22730329	2261	Yadav V	Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma.	The Journal of biological chemistry	2012	47
23661334	2261	Majewski IJ	Identification of recurrent FGFR3 fusion genes in lung cancer through kinome-centred RNA sequencing.	The Journal of pathology	2013	32
23786770	2261	Liao RG	Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma.	Cancer research	2013	50
25194568	2261	Rampias T	A new tumor suppressor role for the Notch pathway in bladder cancer.	Nature medicine	2014	21
26901314	2261	Ward DG	Multiplex PCR and Next Generation Sequencing for the Non-Invasive Detection of Bladder Cancer.	PloS one	2016	11
11865300	2271	Tomlinson IP	Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer.	Nature genetics	2002	253
12772087	2271	Toro JR	Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America.	American journal of human genetics	2003	93
14634372	2271	Linehan WM	The genetic basis of cancer of the kidney.	The Journal of urology	2003	94
16892079	2271	Brandon M	Mitochondrial mutations in cancer.	Oncogene	2006	190
18728283	2271	Ricketts C	Germline SDHB mutations and familial renal cell carcinoma.	Journal of the National Cancer Institute	2008	82
19963135	2271	Yang Y	UOK 262 cell line, fumarate hydratase deficient (FH-/FH-) hereditary leiomyomatosis renal cell carcinoma: in vitro and in vivo model of an aberrant energy metabolic pathway in human cancer.	Cancer genetics and cytogenetics	2010	42
23604282	2271	Hu J	Heterogeneity of tumor-induced gene expression changes in the human metabolic network.	Nature biotechnology	2013	76
24334767	2271	Castro-Vega LJ	Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas.	Human molecular genetics	2014	31
8598045	2272	Ohta M	The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers.	Cell	1996	207
17404569	2305	Dai B	Aberrant FoxM1B expression increases matrix metalloproteinase-2 transcription and enhances the invasion of glioma cells.	Oncogene	2007	64
18974115	2305	Zhang Y	FoxM1B transcriptionally regulates vascular endothelial growth factor expression and promotes the angiogenesis and growth of glioma cells.	Cancer research	2008	73
19287496	2305	Gemenetzidis E	FOXM1 upregulation is an early event in human squamous cell carcinoma and it is enhanced by nicotine during malignant transformation.	PloS one	2009	50
21518729	2305	Millour J	ATM and p53 regulate FOXM1 expression via E2F in breast cancer epirubicin treatment and resistance.	Molecular cancer therapeutics	2011	38
21720365	2305	Cancer Genome Atlas Research Network.	Integrated genomic analyses of ovarian carcinoma.	Nature	2011	1665
22617326	2305	Szabova L	Perturbation of Rb, p53, and Brca1 or Brca2 cooperate in inducing metastatic serous epithelial ovarian cancer.	Cancer research	2012	34
23598278	2305	Kong X	Dysregulated expression of FOXM1 isoforms drives progression of pancreatic cancer.	Cancer research	2013	31
24141789	2305	Khongkow P	FOXM1 targets NBS1 to regulate DNA damage-induced senescence and epirubicin resistance.	Oncogene	2014	22
10216104	2322	Kiyoi H	Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia.	Blood	1999	104
10698507	2322	Hayakawa F	Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines.	Oncogene	2000	92
11290608	2322	Yamamoto Y	Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.	Blood	2001	189
11535508	2322	Kottaridis PD	The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials.	Blood	2001	208
11585760	2322	Whitman SP	Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study.	Cancer research	2001	113
12036858	2322	Thiede C	Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis.	Blood	2002	279
12070009	2322	Schnittger S	Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease.	Blood	2002	141
12194988	2322	Kelly LM	Genetics of myeloid leukemias.	Annual review of genomics and human genetics	2002	97
12393388	2322	FrÃ¶hling S	Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm.	Blood	2002	135
12531805	2322	O'Farrell AM	SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo.	Blood	2003	164
15345597	2322	Stone RM	Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412.	Blood	2005	132
15459012	2322	Fiedler W	A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease.	Blood	2005	80
15514006	2322	George P	Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.	Blood	2005	74
16150941	2322	Heidel F	Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain.	Blood	2006	63
16857985	2322	Knapper S	A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy.	Blood	2006	96
16912228	2322	Meshinchi S	Clinical implications of FLT3 mutations in pediatric AML.	Blood	2006	74
17124058	2322	Small D	FLT3 mutations: biology and treatment.	Hematology. American Society of Hematology. Education Program	2006	60
17940205	2322	Whitman SP	FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications.	Blood	2008	68
17957027	2322	Gale RE	The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia.	Blood	2008	108
18187662	2322	Garzon R	MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia.	Blood	2008	196
18192505	2322	Sallmyr A	Internal tandem duplication of FLT3 (FLT3/ITD) induces increased ROS production, DNA damage, and misrepair: implications for poor prognosis in AML.	Blood	2008	71
18270328	2322	Tomasson MH	Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia.	Blood	2008	67
18450603	2322	Marcucci G	MicroRNA expression in cytogenetically normal acute myeloid leukemia.	The New England journal of medicine	2008	142
19029442	2322	Pratz KW	A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response.	Blood	2009	52
19047294	2322	BÃ¼chner T	Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group.	Journal of clinical oncology 	2009	49
19549778	2322	Meshinchi S	Structural and functional alterations of FLT3 in acute myeloid leukemia.	Clinical cancer research 	2009	51
20007803	2322	Pratz KW	FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML.	Blood	2010	75
20212254	2322	Ravandi F	Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.	Journal of clinical oncology 	2010	94
20656931	2322	Whitman SP	FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.	Blood	2010	58
20733134	2322	Fischer T	Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.	Journal of clinical oncology 	2010	89
20952518	2322	Borthakur G	Phase I study of sorafenib in patients with refractory or relapsed acute leukemias.	Haematologica	2011	45
21127174	2322	Kayser S	The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML.	Blood	2011	45
21148331	2322	Schnittger S	RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosis.	Blood	2011	42
22291086	2322	Brunet S	Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis.	Journal of clinical oncology 	2012	39
22368270	2322	Man CH	Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation.	Blood	2012	59
22504184	2322	Smith CC	Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia.	Nature	2012	146
22614177	2322	Swords R	Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia.	Leukemia	2012	37
22627678	2322	Stone RM	Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia.	Leukemia	2012	47
22715121	2322	Iland HJ	All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4).	Blood	2012	34
23071272	2322	QuintÃ¡s-Cardama A	Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia.	Blood	2012	32
23087056	2322	Tyner JW	Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening.	Cancer research	2013	45
23321257	2322	Jourdan E	Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia.	Blood	2013	32
23377436	2322	Pratcorona M	Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy.	Blood	2013	29
23430109	2322	Smith CC	Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD.	Blood	2013	30
23613521	2322	Ravandi F	Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation.	Blood	2013	58
23631653	2322	Kayser S	FLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations.	Leukemia and lymphoma	2014	28
23897964	2322	Serve H	Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial.	Journal of clinical oncology 	2013	51
24002496	2322	Cortes JE	Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status.	Journal of clinical oncology 	2013	56
24227820	2322	Galanis A	Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants.	Blood	2014	32
24319184	2322	Levis M	FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?	Hematology. American Society of Hematology. Education Program	2013	30
25092144	2322	Gerloff D	NF-ÎºB/STAT5/miR-155 network targets PU.1 in FLT3-ITD-driven acute myeloid leukemia.	Leukemia	2015	18
25231999	2322	Konig H	Targeting FLT3 to treat leukemia.	Expert opinion on therapeutic targets	2015	20
25253770	2322	Irving J	Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition.	Blood	2014	39
25270908	2322	Schlenk RF	Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation.	Blood	2014	26
25280219	2322	Li L	SIRT1 activation by a c-MYC oncogenic network promotes the maintenance and drug resistance of human FLT3-ITD acute myeloid leukemia stem cells.	Cell stem cell	2014	22
12172553	2475	Inoki K	TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling.	Nature cell biology	2002	791
15254063	2475	Sansal I	The biology and clinical relevance of the PTEN tumor suppressor pathway.	Journal of clinical oncology 	2004	215
15797377	2475	Beuvink I	The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation.	Cell	2005	139
16002336	2475	Guertin DA	An expanding role for mTOR in cancer.	Trends in molecular medicine	2005	111
17360675	2475	Urano J	Point mutations in TOR confer Rheb-independent growth in fission yeast and nutrient-independent mammalian TOR signaling in mammalian cells.	Proceedings of the National Academy of Sciences of the United States of America	2007	62
17595159	2475	Chan EY	siRNA screening of the kinome identifies ULK1 as a multidomain modulator of autophagy.	The Journal of biological chemistry	2007	134
17599906	2475	Woo SY	PRR5, a novel component of mTOR complex 2, regulates platelet-derived growth factor receptor beta expression and signaling.	The Journal of biological chemistry	2007	75
18787170	2475	Mao JH	FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.	Science	2008	130
18929564	2475	Villanueva A	Pivotal role of mTOR signaling in hepatocellular carcinoma.	Gastroenterology	2008	182
20190810	2475	Sato T	Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer.	Oncogene	2010	62
20227368	2475	Yan L	PP2A T61 epsilon is an inhibitor of MAP4K3 in nutrient signaling to mTOR.	Molecular cell	2010	46
20457610	2475	Li L	Regulation of mTORC1 by the Rab and Arf GTPases.	The Journal of biological chemistry	2010	46
20479250	2475	Loi S	PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer.	Proceedings of the National Academy of Sciences of the United States of America	2010	106
20664172	2475	Di Nicolantonio F	Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus.	The Journal of clinical investigation	2010	110
21228155	2475	Rieker C	Nucleolar disruption in dopaminergic neurons leads to oxidative damage and parkinsonism through repression of mammalian target of rapamycin signaling.	The Journal of neuroscience 	2011	39
21372221	2475	Santiskulvong C	Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma.	Clinical cancer research 	2011	42
21946274	2475	Muellner MK	A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer.	Nature chemical biology	2011	50
21998291	2475	Wallin JJ	GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway.	Molecular cancer therapeutics	2011	64
22397650	2475	Gerlinger M	Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.	The New England journal of medicine	2012	1540
22685175	2475	Tasian SK	Aberrant STAT5 and PI3K/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia.	Blood	2012	42
22734070	2475	Payne EM	L-Leucine improves the anemia and developmental defects associated with Diamond-Blackfan anemia and del(5q) MDS by activating the mTOR pathway.	Blood	2012	42
23012248	2475	Acquaviva J	Targeting KRAS-mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespib.	Molecular cancer therapeutics	2012	32
23012305	2475	Crown J	Emerging targeted therapies in triple-negative breast cancer.	Annals of oncology 	2012	47
23549875	2475	Coffee EM	Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer.	Clinical cancer research 	2013	28
23619167	2475	Lui VW	Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers.	Cancer discovery	2013	106
23911927	2475	Linares JF	K63 polyubiquitination and activation of mTOR by the p62-TRAF6 complex in nutrient-activated cells.	Molecular cell	2013	41
24055054	2475	Villanueva J	Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma.	Cell reports	2013	43
24430184	2475	Li H	Inactivation of SAG/RBX2 E3 ubiquitin ligase suppresses KrasG12D-driven lung tumorigenesis.	The Journal of clinical investigation	2014	21
24569374	2475	Ma XH	Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma.	The Journal of clinical investigation	2014	77
24625776	2475	Wagle N	Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib.	Cancer discovery	2014	70
24821879	2475	Brugarolas J	Molecular genetics of clear-cell renal cell carcinoma.	Journal of clinical oncology 	2014	37
25103565	2475	Lehmann BD	PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors.	Breast cancer research 	2014	32
25295501	2475	Wagle N	Response and acquired resistance to everolimus in anaplastic thyroid cancer.	The New England journal of medicine	2014	61
25351205	2475	Scelo G	Variation in genomic landscape of clear cell renal cell carcinoma across Europe.	Nature communications	2014	24
25385035	2475	Favier J	Paraganglioma and phaeochromocytoma: from genetics to personalized medicine.	Nature reviews. Endocrinology	2015	26
25512523	2475	Perry JA	Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma.	Proceedings of the National Academy of Sciences of the United States of America	2014	46
25522665	2475	Pollizzi KN	Regulation of T cells by mTOR: the known knowns and the known unknowns.	Trends in immunology	2015	24
25591831	2475	Curatolo P	Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy.	Pediatric neurology	2015	15
26190651	2475	Fu X	2-Hydroxyglutarate Inhibits ATP Synthase and mTOR Signaling.	Cell metabolism	2015	15
26293922	2475	Liu P	PtdIns(3,4,5)P3-Dependent Activation of the mTORC2 Kinase Complex.	Cancer discovery	2015	30
27279227	2475	Rodrik-Outmezguine VS	Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor.	Nature	2016	19
21775669	2778	Wu J	Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development.	Science translational medicine	2011	146
22859495	2778	Kanda M	Mutant GNAS detected in duodenal collections of secretin-stimulated pancreatic juice indicates the presence or emergence of pancreatic cysts.	Gut	2013	40
23846778	2778	Molin MD	Clinicopathological correlates of activating GNAS mutations in intraductal papillary mucinous neoplasm (IPMN) of the pancreas.	Annals of surgical oncology	2013	27
25807286	2778	Gudbjartsson DF	Large-scale whole-genome sequencing of the Icelandic population.	Nature genetics	2015	98
8942985	2956	Acharya S	hMSH2 forms specific mispair-binding complexes with hMSH3 and hMSH6.	Proceedings of the National Academy of Sciences of the United States of America	1996	142
10544223	2956	Lynch HT	Genetic susceptibility to non-polyposis colorectal cancer.	Journal of medical genetics	1999	131
11048711	2956	Lamers MH	The crystal structure of DNA mismatch repair protein MutS binding to a G x T mismatch.	Nature	2000	199
11257106	2956	PeltomÃ¤ki P	Deficient DNA mismatch repair: a common etiologic factor for colon cancer.	Human molecular genetics	2001	94
15236168	2956	Hendriks YM	Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance.	Gastroenterology	2004	82
15872200	2956	Hampel H	Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer).	The New England journal of medicine	2005	244
16618716	2956	Hunter C	A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy.	Cancer research	2006	80
16807412	2956	Barnetson RA	Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer.	The New England journal of medicine	2006	85
16885385	2956	Hampel H	Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients.	Cancer research	2006	102
17003396	2956	Chen S	Prediction of germline mutations and cancer risk in the Lynch syndrome.	JAMA	2006	86
17327285	2956	Vasen HF	Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer).	Journal of medical genetics	2007	103
17404084	2956	Cahill DP	Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment.	Clinical cancer research 	2007	83
17531815	2956	Warren JJ	Structure of the human MutSalpha DNA lesion recognition complex.	Molecular cell	2007	141
17942460	2956	Imai K	Carcinogenesis and microsatellite instability: the interrelationship between genetics and epigenetics.	Carcinogenesis	2008	71
18556767	2956	Shia J	Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry.	The Journal of molecular diagnostics 	2008	71
19584161	2956	Yip S	MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance.	Clinical cancer research 	2009	75
19622357	2956	Stoffel E	Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome.	Gastroenterology	2009	77
20028993	2956	Baglietto L	Risks of Lynch syndrome cancers for MSH6 mutation carriers.	Journal of the National Cancer Institute	2010	73
20516444	2956	de la Chapelle A	Clinical relevance of microsatellite instability in colorectal cancer.	Journal of clinical oncology 	2010	44
21642682	2956	Bonadona V	Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome.	JAMA	2011	114
22331944	2956	Win AK	Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study.	Journal of clinical oncology 	2012	68
22355048	2956	Beamer LC	Reflex immunohistochemistry and microsatellite instability testing of colorectal tumors for Lynch syndrome among US cancer programs and follow-up of abnormal results.	Journal of clinical oncology 	2012	35
22658618	2956	Pritchard CC	ColoSeq provides comprehensive lynch and polyposis syndrome mutational analysis using massively parallel sequencing.	The Journal of molecular diagnostics 	2012	54
23091106	2956	Engel C	Risks of less common cancers in proven mutation carriers with lynch syndrome.	Journal of clinical oncology 	2012	32
24323032	2956	Buchanan DD	Tumor mismatch repair immunohistochemistry and DNA MLH1 methylation testing of patients with endometrial cancer diagnosed at age younger than 60 years optimizes triage for population-level germline mismatch repair gene mutation testing.	Journal of clinical oncology 	2014	24
24844595	2956	Meng B	POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium.	Gynecologic oncology	2014	22
25194673	2956	Haraldsdottir S	Colon and endometrial cancers with mismatch repair deficiency can arise from somatic, rather than germline, mutations.	Gastroenterology	2014	35
25238946	2956	Lancaster JM	Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions.	Gynecologic oncology	2015	24
25305506	2956	Sinicrope FA	Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes.	Gastroenterology	2015	42
26031544	2956	Kawakami H	Microsatellite instability testing and its role in the management of colorectal cancer.	Current treatment options in oncology	2015	17
26657901	2956	MÃ¸ller P	Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database.	Gut	2017	10
26720728	2956	Norquist BM	Inherited Mutations in Women With Ovarian Carcinoma.	JAMA oncology	2016	24
26880610	2956	Dudley JC	Microsatellite Instability as a Biomarker for PD-1 Blockade.	Clinical cancer research 	2016	28
27496117	2956	Provenzale D	Genetic/Familial High-Risk Assessment: Colorectal Version 1.2016, NCCN Clinical Practice Guidelines in Oncology.	Journal of the National Comprehensive Cancer Network 	2016	15
2547513	3265	Bos JL	ras oncogenes in human cancer: a review.	Cancer research	1989	956
6298635	3265	Capon DJ	Complete nucleotide sequences of the T24 human bladder carcinoma oncogene and its normal homologue.	Nature	1983	213
9219684	3265	Scheffzek K	The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants.	Science	1997	327
12727991	3265	Nikiforova MN	RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma.	The Journal of clinical endocrinology and metabolism	2003	103
15188009	3265	Bamford S	The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website.	British journal of cancer	2004	351
16170316	3265	Aoki Y	Germline mutations in HRAS proto-oncogene cause Costello syndrome.	Nature genetics	2005	149
21325462	3265	Moura MM	High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas.	The Journal of clinical endocrinology and metabolism	2011	37
21779495	3265	Castellano E	Functional specificity of ras isoforms: so similar but so different.	Genes and cancer	2011	47
21779504	3265	FernÃ¡ndez-Medarde A	Ras in cancer and developmental diseases.	Genes and cancer	2011	130
22004085	3265	Baines AT	Inhibition of Ras for cancer treatment: the search continues.	Future medicinal chemistry	2011	98
22241789	3265	Hayes DN	Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements.	Clinical cancer research 	2012	36
22589270	3265	Prior IA	A comprehensive survey of Ras mutations in cancer.	Cancer research	2012	192
23264394	3265	Agrawal N	Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS.	The Journal of clinical endocrinology and metabolism	2013	34
23640968	3265	Crona J	Somatic mutations in H-RAS in sporadic pheochromocytoma and paraganglioma identified by exome sequencing.	The Journal of clinical endocrinology and metabolism	2013	25
24695311	3265	Cleary AS	Tumour cell heterogeneity maintained by cooperating subclones in Wnt-driven mammary cancers.	Nature	2014	71
25086355	3265	Lee TH	Oncogenic ras-driven cancer cell vesiculation leads to emission of double-stranded DNA capable of interacting with target cells.	Biochemical and biophysical research communications	2014	27
25514803	3265	Lo Iacono M	Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study.	Journal of thoracic oncology 	2015	21
26276366	3265	Nishida T	The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines.	Gastric cancer 	2016	18
26985062	3265	Hobbs GA	RAS isoforms and mutations in cancer at a glance.	Journal of cell science	2016	17
18772396	3417	Parsons DW	An integrated genomic analysis of human glioblastoma multiforme.	Science	2008	1466
19228619	3417	Yan H	IDH1 and IDH2 mutations in gliomas.	The New England journal of medicine	2009	972
19246647	3417	Watanabe T	IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas.	The American journal of pathology	2009	185
19378339	3417	Kang MR	Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers.	International journal of cancer	2009	86
19554337	3417	Hartmann C	Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.	Acta neuropathologica	2009	219
19636000	3417	Sanson M	Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.	Journal of clinical oncology 	2009	178
19657110	3417	Mardis ER	Recurring mutations found by sequencing an acute myeloid leukemia genome.	The New England journal of medicine	2009	605
19737147	3417	Ohgaki H	Genetic alterations and signaling pathways in the evolution of gliomas.	Cancer science	2009	99
19755387	3417	Nobusawa S	IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas.	Clinical cancer research 	2009	117
19805672	3417	Weller M	Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network.	Journal of clinical oncology 	2009	135
19935646	3417	Dang L	Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.	Nature	2009	672
20097881	3417	Chou WC	Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation.	Blood	2010	56
20127344	3417	Bleeker FE	The prognostic IDH1( R132 ) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma.	Acta neuropathologica	2010	68
20142433	3417	Gross S	Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations.	The Journal of experimental medicine	2010	183
20160062	3417	van den Bent MJ	IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group.	Clinical cancer research 	2010	88
20171147	3417	Ward PS	The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.	Cancer cell	2010	426
20368543	3417	Marcucci G	IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.	Journal of clinical oncology 	2010	179
20399149	3417	Noushmehr H	Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma.	Cancer cell	2010	587
20410924	3417	Pardanani A	IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms.	Leukemia	2010	41
20427748	3417	LabussiÃ¨re M	All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2.	Neurology	2010	56
20508616	3417	Tefferi A	IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis.	Leukemia	2010	72
20513808	3417	Reitman ZJ	Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism.	Journal of the National Cancer Institute	2010	101
20567020	3417	Paschka P	IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.	Journal of clinical oncology 	2010	152
20625116	3417	Boissel N	Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group.	Journal of clinical oncology 	2010	45
20805365	3417	Schnittger S	IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status.	Blood	2010	41
20975057	3417	Houillier C	IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas.	Neurology	2010	84
21075857	3417	Kim YH	Molecular classification of low-grade diffuse gliomas.	The American journal of pathology	2010	43
21088844	3417	Hartmann C	Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.	Acta neuropathologica	2010	98
21129061	3417	von Deimling A	The next generation of glioma biomarkers: MGMT methylation, BRAF fusions and IDH1 mutations.	Brain pathology	2011	41
21130701	3417	Figueroa ME	Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.	Cancer cell	2010	586
21163902	3417	Christensen BC	DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma.	Journal of the National Cancer Institute	2011	89
21289278	3417	Reitman ZJ	Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome.	Proceedings of the National Academy of Sciences of the United States of America	2011	143
21326614	3417	Jin G	2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations.	PloS one	2011	47
21598255	3417	Amary MF	IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours.	The Journal of pathology	2011	161
22015945	3417	Pope WB	Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy.	Journal of neuro-oncology	2012	57
22052461	3417	Jin SG	5-Hydroxymethylcytosine is strongly depleted in human cancers but its levels do not correlate with IDH1 mutations.	Cancer research	2011	110
22180306	3417	Borger DR	Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping.	The oncologist	2012	126
22238332	3417	Andronesi OC	Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy.	Science translational medicine	2012	78
22238333	3417	Elkhaled A	Magnetic resonance of 2-hydroxyglutarate in IDH1-mutated low-grade gliomas.	Science translational medicine	2012	50
22270850	3417	Bleeker FE	Recent advances in the molecular understanding of glioblastoma.	Journal of neuro-oncology	2012	36
22281806	3417	Choi C	2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas.	Nature medicine	2012	130
22343889	3417	Turcan S	IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype.	Nature	2012	385
22343901	3417	Lu C	IDH mutation impairs histone demethylation and results in a block to cell differentiation.	Nature	2012	379
22415316	3417	Gorovets D	IDH mutation and neuroglial developmental features define clinically distinct subclasses of lower grade diffuse astrocytic glioma.	Clinical cancer research 	2012	40
22829908	3417	Orr BA	Decreased 5-hydroxymethylcytosine is associated with neural progenitor phenotype in normal brain and shorter survival in malignant glioma.	PloS one	2012	39
22899282	3417	Duncan CG	A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylation.	Genome research	2012	48
22990979	3417	Zhang W	Whole-genome microRNA expression profiling identifies a 5-microRNA signature as a prognostic biomarker in Chinese patients with primary glioblastoma multiforme.	Cancer	2013	32
23071237	3417	van den Bent MJ	Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951.	Journal of clinical oncology 	2013	134
23071358	3417	Yang H	IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives.	Clinical cancer research 	2012	46
23090983	3417	Yan W	Molecular classification of gliomas based on whole genome gene expression: a systematic report of 225 samples from the Chinese Glioma Cooperative Group.	Neuro-oncology	2012	46
23095825	3417	Weller M	Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice.	Neuro-oncology	2012	31
23115158	3417	Li S	Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation.	Neuro-oncology	2013	30
23209033	3417	Ohgaki H	The definition of primary and secondary glioblastoma.	Clinical cancer research 	2013	107
23558173	3417	Wang F	Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation.	Science	2013	152
23641016	3417	DiNardo CD	Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia.	Blood	2013	35
23896276	3417	Weller M	Molecular neuro-oncology in clinical practice: a new horizon.	The Lancet. Oncology	2013	30
23954893	3417	Chaturvedi A	Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML.	Blood	2013	43
24068788	3417	Wick W	Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation.	Neurology	2013	31
24077805	3417	Borodovsky A	5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft.	Oncotarget	2013	31
24305719	3417	Beiko J	IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection.	Neuro-oncology	2014	36
24333121	3417	Emadi A	Inhibition of glutaminase selectively suppresses the growth of primary acute myeloid leukemia cells with IDH mutations.	Experimental hematology	2014	32
24478380	3417	Borger DR	Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma.	Clinical cancer research 	2014	23
24516018	3417	Cairncross JG	Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH.	Journal of clinical oncology 	2014	50
24722048	3417	Killela PJ	Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas.	Oncotarget	2014	45
24810474	3417	Cai J	ATRX mRNA expression combined with IDH1/2 mutational status and Ki-67 expression refines the molecular classification of astrocytic tumors: evidence from the whole transcriptome sequencing of 169 samples samples.	Oncotarget	2014	22
24857658	3417	Mullen AR	Oxidation of alpha-ketoglutarate is required for reductive carboxylation in cancer cells with mitochondrial defects.	Cell reports	2014	54
25043048	3417	Schumacher T	A vaccine targeting mutant IDH1 induces antitumour immunity.	Nature	2014	73
25091696	3417	Tang X	A joint analysis of metabolomics and genetics of breast cancer.	Breast cancer research 	2014	26
25132561	3417	Huang Y	Connections between TET proteins and aberrant DNA modification in cancer.	Trends in genetics 	2014	41
25143301	3417	Sahm F	Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma.	Acta neuropathologica	2014	32
25369307	3417	Rizvi S	Cholangiocarcinoma: molecular pathways and therapeutic opportunities.	Seminars in liver disease	2014	27
25599133	3417	Chan SM	Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia.	Nature medicine	2015	41
25701198	3417	Olar A	IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas.	Acta neuropathologica	2015	17
25783747	3417	Weller M	Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups.	Acta neuropathologica	2015	26
26124478	3417	Sandmann T	Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial.	Journal of clinical oncology 	2015	38
26534967	3417	Andronesi OC	Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate.	Clinical cancer research 	2016	11
26669865	3417	Emir UE	Noninvasive Quantification of 2-Hydroxyglutarate in Human Gliomas with IDH1 and IDH2 Mutations.	Cancer research	2016	14
26691210	3417	de la Fuente MI	Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma.	Neuro-oncology	2016	18
27005468	3417	Dang L	IDH mutations in cancer and progress toward development of targeted therapeutics.	Annals of oncology 	2016	16
27270107	3417	Wang J	Clonal evolution of glioblastoma under therapy.	Nature genetics	2016	15
27806376	3417	Tirosh I	Single-cell RNA-seq supports a developmental hierarchy in human oligodendroglioma.	Nature	2016	17
18559588	3716	Jeong EG	Somatic mutations of JAK1 and JAK3 in acute leukemias and solid cancers.	Clinical cancer research 	2008	55
19470474	3716	Mullighan CG	JAK mutations in high-risk childhood acute lymphoblastic leukemia.	Proceedings of the National Academy of Sciences of the United States of America	2009	148
20843246	3716	Verstovsek S	Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.	The New England journal of medicine	2010	254
23406773	3716	QuintÃ¡s-Cardama A	Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance.	Clinical cancer research 	2013	59
23415024	3716	Hasselbalch HC	The role of cytokines in the initiation and progression of myelofibrosis.	Cytokine and growth factor reviews	2013	31
27433843	3716	Zaretsky JM	Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.	The New England journal of medicine	2016	91
15781101	3717	Baxter EJ	Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.	Lancet	2005	632
15793561	3717	James C	A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.	Nature	2005	653
15837627	3717	Levine RL	Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.	Cancer cell	2005	608
15858187	3717	Kralovics R	A gain-of-function mutation of JAK2 in myeloproliferative disorders.	The New England journal of medicine	2005	669
15863514	3717	Zhao R	Identification of an acquired JAK2 mutation in polycythemia vera.	The Journal of biological chemistry	2005	161
16037387	3717	Jelinek J	JAK2 mutation 1849G&amp;gt;T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia.	Blood	2005	73
16081687	3717	Levine RL	The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia.	Blood	2005	77
16325696	3717	Campbell PJ	Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study.	Lancet	2005	83
16772604	3717	Scott LM	Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia.	Blood	2006	67
17198871	3717	Nussenzveig RH	Polycythemia vera is not initiated by JAK2V617F mutation.	Experimental hematology	2007	69
17267906	3717	Scott LM	JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.	The New England journal of medicine	2007	223
17363731	3717	Theocharides A	Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation.	Blood	2007	65
17379742	3717	Vannucchi AM	Clinical profile of homozygous JAK2 617V&amp;gt;F mutation in patients with polycythemia vera or essential thrombocythemia.	Blood	2007	63
17488875	3717	Tefferi A	Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel.	Blood	2007	134
17564968	3717	Yamamoto G	Highly sensitive method for genomewide detection of allelic composition in nonpaired, primary tumor specimens by use of affymetrix single-nucleotide-polymorphism genotyping microarrays.	American journal of human genetics	2007	87
17721432	3717	Levine RL	Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders.	Nature reviews. Cancer	2007	134
17976518	3717	Bruchova H	Regulated expression of microRNAs in normal and polycythemia vera erythropoiesis.	Experimental hematology	2007	64
18160670	3717	Tiedt R	Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice.	Blood	2008	123
18496562	3717	Vannucchi AM	Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal.	Leukemia	2008	58
18779404	3717	Levine RL	Myeloproliferative disorders.	Blood	2008	93
18805579	3717	Bercovich D	Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome.	Lancet	2008	91
19474426	3717	Delhommeau F	Mutation in TET2 in myeloid cancers.	The New England journal of medicine	2009	411
19826111	3717	QuintÃ¡s-Cardama A	Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera.	Journal of clinical oncology 	2009	59
19965641	3717	Hertzberg L	Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group.	Blood	2010	85
20008298	3717	Santos FP	Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.	Blood	2010	61
20008300	3717	Beer PA	Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm.	Blood	2010	63
20061559	3717	Schaub FX	Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms.	Blood	2010	46
20548334	3717	Ding L	MiR-375 frequently downregulated in gastric cancer inhibits cell proliferation by targeting JAK2.	Cell research	2010	86
20631743	3717	Passamonti F	A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications.	Leukemia	2010	54
21151131	3717	Griffiths DS	LIF-independent JAK signalling to chromatin in embryonic stem cells uncovered from an adult stem cell disease.	Nature cell biology	2011	36
21220608	3717	Pardanani A	Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis.	Journal of clinical oncology 	2011	111
21283107	3717	QuintÃ¡s-Cardama A	Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond.	Nature reviews. Drug discovery	2011	74
21841788	3717	Ungureanu D	The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling.	Nature structural and molecular biology	2011	55
22319590	3717	Looyenga BD	STAT3 is activated by JAK2 independent of key oncogenic driver mutations in non-small cell lung carcinoma.	PloS one	2012	35
22385957	3717	Hou Y	Single-cell exome sequencing and monoclonal evolution of a JAK2-negative myeloproliferative neoplasm.	Cell	2012	160
22820988	3717	Bandaranayake RM	Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F.	Nature structural and molecular biology	2012	38
22869151	3717	Vainchenker W	JAK/STAT signaling in hematological malignancies.	Oncogene	2013	63
23382536	3717	Hiatt JB	Single molecule molecular inversion probes for targeted, high-accuracy detection of low-frequency variation.	Genome research	2013	68
24478400	3717	Lundberg P	Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms.	Blood	2014	71
24740812	3717	Rampal R	Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis.	Blood	2014	55
24786775	3717	Cazzola M	From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms.	Blood	2014	32
24986690	3717	Rumi E	Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis.	Blood	2014	32
25037629	3717	Tefferi A	Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis.	Blood	2014	35
25418680	3717	Smith C	Efficient and allele-specific genome editing of disease loci in human iPSCs.	Molecular therapy 	2015	31
25572172	3717	Kleppe M	JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response.	Cancer discovery	2015	27
25671252	3717	Ortmann CA	Effect of mutation order on myeloproliferative neoplasms.	The New England journal of medicine	2015	55
26332546	3717	Baerlocher GM	Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia.	The New England journal of medicine	2015	16
26817954	3717	Araki M	Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms.	Blood	2016	18
7479840	3815	Nagata H	Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder.	Proceedings of the National Academy of Sciences of the United States of America	1995	129
9140397	3815	Schmidt L	Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas.	Nature genetics	1997	271
9438854	3815	Hirota S	Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.	Science	1998	672
11213830	3815	Miettinen M	Gastrointestinal stromal tumors--definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis.	Virchows Archiv 	2001	241
11526490	3815	Tuveson DA	STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications.	Oncogene	2001	100
12094370	3815	Fletcher CD	Diagnosis of gastrointestinal stromal tumors: A consensus approach.	Human pathology	2002	490
12424067	3815	Joensuu H	Management of malignant gastrointestinal stromal tumours.	The Lancet. Oncology	2002	83
12522257	3815	Heinrich MC	PDGFRA activating mutations in gastrointestinal stromal tumors.	Science	2003	371
15010069	3815	Debiec-Rychter M	Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group.	European journal of cancer	2004	80
15365079	3815	Corless CL	Biology of gastrointestinal stromal tumors.	Journal of clinical oncology 	2004	170
16624552	3815	Debiec-Rychter M	KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours.	European journal of cancer	2006	162
16921041	3815	Paschka P	Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study.	Journal of clinical oncology 	2006	105
17090188	3815	Miettinen M	Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis.	Archives of pathology and laboratory medicine	2006	262
17325667	3815	Mahadevan D	A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors.	Oncogene	2007	72
17913750	3815	Patel DJ	Human telomere, oncogenic promoter and 5'-UTR G-quadruplexes: diverse higher order DNA and RNA targets for cancer therapeutics.	Nucleic acids research	2007	176
18076015	3815	Dematteo RP	Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST).	Cancer	2008	96
18223323	3815	Espinosa I	A novel monoclonal antibody against DOG1 is a sensitive and specific marker for gastrointestinal stromal tumors.	The American journal of surgical pathology	2008	84
18235121	3815	Blanke CD	Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.	Journal of clinical oncology 	2008	195
18623623	3815	Liegl B	Heterogeneity of kinase inhibitor resistance mechanisms in GIST.	The Journal of pathology	2008	77
18980976	3815	Beadling C	KIT gene mutations and copy number in melanoma subtypes.	Clinical cancer research 	2008	104
19522824	3815	Stratakis CA	The triad of paragangliomas, gastric stromal tumours and pulmonary chondromas (Carney triad), and the dyad of paragangliomas and gastric stromal sarcomas (Carney-Stratakis syndrome): molecular genetics and clinical implications.	Journal of internal medicine	2009	55
19768731	3815	Haller F	Localization- and mutation-dependent microRNA (miRNA) expression signatures in gastrointestinal stromal tumours (GISTs), with a cluster of co-expressed miRNAs located at 14q32.31.	The Journal of pathology	2010	43
19789626	3815	Dubreuil P	Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT.	PloS one	2009	50
19865100	3815	Bodemer C	Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations.	The Journal of investigative dermatology	2010	45
21399664	3815	Gao XN	MicroRNA-193a represses c-kit expression and functions as a methylation-silenced tumor suppressor in acute myeloid leukemia.	Oncogene	2011	41
21642685	3815	Carvajal RD	KIT as a therapeutic target in metastatic melanoma.	JAMA	2011	114
21690468	3815	Guo J	Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification.	Journal of clinical oncology 	2011	91
23775962	3815	Hodi FS	Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.	Journal of clinical oncology 	2013	46
24638003	3815	Corless CL	Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial.	Journal of clinical oncology 	2014	30
25605837	3815	Joensuu H	KIT and PDGFRA mutations and the risk of GI stromal tumor recurrence.	Journal of clinical oncology 	2015	17
26091043	3815	Cancer Genome Atlas Network.	Genomic Classification of Cutaneous Melanoma.	Cell	2015	197
27011036	3815	Boikos SA	Molecular Subtypes of KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Gastrointestinal Stromal Tumor Clinic.	JAMA oncology	2016	15
2438556	3845	Forrester K	Detection of high incidence of K-ras oncogenes during human colon tumorigenesis.	Nature	1987	165
2453289	3845	Almoguera C	Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes.	Cell	1988	407
3587348	3845	Bos JL	Prevalence of ras gene mutations in human colorectal cancers.	Nature	1987	293
6888561	3845	Schwab M	Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour.	Nature	1983	261
8342602	3845	Hruban RH	K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization.	The American journal of pathology	1993	134
9586664	3845	Andreyev HJ	Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study.	Journal of the National Cancer Institute	1998	155
9727023	3845	Yan J	Ras isoforms vary in their ability to activate Raf-1 and phosphoinositide 3-kinase.	The Journal of biological chemistry	1998	102
9918209	3845	Wang W	The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells.	Clinical cancer research 	1999	146
11097226	3845	Samowitz WS	Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study.	Cancer epidemiology, biomarkers and prevention 	2000	99
11459867	3845	Adjei AA	Blocking oncogenic Ras signaling for cancer therapy.	Journal of the National Cancer Institute	2001	157
11531254	3845	Andreyev HJ	Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study.	British journal of cancer	2001	201
12093899	3845	Smith G	Mutations in APC, Kirsten-ras, and p53--alternative genetic pathways to colorectal cancer.	Proceedings of the National Academy of Sciences of the United States of America	2002	98
12644542	3845	Singer G	Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma.	Journal of the National Cancer Institute	2003	164
15494427	3845	Yu JL	Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis.	Blood	2005	108
15597105	3845	Mascaux C	The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis.	British journal of cancer	2005	130
15608639	3845	Sweet-Cordero A	An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis.	Nature genetics	2005	159
15720814	3845	LÃ¶hr M	Frequency of K-ras mutations in pancreatic intraductal neoplasias associated with pancreatic ductal adenocarcinoma and chronic pancreatitis: a meta-analysis.	Neoplasia	2005	69
15998951	3845	Ince WL	Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab.	Journal of the National Cancer Institute	2005	69
16618717	3845	LiÃ¨vre A	KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.	Cancer research	2006	491
16931950	3845	Brune K	Multifocal neoplastic precursor lesions associated with lobular atrophy of the pancreas in patients having a strong family history of pancreatic cancer.	The American journal of surgical pathology	2006	69
17101316	3845	Spring KJ	High prevalence of sessile serrated adenomas with BRAF mutations: a prospective study of patients undergoing colonoscopy.	Gastroenterology	2006	82
17184525	3845	Krypuy M	High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer.	BMC cancer	2006	78
17375050	3845	Di Fiore F	Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy.	British journal of cancer	2007	192
17998284	3845	De Roock W	KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab.	Annals of oncology 	2008	206
18202412	3845	LiÃ¨vre A	KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.	Journal of clinical oncology 	2008	336
18224685	3845	Barault L	Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers.	International journal of cancer	2008	84
18316791	3845	Amado RG	Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.	Journal of clinical oncology 	2008	728
18669866	3845	Perrone F	PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients.	Annals of oncology 	2009	112
18794081	3845	Riely GJ	Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma.	Clinical cancer research 	2008	131
18804418	3845	Linardou H	Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer.	The Lancet. Oncology	2008	184
18946061	3845	Karapetis CS	K-ras mutations and benefit from cetuximab in advanced colorectal cancer.	The New England journal of medicine	2008	797
19001320	3845	Di Nicolantonio F	Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.	Journal of clinical oncology 	2008	416
19056857	3845	Santini D	High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice.	The oncologist	2008	57
19114683	3845	Bokemeyer C	Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.	Journal of clinical oncology 	2009	369
19124802	3845	Jimeno A	KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection.	Journal of clinical oncology 	2009	58
19196673	3845	Tol J	Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer.	The New England journal of medicine	2009	287
19237633	3845	Ogino S	PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer.	Journal of clinical oncology 	2009	111
19339720	3845	Van Cutsem E	Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.	The New England journal of medicine	2009	786
19349489	3845	Riely GJ	KRAS mutations in non-small cell lung cancer.	Proceedings of the American Thoracic Society	2009	142
19398573	3845	Loupakis F	PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.	Journal of clinical oncology 	2009	123
19401449	3845	Wee S	PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers.	Cancer research	2009	116
19490892	3845	Scholl C	Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells.	Cell	2009	189
19603018	3845	Loupakis F	KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.	British journal of cancer	2009	136
19603024	3845	Souglakos J	Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer.	British journal of cancer	2009	76
19661383	3845	Yun J	Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells.	Science	2009	210
19686742	3845	Nosho K	A prospective cohort study shows unique epigenetic, genetic, and prognostic features of synchronous colorectal cancers.	Gastroenterology	2009	53
19738126	3845	Jacobs B	Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab.	Journal of clinical oncology 	2009	84
19884549	3845	Richman SD	KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial.	Journal of clinical oncology 	2009	146
19908233	3845	Zlobec I	Clinicopathological and protein characterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosis.	International journal of cancer	2010	58
19934290	3845	Ogino S	KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803.	Clinical cancer research 	2009	62
20005451	3845	Oh JS	Lin28-let7 modulates radiosensitivity of human cancer cells with activation of K-Ras.	International journal of radiation oncology, biology, physics	2010	59
20008640	3845	Roth AD	Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.	Journal of clinical oncology 	2010	282
20022659	3845	Mao C	KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies.	Lung cancer	2010	74
20102720	3845	Goel A	Aberrant DNA methylation in hereditary nonpolyposis colorectal cancer without mismatch repair deficiency.	Gastroenterology	2010	42
20413299	3845	Tol J	Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.	European journal of cancer	2010	61
20501503	3845	FariÃ±a-Sarasqueta A	The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients.	Annals of oncology 	2010	72
20505728	3845	Lee W	The mutation spectrum revealed by paired genome sequences from a lung cancer patient.	Nature	2010	197
20512148	3845	Lauth M	DYRK1B-dependent autocrine-to-paracrine shift of Hedgehog signaling by mutant RAS.	Nature structural and molecular biology	2010	48
20570890	3845	Janakiraman M	Genomic and biological characterization of exon 4 KRAS mutations in human cancer.	Cancer research	2010	92
20603437	3845	Zhang W	A let-7 microRNA-binding site polymorphism in 3'-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy.	Annals of oncology 	2011	37
20619739	3845	De Roock W	Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.	The Lancet. Oncology	2010	475
20699365	3845	Halilovic E	PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling.	Cancer research	2010	49
20736745	3845	Irahara N	NRAS mutations are rare in colorectal cancer.	Diagnostic molecular pathology 	2010	43
20841479	3845	Cepero V	MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors.	Cancer research	2010	46
20927778	3845	Nosho K	Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review.	The Journal of pathology	2010	104
20978259	3845	De Roock W	Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.	JAMA	2010	186
21228335	3845	Bokemeyer C	Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.	Annals of oncology 	2011	163
21239505	3845	Tie J	KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer.	Clinical cancer research 	2011	47
21305640	3845	Vaughn CP	Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer.	Genes, chromosomes and cancer	2011	59
21364579	3845	Knijn N	KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients.	British journal of cancer	2011	63
21383284	3845	Hutchins G	Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer.	Journal of clinical oncology 	2011	125
21435948	3845	Paranjape T	A 3'-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis.	The Lancet. Oncology	2011	44
21519026	3845	Bekaii-Saab T	Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers.	Journal of clinical oncology 	2011	60
21543894	3845	Chan E	MicroRNA signatures differentiate melanoma subtypes.	Cell cycle	2011	35
21594292	3845	Pekin D	Quantitative and sensitive detection of rare mutations using droplet-based microfluidics.	Lab on a chip	2011	61
21632860	3845	Molinari F	Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer.	Clinical cancer research 	2011	56
21943101	3845	Makrodouli E	BRAF and RAS oncogenes regulate Rho GTPase pathways to mediate migration and invasion properties in human colon cancer cells: a comparative study.	Molecular cancer	2011	36
21985784	3845	Ebi H	Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers.	The Journal of clinical investigation	2011	63
22228631	3845	Spindler KL	Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan.	Clinical cancer research 	2012	44
22247021	3845	Ihle NT	Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome.	Journal of the National Cancer Institute	2012	83
22266220	3845	O'Dell MR	Kras(G12D) and p53 mutation cause primary intrahepatic cholangiocarcinoma.	Cancer research	2012	33
22282465	3845	Miranda C	KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors.	Clinical cancer research 	2012	38
22314188	3845	Pai RK	BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features.	The American journal of surgical pathology	2012	35
22341439	3845	Singh A	TAK1 inhibition promotes apoptosis in KRAS-dependent colon cancers.	Cell	2012	84
22446022	3845	Bokemeyer C	Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials.	European journal of cancer	2012	123
22473155	3845	Tveit KM	Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study.	Journal of clinical oncology 	2012	106
22474202	3845	Alberts SR	Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial.	JAMA	2012	89
22481281	3845	Chang DT	Clinicopathologic and molecular features of sporadic early-onset colorectal adenocarcinoma: an adenocarcinoma with frequent signet ring cell differentiation, rectal and sigmoid involvement, and adverse morphologic features.	Modern pathology 	2012	33
22613949	3845	Steckel M	Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies.	Cell research	2012	45
22665543	3845	Vakiani E	Comparative genomic analysis of primary versus metastatic colorectal carcinomas.	Journal of clinical oncology 	2012	67
22734028	3845	Tejpar S	Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab.	Journal of clinical oncology 	2012	98
22753589	3845	Imamura Y	Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers.	Clinical cancer research 	2012	62
22798500	3845	Tian S	A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction.	Gut	2013	26
22898602	3845	Ward AF	Targeting oncogenic Ras signaling in hematologic malignancies.	Blood	2012	50
23122493	3845	Karachaliou N	KRAS mutations in lung cancer.	Clinical lung cancer	2013	31
23178454	3845	Baker R	Site-specific monoubiquitination activates Ras by impeding GTPase-activating protein function.	Nature structural and molecular biology	2013	30
23182985	3845	Peeters M	Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab.	Journal of clinical oncology 	2013	63
23200175	3845	JÃ¤nne PA	Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.	The Lancet. Oncology	2013	153
23293113	3845	Tougeron D	Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer.	Annals of oncology 	2013	29
23295441	3845	Sia D	Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.	Gastroenterology	2013	61
23334325	3845	Huang H	Oncogenic K-Ras requires activation for enhanced activity.	Oncogene	2014	31
23348904	3845	Rosty C	Colorectal carcinomas with KRAS mutation are associated with distinctive morphological and molecular features.	Modern pathology 	2013	47
23374602	3845	Pentheroudakis G	Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes.	BMC cancer	2013	33
23419522	3845	Fabbri F	Detection and recovery of circulating colon cancer cells using a dielectrophoresis-based device: KRAS mutation status in pure CTCs.	Cancer letters	2013	47
23471846	3845	Heitzer E	Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing.	Cancer research	2013	122
23511557	3845	Phipps AI	KRAS-mutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers.	British journal of cancer	2013	40
23614898	3845	Morris EJ	Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors.	Cancer discovery	2013	94
23630215	3845	Shepherd FA	Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy.	Journal of clinical oncology 	2013	45
23660947	3845	EklÃ¶f V	The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer.	British journal of cancer	2013	38
23725851	3845	Seymour MT	Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial.	The Lancet. Oncology	2013	65
23792451	3845	Ogino S	Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology.	Oncogene	2014	38
23912084	3845	Murphy SJ	Genetic alterations associated with progression from pancreatic intraepithelial neoplasia to invasive pancreatic tumor.	Gastroenterology	2013	33
23943799	3845	Licciulli S	Notch1 is required for Kras-induced lung adenocarcinoma and controls tumor cell survival via p53.	Cancer research	2013	27
24018645	3845	Vauthey JN	RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases.	Annals of surgery	2013	29
24024839	3845	Douillard JY	Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.	The New England journal of medicine	2013	383
24042191	3845	Mouradov D	Survival in stage II/III colorectal cancer is independently predicted by chromosomal and microsatellite instability, but not by specific driver mutations.	The American journal of gastroenterology	2013	27
24043732	3845	Piessevaux H	Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab.	Journal of clinical oncology 	2013	28
24297898	3845	Zorde Khvalevsky E	Mutant KRAS is a druggable target for pancreatic cancer.	Proceedings of the National Academy of Sciences of the United States of America	2013	37
24385213	3845	Tahara T	Fusobacterium in colonic flora and molecular features of colorectal carcinoma.	Cancer research	2014	46
24398677	3845	Kahlert C	Identification of double-stranded genomic DNA spanning all chromosomes with mutated KRAS and p53 DNA in the serum exosomes of patients with pancreatic cancer.	The Journal of biological chemistry	2014	94
24525237	3845	Grabocka E	Wild-type H- and N-Ras promote mutant K-Ras-driven tumorigenesis by modulating the DNA damage response.	Cancer cell	2014	31
24645800	3845	Imperiale TF	Multitarget stool DNA testing for colorectal-cancer screening.	The New England journal of medicine	2014	144
24658074	3845	Thierry AR	Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA.	Nature medicine	2014	70
24681997	3845	Thege FI	Microfluidic immunocapture of circulating pancreatic cells using parallel EpCAM and MUC1 capture: characterization, optimization and downstream analysis.	Lab on a chip	2014	23
24687927	3845	Yoon HH	KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance).	Clinical cancer research 	2014	22
24929527	3845	Spiegel J	Small-molecule modulation of Ras signaling.	Nature chemical biology	2014	33
25051912	3845	Zoratto F	Focus on genetic and epigenetic events of colorectal cancer pathogenesis: implications for molecular diagnosis.	Tumour biology 	2014	35
25280443	3845	Phipps AI	Association between molecular subtypes of colorectal cancer and patient survival.	Gastroenterology	2015	75
25361982	3845	Klingbiel D	Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial.	Annals of oncology 	2015	20
25632066	3845	Chen JS	A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer.	Annals of oncology 	2015	17
25706875	3845	Matano M	Modeling colorectal cancer using CRISPR-Cas9-mediated engineering of human intestinal organoids.	Nature medicine	2015	74
25722381	3845	Blumenschein GR Jr	A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)â .	Annals of oncology 	2015	18
25823825	3845	Kinugasa H	Detection of K-ras gene mutation by liquid biopsy in patients with pancreatic cancer.	Cancer	2015	26
25877855	3845	Tabernero J	Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.	The Lancet. Oncology	2015	69
25937522	3845	Bokemeyer C	FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer.	European journal of cancer	2015	24
25961927	3845	Garcia PL	The BET bromodomain inhibitor JQ1 suppresses growth of pancreatic ductal adenocarcinoma in patient-derived xenograft models.	Oncogene	2016	23
26084335	3845	Kim KT	Single-cell mRNA sequencing identifies subclonal heterogeneity in anti-cancer drug responses of lung adenocarcinoma cells.	Genome biology	2015	32
26085511	3845	Frenel JS	Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration.	Clinical cancer research 	2015	31
26216840	3845	Carethers JM	Genetics and Genetic Biomarkers in Sporadic Colorectal Cancer.	Gastroenterology	2015	32
26608120	3845	Johnson DB	Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms.	European journal of cancer	2015	18
26627737	3845	Hart T	High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities.	Cell	2015	78
26739882	3845	Patricelli MP	Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State.	Cancer discovery	2016	22
8553070	4089	Hahn SA	DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1.	Science	1996	423
8653691	4089	Schutte M	DPC4 gene in various tumor types.	Cancer research	1996	133
12097290	4089	Murphy KM	Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%.	Cancer research	2002	93
15031030	4089	Gallione CJ	A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4).	Lancet	2004	107
16135802	4089	Levy L	Smad4 dependency defines two classes of transforming growth factor {beta} (TGF-{beta}) target genes and distinguishes TGF-{beta}-induced epithelial-mesenchymal transition from its antiproliferative and migratory responses.	Molecular and cellular biology	2005	90
19584151	4089	Blackford A	SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer.	Clinical cancer research 	2009	91
21112326	4089	Hao J	MicroRNA 483-3p suppresses the expression of DPC4/Smad4 in pancreatic cancer.	FEBS letters	2011	38
27432539	4089	Yu J	Digital next-generation sequencing identifies low-abundance mutations in pancreatic juice samples collected from the duodenum of patients with pancreatic cancer and intraductal papillary mucinous neoplasms.	Gut	2017	5
9671804	4193	Momand J	The MDM2 gene amplification database.	Nucleic acids research	1998	217
15550242	4193	Bond GL	A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans.	Cell	2004	335
15652475	4193	Vousden KH	P53 and prognosis: new insights and further complexity.	Cell	2005	67
17116689	4193	LindstrÃ¶m MS	Cancer-associated mutations in the MDM2 zinc finger domain disrupt ribosomal protein interaction and attenuate MDM2-induced p53 degradation.	Molecular and cellular biology	2007	59
19147532	4193	Wade M	Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry?	Molecular cancer research 	2009	61
19448627	4193	Wang SP	p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug.	Nature cell biology	2009	92
19935675	4193	Brown CJ	Awakening guardian angels: drugging the p53 pathway.	Nature reviews. Cancer	2009	252
20975744	4193	Cheok CF	Translating p53 into the clinic.	Nature reviews. Clinical oncology	2011	118
21317459	4193	Rao B	Evaluation of an Actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapy.	Oncotarget	2010	50
23084521	4193	Ray-Coquard I	Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study.	The Lancet. Oncology	2012	111
24356649	4193	Zheng T	Spliced MDM2 isoforms promote mutant p53 accumulation and gain-of-function in tumorigenesis.	Nature communications	2013	34
25477334	4193	Meng X	MDM2-p53 pathway in hepatocellular carcinoma.	Cancer research	2014	23
25621662	4193	Macheret M	DNA replication stress as a hallmark of cancer.	Annual review of pathology	2015	55
17879353	4221	Lemos MC	Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the gene.	Human mutation	2008	88
23850066	4221	Matkar S	Menin: a scaffold protein that controls gene expression and cell signaling.	Trends in biochemical sciences	2013	32
10029064	4255	Esteller M	Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia.	Cancer research	1999	212
16174854	4255	Shen L	MGMT promoter methylation and field defect in sporadic colorectal cancer.	Journal of the National Cancer Institute	2005	149
25140036	4255	Simon M	TERT promoter mutations: a novel independent prognostic factor in primary glioblastomas.	Neuro-oncology	2015	22
7661930	4292	Hamilton SR	The molecular basis of Turcot's syndrome.	The New England journal of medicine	1995	130
8044777	4292	Koi M	Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N'-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation.	Cancer research	1994	139
8128251	4292	Papadopoulos N	Mutation of a mutL homolog in hereditary colon cancer.	Science	1994	298
8145827	4292	Bronner CE	Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer.	Nature	1994	303
9354436	4292	Dietmaier W	Diagnostic microsatellite instability: definition and correlation with mismatch repair protein expression.	Cancer research	1997	129
9593786	4292	Aaltonen LA	Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease.	The New England journal of medicine	1998	185
9699680	4292	Cunningham JM	Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability.	Cancer research	1998	142
11844828	4292	Lindor NM	Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors.	Journal of clinical oncology 	2002	153
15000146	4292	Grady WM	Genomic instability and colon cancer.	Cancer metastasis reviews	2004	75
15342696	4292	Domingo E	BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing.	Journal of medical genetics	2004	77
15855432	4292	PiÃ±ol V	Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer.	JAMA	2005	99
16873062	4292	Kadyrov FA	Endonucleolytic function of MutLalpha in human mismatch repair.	Cell	2006	211
17301300	4292	Hitchins MP	Inheritance of a cancer-associated MLH1 germ-line epimutation.	The New England journal of medicine	2007	89
18398828	4292	Watson P	The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome.	International journal of cancer	2008	95
19273709	4292	Bertagnolli MM	Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803.	Journal of clinical oncology 	2009	103
20420947	4292	Boland CR	Microsatellite instability in colorectal cancer.	Gastroenterology	2010	270
22156295	4292	Wang L	Whole-exome sequencing of human pancreatic cancers and characterization of genomic instability caused by MLH1 haploinsufficiency and complete deficiency.	Genome research	2012	33
22302899	4292	Sinicrope FA	Molecular pathways: microsatellite instability in colorectal cancer: prognostic, predictive, and therapeutic implications.	Clinical cancer research 	2012	50
23049789	4292	Antelo M	A high degree of LINE-1 hypomethylation is a unique feature of early-onset colorectal cancer.	PloS one	2012	36
23354017	4292	RodrÃ­guez-Soler M	Risk of cancer in cases of suspected lynch syndrome without germline mutation.	Gastroenterology	2013	29
23603115	4292	Ghodgaonkar MM	Ribonucleotides misincorporated into DNA act as strand-discrimination signals in eukaryotic mismatch repair.	Molecular cell	2013	59
23821616	4292	Lang GI	Mutation rates, spectra, and genome-wide distribution of spontaneous mutations in mismatch repair deficient yeast.	G3	2013	27
25224212	4292	Billingsley CC	Polymerase É (POLE) mutations in endometrial cancer: clinical outcomes and implications for Lynch syndrome testing.	Cancer	2015	17
15464450	4297	Hess JL	MLL: a histone methyltransferase disrupted in leukemia.	Trends in molecular medicine	2004	96
18538732	4297	Wei J	Microenvironment determines lineage fate in a human model of MLL-AF9 leukemia.	Cancer cell	2008	108
19262598	4297	Meyer C	New insights to the MLL recombinome of acute leukemias.	Leukemia	2009	93
19528532	4297	Balgobind BV	Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study.	Blood	2009	58
20016527	4297	Salzer WL	Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001: a report from the children's oncology group.	Leukemia	2010	46
22017583	4297	Muntean AG	The pathogenesis of mixed-lineage leukemia.	Annual review of pathology	2012	73
22936661	4297	Shi A	Structural insights into inhibition of the bivalent menin-MLL interaction by small molecules in leukemia.	Blood	2012	36
23628958	4297	Meyer C	The MLL recombinome of acute leukemias in 2013.	Leukemia	2013	81
25730765	4297	Andersson AK	The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias.	Nature genetics	2015	46
25998713	4297	Rao RC	Hijacked in cancer: the KMT2 (MLL) family of methyltransferases.	Nature reviews. Cancer	2015	36
26237430	4297	LavallÃ©e VP	The transcriptomic landscape and directed chemical interrogation of MLL-rearranged acute myeloid leukemias.	Nature genetics	2015	16
26331536	4297	Zhu J	Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth.	Nature	2015	51
7604264	4436	Drummond JT	Isolation of an hMSH2-p160 heterodimer that restores DNA mismatch repair to tumor cells.	Science	1995	143
8252616	4436	Fishel R	The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer.	Cell	1993	461
16951683	4436	Chan TL	Heritable germline epimutation of MSH2 in a family with hereditary nonpolyposis colorectal cancer.	Nature genetics	2006	65
11818965	4595	Al-Tassan N	Inherited variants of MYH associated with somatic G:C--&amp;gt;T:A mutations in colorectal tumors.	Nature genetics	2002	265
12606733	4595	Sieber OM	Multiple colorectal adenomas, classic adenomatous polyposis, and germ-line mutations in MYH.	The New England journal of medicine	2003	141
16454848	4595	Galiatsatos P	Familial adenomatous polyposis.	The American journal of gastroenterology	2006	79
19822006	4595	Half E	Familial adenomatous polyposis.	Orphanet journal of rare diseases	2009	81
25645574	4595	Syngal S	ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes.	The American journal of gastroenterology	2015	62
25980754	4595	Yurgelun MB	Identification of a Variety of Mutations in Cancer Predisposition Genes in Patients With Suspected Lynch Syndrome.	Gastroenterology	2015	18
6414718	4609	Battey J	The human c-myc oncogene: structural consequences of translocation into the IgH locus in Burkitt lymphoma.	Cell	1983	212
9927431	4609	Salghetti SE	Destruction of Myc by ubiquitin-mediated proteolysis: cancer-associated and transforming mutations stabilize Myc.	The EMBO journal	1999	112
10637317	4609	Kyo S	Sp1 cooperates with c-Myc to activate transcription of the human telomerase reverse transcriptase gene (hTERT).	Nucleic acids research	2000	110
10713166	4609	Gregory MA	c-Myc proteolysis by the ubiquitin-proteasome pathway: stabilization of c-Myc in Burkitt's lymphoma cells.	Molecular and cellular biology	2000	117
11509179	4609	Fuchs M	The p400 complex is an essential E1A transformation target.	Cell	2001	102
11607812	4609	Boxer LM	Translocations involving c-myc and c-myc function.	Oncogene	2001	95
12808131	4609	Li Z	A global transcriptional regulatory role for c-Myc in Burkitt's lymphoma cells.	Proceedings of the National Academy of Sciences of the United States of America	2003	192
12808455	4609	Roix JJ	Spatial proximity of translocation-prone gene loci in human lymphomas.	Nature genetics	2003	105
15048125	4609	Yeh E	A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells.	Nature cell biology	2004	237
16094360	4609	Hemann MT	Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants.	Nature	2005	152
16760443	4609	Dave SS	Molecular diagnosis of Burkitt's lymphoma.	The New England journal of medicine	2006	179
17646408	4609	Thompson BJ	The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia.	The Journal of experimental medicine	2007	147
17908964	4609	Guan Y	Amplification of PVT1 contributes to the pathophysiology of ovarian and breast cancer.	Clinical cancer research 	2007	98
18397753	4609	Wong DJ	Module map of stem cell genes guides creation of epithelial cancer stem cells.	Cell stem cell	2008	251
18679422	4609	Zhuang D	C-MYC overexpression is required for continuous suppression of oncogene-induced senescence in melanoma cells.	Oncogene	2008	52
19255330	4609	Pfister S	Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci.	Journal of clinical oncology 	2009	77
19448666	4609	Morrish F	c-Myc activates multiple metabolic networks to generate substrates for cell-cycle entry.	Oncogene	2009	54
19597184	4609	Johnson NA	Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival.	Blood	2009	73
20498406	4609	Barrans S	Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab.	Journal of clinical oncology 	2010	71
22002575	4609	Li S	B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome.	Modern pathology 	2012	34
22851565	4609	Johnson NA	Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.	Journal of clinical oncology 	2012	96
23001146	4609	Calado DP	The cell-cycle regulator c-Myc is essential for the formation and maintenance of germinal centers.	Nature immunology	2012	53
23352430	4609	Barlow JH	Identification of early replicating fragile sites that contribute to genome instability.	Cell	2013	80
25038584	4609	WahlstrÃ¶m T	Impact of MYC in regulation of tumor cell metabolism.	Biochimica et biophysica acta	2015	33
26099045	4609	Yates LR	Subclonal diversification of primary breast cancer revealed by multiregion sequencing.	Nature medicine	2015	74
4047115	4613	Seeger RC	Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas.	The New England journal of medicine	1985	281
6719137	4613	Brodeur GM	Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage.	Science	1984	340
16306521	4613	Attiyeh EF	Chromosome 1p and 11q deletions and outcome in neuroblastoma.	The New England journal of medicine	2005	112
16954472	4613	Asgharzadeh S	Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification.	Journal of the National Cancer Institute	2006	81
19171713	4613	Janoueix-Lerosey I	Overall genomic pattern is a predictor of outcome in neuroblastoma.	Journal of clinical oncology 	2009	64
19401703	4613	Ambros PF	International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee.	British journal of cancer	2009	60
19924232	4613	Bray I	Widespread dysregulation of MiRNAs by MYCN amplification and chromosomal imbalances in neuroblastoma: association of miRNA expression with survival.	PloS one	2009	47
20961996	4613	Qing G	Combinatorial regulation of neuroblastoma tumor progression by N-Myc and hypoxia inducible factor HIF-1alpha.	Cancer research	2010	43
23358695	4613	Mosquera JM	Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer.	Neoplasia	2013	44
23430699	4613	Puissant A	Targeting MYCN in neuroblastoma by BET bromodomain inhibition.	Cancer discovery	2013	135
23498719	4613	Rushlow DE	Characterisation of retinoblastomas without RB1 mutations: genomic, gene expression, and clinical studies.	The Lancet. Oncology	2013	43
25142020	4613	Ren P	ATF4 and N-Myc coordinate glutamine metabolism in MYCN-amplified neuroblastoma cells through ASCT2 activation.	The Journal of pathology	2015	21
25533335	4613	Hill RM	Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable disease.	Cancer cell	2015	18
27040285	4613	Ramaswamy V	Risk stratification of childhood medulloblastoma in the molecular era: the current consensus.	Acta neuropathologica	2016	17
21179087	4615	Ngo VN	Oncogenically active MYD88 mutations in human lymphoma.	Nature	2011	264
21642962	4615	Puente XS	Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia.	Nature	2011	365
22837180	4615	Gonzalez-Aguilar A	Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas.	Clinical cancer research 	2012	38
22931316	4615	Treon SP	MYD88 L265P somatic mutation in WaldenstrÃ¶m's macroglobulinemia.	The New England journal of medicine	2012	116
23321251	4615	Xu L	MYD88 L265P in WaldenstrÃ¶m macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction.	Blood	2013	39
25853747	4615	Treon SP	Ibrutinib in previously treated WaldenstrÃ¶m's macroglobulinemia.	The New England journal of medicine	2015	63
9590180	4683	Varon R	Nibrin, a novel DNA double-strand break repair protein, is mutated in Nijmegen breakage syndrome.	Cell	1998	181
10839545	4683	Wu X	ATM phosphorylation of Nijmegen breakage syndrome protein is required in a DNA damage response.	Nature	2000	98
12509764	4683	D'Andrea AD	The Fanconi anaemia/BRCA pathway.	Nature reviews. Cancer	2003	214
19804755	4683	Williams RS	Nbs1 flexibly tethers Ctp1 and Mre11-Rad50 to coordinate DNA double-strand break processing and repair.	Cell	2009	128
19804756	4683	Lloyd J	A supramodular FHA/BRCT-repeat architecture mediates Nbs1 adaptor function in response to DNA damage.	Cell	2009	70
23468639	4683	Wang H	The interaction of CtIP and Nbs1 connects CDK and ATM to regulate HR-mediated double-strand break repair.	PLoS genetics	2013	42
26315354	4683	Ramus SJ	Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer.	Journal of the National Cancer Institute	2015	22
1694727	4763	Viskochil D	Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus.	Cell	1990	165
2114220	4763	Cawthon RM	A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations.	Cell	1990	171
2116237	4763	Xu GF	The neurofibromatosis type 1 gene encodes a protein related to GAP.	Cell	1990	172
2134734	4763	Wallace MR	Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients.	Science	1990	223
16330947	4763	Miettinen M	Gastrointestinal stromal tumors in patients with neurofibromatosis 1: a clinicopathologic and molecular genetic study of 45 cases.	The American journal of surgical pathology	2006	69
19576851	4763	van Nederveen FH	An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis.	The Lancet. Oncology	2009	69
21262951	4763	Eisenhofer G	Measurements of plasma methoxytyramine, normetanephrine, and metanephrine as discriminators of different hereditary forms of pheochromocytoma.	Clinical chemistry	2011	40
22328163	4763	Gimenez-Roqueplo AP	An update on the genetics of paraganglioma, pheochromocytoma, and associated hereditary syndromes.	Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme	2012	39
22544022	4763	Carter SL	Absolute quantification of somatic DNA alterations in human cancer.	Nature biotechnology	2012	316
23288408	4763	Whittaker SR	A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition.	Cancer discovery	2013	79
25049390	4763	Chen PC	Next-generation sequencing identifies rare variants associated with Noonan syndrome.	Proceedings of the National Academy of Sciences of the United States of America	2014	21
25877329	4763	Ratner N	A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor.	Nature reviews. Cancer	2015	35
26017449	4763	Patch AM	Whole-genome characterization of chemoresistant ovarian cancer.	Nature	2015	123
26214590	4763	Krauthammer M	Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas.	Nature genetics	2015	40
26580448	4763	Zhang J	Germline Mutations in Predisposition Genes in Pediatric Cancer.	The New England journal of medicine	2015	43
27165744	4763	Zheng S	Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma.	Cancer cell	2016	23
8453669	4771	Trofatter JA	A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor.	Cell	1993	200
19476995	4771	Asthagiri AR	Neurofibromatosis type 2.	Lancet	2009	56
24261697	4771	Goutagny S	High incidence of activating TERT promoter mutations in meningiomas undergoing malignant progression.	Brain pathology	2014	22
25893302	4771	Petrilli AM	Role of Merlin/NF2 inactivation in tumor biology.	Oncogene	2016	13
1831692	4851	Ellisen LW	TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms.	Cell	1991	380
15472075	4851	Weng AP	Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia.	Science	2004	749
16738328	4851	Malecki MJ	Leukemia-associated mutations within the NOTCH1 heterodimerization domain fall into at least two distinct mechanistic classes.	Molecular and cellular biology	2006	88
17173050	4851	Vilimas T	Targeting the NF-kappaB signaling pathway in Notch1-induced T-cell leukemia.	Nature medicine	2007	91
17575125	4851	Malyukova A	The tumor suppressor gene hCDC4 is frequently mutated in human T-cell acute lymphoblastic leukemia with functional consequences for Notch signaling.	Cancer research	2007	57
17873882	4851	Palomero T	Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia.	Nature medicine	2007	277
20007775	4851	Westhoff B	Alterations of the Notch pathway in lung cancer.	Proceedings of the National Academy of Sciences of the United States of America	2009	110
20008221	4851	Ferrando AA	The role of NOTCH1 signaling in T-ALL.	Hematology. American Society of Hematology. Education Program	2009	51
21798897	4851	Agrawal N	Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1.	Science	2011	496
21948802	4851	Lobry C	Oncogenic and tumor suppressor functions of Notch in cancer: it's NOTCH what you think.	The Journal of experimental medicine	2011	94
22006338	4851	Wang NJ	Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma.	Proceedings of the National Academy of Sciences of the United States of America	2011	108
22077063	4851	Rossi D	Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia.	Blood	2012	63
22207691	4851	Del Giudice I	NOTCH1 mutations in +12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of +12 CLL.	Haematologica	2012	36
22210878	4851	Kridel R	Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma.	Blood	2012	52
23295735	4851	Villamor N	NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome.	Leukemia	2013	26
23825651	4851	Kluk MJ	Gauging NOTCH1 Activation in Cancer Using Immunohistochemistry.	PloS one	2013	28
24662767	4851	South AP	NOTCH1 mutations occur early during cutaneous squamous cell carcinogenesis.	The Journal of investigative dermatology	2014	30
25104330	4851	Stoeck A	Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma.	Cancer discovery	2014	25
25194570	4851	Herranz D	A NOTCH1-driven MYC enhancer promotes T cell development, transformation and acute lymphoblastic leukemia.	Nature medicine	2014	45
26681674	4851	San Lucas FA	Minimally invasive genomic and transcriptomic profiling of visceral cancers by next-generation sequencing of circulating exosomes.	Annals of oncology 	2016	13
15659725	4869	Falini B	Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.	The New England journal of medicine	2005	301
16041368	4869	Wang W	Temporal and spatial control of nucleophosmin by the Ran-Crm1 complex in centrosome duplication.	Nature cell biology	2005	79
16455956	4869	Thiede C	Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML).	Blood	2006	106
16794633	4869	Grisendi S	Nucleophosmin and cancer.	Nature reviews. Cancer	2006	205
18308931	4869	Garzon R	Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin.	Proceedings of the National Academy of Sciences of the United States of America	2008	152
20026798	4869	Becker H	Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study.	Journal of clinical oncology 	2010	83
21030560	4869	Falini B	Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity?	Blood	2011	40
21555683	4869	KrÃ¶nke J	Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group.	Journal of clinical oncology 	2011	47
22370328	4869	Jerez A	Topography, clinical, and genomic correlates of 5q myeloid malignancies revisited.	Journal of clinical oncology 	2012	33
23634996	4869	Cancer Genome Atlas Research Network.	Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia.	The New England journal of medicine	2013	712
24220271	4869	Dawson MA	Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional program in acute myeloid leukemia.	Leukemia	2014	29
26789727	4869	Ivey A	Assessment of Minimal Residual Disease in Standard-Risk AML.	The New England journal of medicine	2016	31
14695152	4893	Omholt K	NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression.	Clinical cancer research 	2003	84
17119447	4893	Edlundh-Rose E	NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing.	Melanoma research	2006	78
18615679	4893	Agaram NP	Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors.	Genes, chromosomes and cancer	2008	64
20975100	4893	Ellerhorst JA	Clinical correlates of NRAS and BRAF mutations in primary human melanoma.	Clinical cancer research 	2011	49
21107323	4893	Nazarian R	Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.	Nature	2010	594
21166657	4893	Lee JH	Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis.	The British journal of dermatology	2011	68
21615881	4893	Devitt B	Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma.	Pigment cell and melanoma research	2011	52
21880806	4893	Nikiforov YE	Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples.	The Journal of clinical endocrinology and metabolism	2011	95
22048237	4893	Kirkwood JM	Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.	Clinical cancer research 	2012	76
22130161	4893	Joseph RW	Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma.	Journal of immunotherapy	2012	32
22180178	4893	Jakob JA	NRAS mutation status is an independent prognostic factor in metastatic melanoma.	Cancer	2012	97
22614978	4893	Colombino M	BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma.	Journal of clinical oncology 	2012	72
22931913	4893	Mann GJ	BRAF mutation, NRAS mutation, and the absence of an immune-related expressed gene profile predict poor outcome in patients with stage III melanoma.	The Journal of investigative dermatology	2013	33
23392294	4893	Kinsler VA	Multiple congenital melanocytic nevi and neurocutaneous melanosis are caused by postzygotic mutations in codon 61 of NRAS.	The Journal of investigative dermatology	2013	31
23406027	4893	Ho AL	Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.	The New England journal of medicine	2013	83
23414587	4893	Ascierto PA	MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.	The Lancet. Oncology	2013	129
23515407	4893	Ohashi K	Characteristics of lung cancers harboring NRAS mutations.	Clinical cancer research 	2013	30
23833303	4893	Mar VJ	BRAF/NRAS wild-type melanomas have a high mutation load correlating with histologic and molecular signatures of UV damage.	Clinical cancer research 	2013	29
24885028	4893	Wong SQ	Sequence artefacts in a prospective series of formalin-fixed tumours tested for mutations in hotspot regions by massively parallel sequencing.	BMC medical genomics	2014	37
25148578	4893	Siroy AE	Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma.	The Journal of investigative dermatology	2015	17
25180764	4893	Fedorenko IV	Beyond BRAF: where next for melanoma therapy?	British journal of cancer	2015	28
26095797	4893	Tsao SC	Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations.	Scientific reports	2015	18
26673799	4893	Krepler C	Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies.	Clinical cancer research 	2016	18
14645423	5156	Heinrich MC	Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.	Journal of clinical oncology 	2003	355
15685537	5156	Debiec-Rychter M	Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants.	Gastroenterology	2005	99
15930355	5156	Antonescu CR	Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation.	Clinical cancer research 	2005	150
18955458	5156	Heinrich MC	Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.	Journal of clinical oncology 	2008	123
20124181	5156	Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST).	Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients.	Journal of clinical oncology 	2010	78
21125679	5156	Antonescu CR	The GIST paradigm: lessons for other kinase-driven cancers.	The Journal of pathology	2011	35
21931021	5156	Paugh BS	Genome-wide analyses identify recurrent amplifications of receptor tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine glioma.	Journal of clinical oncology 	2011	68
22389665	5156	Puget S	Mesenchymal transition and PDGFRA amplification/mutation are key distinct oncogenic events in pediatric diffuse intrinsic pontine gliomas.	PloS one	2012	61
22453568	5156	Joensuu H	One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.	JAMA	2012	139
23623056	5156	Joensuu H	Gastrointestinal stromal tumour.	Lancet	2013	55
23970477	5156	Paugh BS	Novel oncogenic PDGFRA mutations in pediatric high-grade gliomas.	Cancer research	2013	35
24925196	5156	von Mehren M	Gastrointestinal stromal tumors, version 2.2014.	Journal of the National Comprehensive Cancer Network 	2014	25
25047029	5156	Buczkowicz P	Histopathological spectrum of paediatric diffuse intrinsic pontine glioma: diagnostic and therapeutic implications.	Acta neuropathologica	2014	32
15016963	5290	Samuels Y	High frequency of mutations of the PIK3CA gene in human cancers.	Science	2004	909
15254419	5290	Bachman KE	The PIK3CA gene is mutated with high frequency in human breast cancers.	Cancer biology and therapy	2004	179
15467468	5290	Samuels Y	Oncogenic mutations of PIK3CA in human cancers.	Cell cycle	2004	125
15520168	5290	Campbell IG	Mutation of the PIK3CA gene in ovarian and breast cancer.	Cancer research	2004	221
15608678	5290	Lee JW	PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas.	Oncogene	2005	111
15647370	5290	Kang S	Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic.	Proceedings of the National Academy of Sciences of the United States of America	2005	205
15805248	5290	Saal LH	PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma.	Cancer research	2005	253
15950905	5290	Samuels Y	Mutant PIK3CA promotes cell growth and invasion of human cancer cells.	Cancer cell	2005	287
16288007	5290	GarcÃ­a-RostÃ¡n G	Mutation of the PIK3CA gene in anaplastic thyroid cancer.	Cancer research	2005	81
16322209	5290	Oda K	High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma.	Cancer research	2005	110
16322248	5290	Isakoff SJ	Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells.	Cancer research	2005	167
16339315	5290	Zhao JJ	The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells.	Proceedings of the National Academy of Sciences of the United States of America	2005	119
16357568	5290	Samuels Y	Oncogenic PI3K and its role in cancer.	Current opinion in oncology	2006	127
16432179	5290	Bader AG	Cancer-specific mutations in PIK3CA are oncogenic in vivo.	Proceedings of the National Academy of Sciences of the United States of America	2006	114
16449998	5290	Karakas B	Mutation of the PIK3CA oncogene in human cancers.	British journal of cancer	2006	97
16930767	5290	Kawano O	PIK3CA mutation status in Japanese lung cancer patients.	Lung cancer	2006	72
17060456	5290	Kim JS	Activation of p53-dependent growth suppression in human cells by mutations in PTEN or PIK3CA.	Molecular and cellular biology	2007	59
17314276	5290	Hollestelle A	Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines.	Molecular cancer research 	2007	106
17575221	5290	PÃ©rez-Tenorio G	PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer.	Clinical cancer research 	2007	91
17936563	5290	Berns K	A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.	Cancer cell	2007	406
18079394	5290	Huang CH	The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations.	Science	2007	144
18757405	5290	Yamamoto H	PIK3CA mutations and copy number gains in human lung cancers.	Cancer research	2008	140
19223544	5290	Sartore-Bianchi A	PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.	Cancer research	2009	197
19261849	5290	Salvesen HB	Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation.	Proceedings of the National Academy of Sciences of the United States of America	2009	83
19276248	5290	Gonzalez-Angulo AM	Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer.	Clinical cancer research 	2009	67
19349352	5290	Kuo KT	Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma.	The American journal of pathology	2009	89
19573809	5290	Vasudevan KM	AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer.	Cancer cell	2009	179
19671852	5290	Kalinsky K	PIK3CA mutation associates with improved outcome in breast cancer.	Clinical cancer research 	2009	102
19685490	5290	LÃ³pez-Knowles E	PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality.	International journal of cancer	2010	65
19805105	5290	Mandelker D	A frequent kinase domain mutation that changes the interaction between PI3Kalpha and the membrane.	Proceedings of the National Academy of Sciences of the United States of America	2009	92
20813970	5290	Esteva FJ	PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.	The American journal of pathology	2010	94
20940279	5290	Dupont Jensen J	PIK3CA mutations may be discordant between primary and corresponding metastatic disease in breast cancer.	Clinical cancer research 	2011	54
21266528	5290	Rudd ML	A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas.	Clinical cancer research 	2011	71
21358673	5290	Weigelt B	PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs.	Oncogene	2011	65
21474066	5290	Kennedy AL	Activation of the PIK3CA/AKT pathway suppresses senescence induced by an activated RAS oncogene to promote tumorigenesis.	Molecular cell	2011	66
21482677	5290	Meyer DS	Luminal expression of PIK3CA mutant H1047R in the mammary gland induces heterogeneous tumors.	Cancer research	2011	40
21490305	5290	Gonzalez-Angulo AM	PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer.	Molecular cancer therapeutics	2011	71
21594665	5290	Razis E	Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.	Breast cancer research and treatment	2011	67
21676217	5290	Wang L	PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib.	BMC cancer	2011	50
21822287	5290	Liu P	Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms.	Nature medicine	2011	88
21829508	5290	Janku F	PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers.	PloS one	2011	60
22039088	5290	Mao C	PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis.	Annals of oncology 	2012	51
22157930	5290	Yamamoto S	Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations.	Modern pathology 	2012	43
22188813	5290	Maira SM	Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor.	Molecular cancer therapeutics	2012	118
22252965	5290	Hernandez L	Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra-tumour genetic heterogeneity and clonal selection.	The Journal of pathology	2012	40
22271473	5290	Janku F	PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations.	Journal of clinical oncology 	2012	145
22285706	5290	Sood A	PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer.	Clinical colorectal cancer	2012	33
22330809	5290	Cizkova M	PIK3CA mutation impact on survival in breast cancer patients and in ERÎ±, PR and ERBB2-based subgroups.	Breast cancer research 	2012	41
22357840	5290	Liao X	Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review.	Clinical cancer research 	2012	88
22421194	5290	Higgins MJ	Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood.	Clinical cancer research 	2012	56
22923510	5290	Kuhn E	Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses.	Journal of the National Cancer Institute	2012	58
23066039	5290	Janku F	PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials.	Cancer research	2013	76
23092874	5290	Chandarlapaty S	Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer.	Clinical cancer research 	2012	43
23094721	5290	Liao X	Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival.	The New England journal of medicine	2012	204
23136191	5290	Spoerke JM	Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models.	Clinical cancer research 	2012	41
23248156	5290	Janku F	PIK3CA mutations in advanced cancers: characteristics and outcomes.	Oncotarget	2012	30
23532889	5290	Shigaki H	PIK3CA mutation is associated with a favorable prognosis among patients with curatively resected esophageal squamous cell carcinoma.	Clinical cancer research 	2013	28
23739063	5290	Loi S	Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer.	Journal of the National Cancer Institute	2013	34
23785428	5290	Rosty C	PIK3CA activating mutation in colorectal carcinoma: associations with molecular features and survival.	PloS one	2013	31
23903756	5290	Elkabets M	mTORC1 inhibition is required for sensitivity to PI3K p110Î± inhibitors in PIK3CA-mutant breast cancer.	Science translational medicine	2013	68
24062397	5290	Domingo E	Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer.	Journal of clinical oncology 	2013	44
24218517	5290	Karapetis CS	PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer--results from NCIC CTG/AGITG CO.17.	Clinical cancer research 	2014	25
24504125	5290	Beaver JA	Detection of cancer DNA in plasma of patients with early-stage breast cancer.	Clinical cancer research 	2014	34
24533074	5290	Wang L	PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroup.	PloS one	2014	25
24608574	5290	Fritsch C	Characterization of the novel and specific PI3KÎ± inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.	Molecular cancer therapeutics	2014	52
24910434	5290	Henderson S	APOBEC-mediated cytosine deamination links PIK3CA helical domain mutations to human papillomavirus-driven tumor development.	Cell reports	2014	55
25099740	5290	Wang Z	mTOR co-targeting in cetuximab resistance in head and neck cancers harboring PIK3CA and RAS mutations.	Journal of the National Cancer Institute	2014	22
25199759	5290	Loibl S	PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.	Journal of clinical oncology 	2014	41
25409150	5290	Juric D	Convergent loss of PTEN leads to clinical resistance to a PI(3)KÎ± inhibitor.	Nature	2015	60
25539732	5290	Pestrin M	Heterogeneity of PIK3CA mutational status at the single cell level in circulating tumor cells from metastatic breast cancer patients.	Molecular oncology	2015	22
25847936	5290	Isakoff SJ	TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer.	Journal of clinical oncology 	2015	43
26392102	5290	Corcoran RB	Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.	Journal of clinical oncology 	2015	48
27096951	5290	Elwood PC	Aspirin in the Treatment of Cancer: Reductions in Metastatic Spread and in Mortality: A Systematic Review and Meta-Analyses of Published Studies.	PloS one	2016	16
1652368	5371	Kakizuka A	Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML.	Cell	1991	267
1652369	5371	de ThÃ© H	The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR.	Cell	1991	256
8131741	5371	Koken MH	The t(15;17) translocation alters a nuclear body in a retinoic acid-reversible fashion.	The EMBO journal	1994	120
8293468	5371	Weis K	Retinoic acid regulates aberrant nuclear localization of PML-RAR alpha in acute promyelocytic leukemia cells.	Cell	1994	163
14970276	5371	Gurrieri C	Loss of the tumor suppressor PML in human cancers of multiple histologic origins.	Journal of the National Cancer Institute	2004	93
20378816	5371	Zhang XW	Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML.	Science	2010	152
17652623	5609	Wang YF	Apoptosis induction in human melanoma cells by inhibition of MEK is caspase-independent and mediated by the Bcl-2 family members PUMA, Bim, and Mcl-1.	Clinical cancer research 	2007	71
20802351	5609	Hainsworth JD	A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens.	Journal of thoracic oncology 	2010	45
22663011	5609	Flaherty KT	Improved survival with MEK inhibition in BRAF-mutated melanoma.	The New England journal of medicine	2012	379
22805292	5609	Falchook GS	Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.	The Lancet. Oncology	2012	105
23020132	5609	Flaherty KT	Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.	The New England journal of medicine	2012	534
24080641	5609	Jang S	Treatment of BRAF-mutant melanoma: the role of vemurafenib and other therapies.	Clinical pharmacology and therapeutics	2014	23
25037139	5609	Ribas A	Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study.	The Lancet. Oncology	2014	33
25265492	5609	Long GV	Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.	The New England journal of medicine	2014	184
25265494	5609	Larkin J	Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.	The New England journal of medicine	2014	196
25287827	5609	Johnson DB	Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor.	Journal of clinical oncology 	2014	37
25399551	5609	Robert C	Improved overall survival in melanoma with combined dabrafenib and trametinib.	The New England journal of medicine	2015	237
26115796	5609	Ribas A	Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.	The Lancet. Oncology	2015	136
26121087	5609	Eleveld TF	Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations.	Nature genetics	2015	54
27283860	5609	Planchard D	Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.	The Lancet. Oncology	2016	17
9041183	5727	Raffel C	Sporadic medulloblastomas contain PTCH mutations.	Cancer research	1997	107
10984056	5727	Taipale J	Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine.	Nature	2000	350
19032739	5727	Lo Muzio L	Nevoid basal cell carcinoma syndrome (Gorlin syndrome).	Orphanet journal of rare diseases	2008	58
19726761	5727	Rudin CM	Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449.	The New England journal of medicine	2009	289
19726763	5727	Von Hoff DD	Inhibition of the hedgehog pathway in advanced basal-cell carcinoma.	The New England journal of medicine	2009	281
9090379	5728	Steck PA	Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers.	Nature genetics	1997	558
9187108	5728	Li DM	TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta.	Cancer research	1997	175
9307275	5728	Tashiro H	Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies.	Cancer research	1997	127
9443392	5728	Suzuki H	Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues.	Cancer research	1998	100
9467011	5728	Marsh DJ	Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation.	Human molecular genetics	1998	118
9560261	5728	Whang YE	Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression.	Proceedings of the National Academy of Sciences of the United States of America	1998	137
10555148	5728	Lee JO	Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association.	Cell	1999	274
10564676	5728	Ali IU	Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity.	Journal of the National Cancer Institute	1999	113
15193142	5728	Leslie NR	PTEN function: how normal cells control it and tumour cells lose it.	The Biochemical journal	2004	104
15805158	5728	Butler MG	Subset of individuals with autism spectrum disorders and extreme macrocephaly associated with germline PTEN tumour suppressor gene mutations.	Journal of medical genetics	2005	196
15960972	5728	Westbrook TF	A genetic screen for candidate tumor suppressors identifies REST.	Cell	2005	166
17218261	5728	Trotman LC	Ubiquitination regulates PTEN nuclear import and tumor suppression.	Cell	2007	205
17940504	5728	Frattini M	PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients.	British journal of cancer	2007	135
18767981	5728	Chalhoub N	PTEN and the PI3-kinase pathway in cancer.	Annual review of pathology	2009	251
18794879	5728	Yin Y	PTEN: a new guardian of the genome.	Oncogene	2008	93
19402094	5728	Sircar K	PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer.	The Journal of pathology	2009	70
19458356	5728	Gutierrez A	High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia.	Blood	2009	122
19729658	5728	Fine B	Activation of the PI3K pathway in cancer through inhibition of PTEN by exchange factor P-REX2a.	Science	2009	79
20533527	5728	McBride KL	Confirmation study of PTEN mutations among individuals with autism or developmental delays/mental retardation and macrocephaly.	Autism research 	2010	61
20600018	5728	Heald B	Frequent gastrointestinal polyps and colorectal adenocarcinomas in a prospective series of PTEN mutation carriers.	Gastroenterology	2010	42
21194675	5728	Tan MH	A clinical scoring system for selection of patients for PTEN mutation testing is proposed on the basis of a prospective study of 3042 probands.	American journal of human genetics	2011	68
21725359	5728	Xing F	Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF.	Oncogene	2012	60
21828076	5728	RodrÃ­guez-Escudero I	A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes.	Human molecular genetics	2011	46
21878536	5728	Lotan TL	PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients.	Clinical cancer research 	2011	73
22252256	5728	Tan MH	Lifetime cancer risks in individuals with germline PTEN mutations.	Clinical cancer research 	2012	93
22473468	5728	Song MS	The functions and regulation of the PTEN tumour suppressor.	Nature reviews. Molecular cell biology	2012	431
22628410	5728	Martins FC	Evolutionary pathways in BRCA1-associated breast tumors.	Cancer discovery	2012	41
22970944	5728	Pal A	PTEN mutations as a cause of constitutive insulin sensitivity and obesity.	The New England journal of medicine	2012	41
23335809	5728	Bubien V	High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome.	Journal of medical genetics	2013	30
23613428	5728	Mester J	When overgrowth bumps into cancer: the PTEN-opathies.	American journal of medical genetics. Part C, Seminars in medical genetics	2013	33
23670029	5728	Said R	P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy.	Oncotarget	2013	27
24135135	5728	Haffner MC	Tracking the clonal origin of lethal prostate cancer.	The Journal of clinical investigation	2013	95
25190698	5728	Daly MB	Genetic/familial high-risk assessment: breast and ovarian, version 1.2014.	Journal of the National Comprehensive Cancer Network 	2014	30
26546618	5728	Aparicio AM	Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers.	Clinical cancer research 	2016	11
10446958	5888	Yuan SS	BRCA2 is required for ionizing radiation-induced assembly of Rad51 complex in vivo.	Cancer research	1999	139
11278509	5888	Wu L	Potential role for the BLM helicase in recombinational repair via a conserved interaction with RAD51.	The Journal of biological chemistry	2001	111
12941707	5888	Shin DS	Full-length archaeal Rad51 structure and mutants: mechanisms for RAD51 assembly and control by BRCA2.	The EMBO journal	2003	102
15723711	5888	Thacker J	The RAD51 gene family, genetic instability and cancer.	Cancer letters	2005	90
20400964	5888	Meindl A	Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene.	Nature genetics	2010	179
20729832	5888	Jensen RB	Purified human BRCA2 stimulates RAD51-mediated recombination.	Nature	2010	184
22153967	5888	Moldovan GL	Inhibition of homologous recombination by the PCNA-interacting protein PARI.	Molecular cell	2012	79
22789542	5888	Schlacher K	A distinct replication fork protection pathway connects Fanconi anemia tumor suppressors to RAD51-BRCA1/2.	Cancer cell	2012	184
25472942	5888	Sawyer SL	Biallelic mutations in BRCA1 cause a new Fanconi anemia subtype.	Cancer discovery	2015	66
26261251	5888	Song H	Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population.	Journal of clinical oncology 	2015	21
1316611	5925	Chellappan S	Adenovirus E1A, simian virus 40 tumor antigen, and human papillomavirus E7 protein share the capacity to disrupt the interaction between transcription factor E2F and the retinoblastoma gene product.	Proceedings of the National Academy of Sciences of the United States of America	1992	172
1648218	5925	Scheffner M	The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines.	Proceedings of the National Academy of Sciences of the United States of America	1991	178
2157286	5925	Werness BA	Association of human papillomavirus types 16 and 18 E6 proteins with p53.	Science	1990	524
2673546	5925	Chen PL	Phosphorylation of the retinoblastoma gene product is modulated during the cell cycle and cellular differentiation.	Cell	1989	215
6633649	5925	Cavenee WK	Expression of recessive alleles by chromosomal mechanisms in retinoblastoma.	Nature	1983	314
12853964	5925	Sage J	Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entry.	Nature	2003	193
15240783	5925	Braakhuis BJ	Genetic patterns in head and neck cancers that contain or lack transcriptionally active human papillomavirus.	Journal of the National Cancer Institute	2004	87
18211953	5925	Dimaras H	Loss of RB1 induces non-proliferative retinoma: increasing genomic instability correlates with progression to retinoblastoma.	Human molecular genetics	2008	58
18650841	5925	Burkhart DL	Cellular mechanisms of tumour suppression by the retinoblastoma gene.	Nature reviews. Cancer	2008	271
18782450	5925	Herschkowitz JI	The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas.	Breast cancer research 	2008	86
22529291	5925	Egan JB	Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides.	Blood	2012	85
25252974	5925	Xu XL	Rb suppresses human cone-precursor-derived retinoblastoma tumours.	Nature	2014	24
25621664	5925	Benavente CA	Genetics and epigenetics of human retinoblastoma.	Annual review of pathology	2015	16
26168399	5925	George J	Comprehensive genomic profiles of small cell lung cancer.	Nature	2015	94
27401552	5925	Dyson NJ	RB1: a prototype tumor suppressor and an enigma.	Genes and development	2016	17
11980631	5928	Duval A	Mutations at coding repeat sequences in mismatch repair-deficient human cancers: toward a new concept of target genes for instability.	Cancer research	2002	97
15247181	5928	Kambara T	BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum.	Gut	2004	144
16322293	5928	Benatti P	Microsatellite instability and colorectal cancer prognosis.	Clinical cancer research 	2005	66
17228023	5928	Kim GP	Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study.	Journal of clinical oncology 	2007	83
17631130	5928	Jenkins MA	Pathology features in Bethesda guidelines predict colorectal cancer microsatellite instability: a population-based study.	Gastroenterology	2007	69
18395080	5928	Schwitalle Y	Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers.	Gastroenterology	2008	56
20197478	5928	Dahlin AM	The role of the CpG island methylator phenotype in colorectal cancer prognosis depends on microsatellite instability screening status.	Clinical cancer research 	2010	75
24585723	5928	Goldstein J	Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H).	Annals of oncology 	2014	30
8099202	5979	Mulligan LM	Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A.	Nature	1993	182
12000816	5979	Neumann HP	Germ-line mutations in nonsyndromic pheochromocytoma.	The New England journal of medicine	2002	169
12670889	5979	Kimura ET	High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma.	Cancer research	2003	259
12881714	5979	Soares P	BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC.	Oncogene	2003	101
15769183	5979	Cerchia L	Neutralizing aptamers from whole-cell SELEX inhibit the RET receptor tyrosine kinase.	PLoS biology	2005	67
15982921	5979	Arighi E	RET tyrosine kinase signaling in development and cancer.	Cytokine and growth factor reviews	2005	69
16314641	5979	Amar L	Genetic testing in pheochromocytoma or functional paraganglioma.	Journal of clinical oncology 	2005	92
18073307	5979	Elisei R	Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study.	The Journal of clinical endocrinology and metabolism	2008	56
19164557	5979	Gajiwala KS	KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients.	Proceedings of the National Academy of Sciences of the United States of America	2009	73
20130073	5979	Cantara S	Impact of proto-oncogene mutation detection in cytological specimens from thyroid nodules improves the diagnostic accuracy of cytology.	The Journal of clinical endocrinology and metabolism	2010	51
21878896	5979	Nikiforov YE	Molecular genetics and diagnosis of thyroid cancer.	Nature reviews. Endocrinology	2011	126
24248188	5979	Jung CK	The increase in thyroid cancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutations.	The Journal of clinical endocrinology and metabolism	2014	49
15328326	6390	Neumann HP	Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations.	JAMA	2004	131
16317055	6390	Benn DE	Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes.	The Journal of clinical endocrinology and metabolism	2006	78
16912137	6390	Brouwers FM	High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing.	The Journal of clinical endocrinology and metabolism	2006	62
17200167	6390	Timmers HJ	Clinical presentations, biochemical phenotypes, and genotype-phenotype correlations in patients with succinate dehydrogenase subunit B-associated pheochromocytomas and paragangliomas.	The Journal of clinical endocrinology and metabolism	2007	57
17538171	6390	Timmers HJ	Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma.	Journal of clinical oncology 	2007	59
17652212	6390	Amar L	Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas.	The Journal of clinical endocrinology and metabolism	2007	59
17667967	6390	Pasini B	Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD.	European journal of human genetics 	2008	84
19454582	6390	Burnichon N	The succinate dehydrogenase genetic testing in a large prospective series of patients with paragangliomas.	The Journal of clinical endocrinology and metabolism	2009	53
19802898	6390	Ricketts CJ	Tumor risks and genotype-phenotype-proteotype analysis in 358 patients with germline mutations in SDHB and SDHD.	Human mutation	2010	58
19864450	6390	Timmers HJ	Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma.	The Journal of clinical endocrinology and metabolism	2009	64
20305538	6390	Gill AJ	Immunohistochemistry for SDHB divides gastrointestinal stromal tumors (GISTs) into 2 distinct types.	The American journal of surgical pathology	2010	46
21173220	6390	Janeway KA	Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations.	Proceedings of the National Academy of Sciences of the United States of America	2011	115
22036874	6390	Eisenhofer G	Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status.	European journal of cancer	2012	40
23083876	6390	Ricketts CJ	Succinate dehydrogenase kidney cancer: an aggressive example of the Warburg effect in cancer.	The Journal of urology	2012	34
25873086	6390	Janssen I	Superiority of 68Ga-DOTATATE PET/CT to Other Functional Imaging Modalities in the Localization of SDHB-Associated Metastatic Pheochromocytoma and Paraganglioma.	Clinical cancer research 	2015	17
9892189	6598	Biegel JA	Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors.	Cancer research	1999	129
17357086	6598	Hulsebos TJ	Germline mutation of INI1/SMARCB1 in familial schwannomatosis.	American journal of human genetics	2007	67
21108436	6598	Eaton KW	Spectrum of SMARCB1/INI1 mutations in familial and sporadic rhabdoid tumors.	Pediatric blood and cancer	2011	40
25387058	6598	Masliah-Planchon J	SWI/SNF chromatin remodeling and human malignancies.	Annual review of pathology	2015	32
26923874	6598	Johann PD	Atypical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups with Distinct Enhancer Landscapes.	Cancer cell	2016	18
9771714	6790	Zhou H	Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation.	Nature genetics	1998	306
11784863	6790	Crosio C	Mitotic phosphorylation of histone H3: spatio-temporal regulation by mammalian Aurora kinases.	Molecular and cellular biology	2002	176
12559175	6790	Anand S	AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol.	Cancer cell	2003	158
12631597	6790	Li D	Overexpression of oncogenic STK15/BTAK/Aurora A kinase in human pancreatic cancer.	Clinical cancer research 	2003	80
9425897	6794	Jenne DE	Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase.	Nature genetics	1998	216
12847291	6794	Hong SP	Activation of yeast Snf1 and mammalian AMP-activated protein kinase by upstream kinases.	Proceedings of the National Academy of Sciences of the United States of America	2003	174
16707622	6794	Hearle N	Frequency and spectrum of cancers in the Peutz-Jeghers syndrome.	Clinical cancer research 	2006	117
17599048	6794	Sanchez-Cespedes M	A role for LKB1 gene in human cancer beyond the Peutz-Jeghers syndrome.	Oncogene	2007	67
19340305	6794	Wingo SN	Somatic LKB1 mutations promote cervical cancer progression.	PloS one	2009	80
19584313	6794	Jansen M	LKB1 and AMPK family signaling: the intimate link between cell polarity and energy metabolism.	Physiological reviews	2009	70
20581245	6794	Beggs AD	Peutz-Jeghers syndrome: a systematic review and recommendations for management.	Gut	2010	66
12887925	7015	Masutomi K	Telomerase maintains telomere structure in normal human cells.	Cell	2003	142
19147845	7015	Calado RT	Constitutional hypomorphic telomerase mutations in patients with acute myeloid leukemia.	Proceedings of the National Academy of Sciences of the United States of America	2009	65
22661914	7015	Aubert G	Collapse of telomere homeostasis in hematopoietic cells caused by heterozygous mutations in telomerase genes.	PLoS genetics	2012	43
22863003	7015	Zhong FL	TPP1 OB-fold domain controls telomere maintenance by recruiting telomerase to chromosome ends.	Cell	2012	89
23348503	7015	Horn S	TERT promoter mutations in familial and sporadic melanoma.	Science	2013	316
23348506	7015	Huang FW	Highly recurrent TERT promoter mutations in human melanoma.	Science	2013	346
23535731	7015	Bojesen SE	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer.	Nature genetics	2013	181
23610451	7015	Listerman I	The major reverse transcriptase-incompetent splice variant of the human telomerase protein inhibits telomerase activity but protects from apoptosis.	Cancer research	2013	29
23629941	7015	Pellatt AJ	Telomere length, telomere-related genes, and breast cancer risk: the breast cancer health disparities study.	Genes, chromosomes and cancer	2013	28
23766237	7015	Liu X	Highly prevalent TERT promoter mutations in aggressive thyroid cancers.	Endocrine-related cancer	2013	68
23887589	7015	Vinagre J	Frequency of TERT promoter mutations in human cancers.	Nature communications	2013	120
23901009	7015	Zaug AJ	Many disease-associated variants of hTERT retain high telomerase enzymatic activity.	Nucleic acids research	2013	26
23955565	7015	Nonoguchi N	TERT promoter mutations in primary and secondary glioblastomas.	Acta neuropathologica	2013	40
24018021	7015	Allory Y	Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.	European urology	2014	37
24101484	7015	Rachakonda PS	TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism.	Proceedings of the National Academy of Sciences of the United States of America	2013	55
24121487	7015	Kinde I	TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine.	Cancer research	2013	41
24141777	7015	Liu T	The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas.	Oncogene	2014	43
24154961	7015	Koelsche C	Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system.	Acta neuropathologica	2013	36
24174164	7015	Remke M	TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma.	Acta neuropathologica	2013	28
24476079	7015	Melo M	TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas.	The Journal of clinical endocrinology and metabolism	2014	49
24569790	7015	Heidenreich B	Telomerase reverse transcriptase promoter mutations in primary cutaneous melanoma.	Nature communications	2014	24
24657534	7015	Heidenreich B	TERT promoter mutations in cancer development.	Current opinion in genetics and development	2014	61
25217772	7015	Griewank KG	TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma.	Journal of the National Cancer Institute	2014	30
25314060	7015	LabussiÃ¨re M	TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations.	British journal of cancer	2014	28
25722414	7015	Borah S	Cancer. TERT promoter mutations and telomerase reactivation in urothelial cancer.	Science	2015	59
25843513	7015	Huang DS	Recurrent TERT promoter mutations identified in a large-scale study of multiple tumour types are associated with increased TERT expression and telomerase activation.	European journal of cancer	2015	20
26053494	7015	Melton C	Recurrent somatic mutations in regulatory regions of human cancer genomes.	Nature genetics	2015	44
26194807	7015	Chiba K	Cancer-associated TERT promoter mutations abrogate telomerase silencing.	eLife	2015	38
26553065	7015	Xi L	A novel two-step genome editing strategy with CRISPR-Cas9 provides new insights into telomerase action and TERT gene expression.	Genome biology	2015	16
26846696	7015	Akincilar SC	Reactivation of telomerase in cancer.	Cellular and molecular life sciences 	2016	13
1525830	7157	Yin Y	Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles.	Cell	1992	204
1533443	7157	Yew PR	Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein.	Nature	1992	177
1672732	7157	Bressac B	Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa.	Nature	1991	191
1849234	7157	Hsu IC	Mutational hotspot in the p53 gene in human hepatocellular carcinomas.	Nature	1991	202
1905840	7157	Hollstein M	p53 mutations in human cancers.	Science	1991	1290
1978757	7157	Malkin D	Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms.	Science	1990	522
2046748	7157	Levine AJ	The p53 tumour suppressor gene.	Nature	1991	554
2143698	7157	Michalovitz D	Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53.	Cell	1990	217
2144057	7157	Baker SJ	Suppression of human colorectal carcinoma cell growth by wild-type p53.	Science	1990	393
2253215	7157	Baker SJ	p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis.	Cancer research	1990	157
2259385	7157	Srivastava S	Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome.	Nature	1990	174
2531845	7157	Nigro JM	Mutations in the p53 gene occur in diverse human tumour types.	Nature	1989	402
7937055	7157	Hollstein M	Database of p53 gene somatic mutations in human tumors and cell lines.	Nucleic acids research	1994	185
8023157	7157	Cho Y	Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations.	Science	1994	486
8030745	7157	Kim H	Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences.	The American journal of pathology	1994	124
8423624	7157	Allred DC	Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer.	Journal of the National Cancer Institute	1993	132
8832894	7157	Denissenko MF	Preferential formation of benzoapyrene adducts at lung cancer mutational hotspots in P53.	Science	1996	229
8876633	7157	zur Hausen H	Papillomavirus infections--a major cause of human cancers.	Biochimica et biophysica acta	1996	300
8994024	7157	Weinstein JN	An information-intensive approach to the molecular pharmacology of cancer.	Science	1997	198
9607760	7157	Storey A	Role of a p53 polymorphism in the development of human papillomavirus-associated cancer.	Nature	1998	122
10549356	7157	Hainaut P	p53 and human cancer: the first ten thousand mutations.	Advances in cancer research	2000	197
10623654	7157	Vona G	Isolation by size of epithelial tumor cells : a new method for the immunomorphological and molecular characterization of circulatingtumor cells.	The American journal of pathology	2000	212
10713666	7157	Bullock AN	Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy.	Oncogene	2000	94
10720328	7157	Fliss MS	Facile detection of mitochondrial DNA mutations in tumors and bodily fluids.	Science	2000	182
10766157	7157	Soussi T	p53 Antibodies in the sera of patients with various types of cancer: a review.	Cancer research	2000	117
11238924	7157	Gaiddon C	A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain.	Molecular and cellular biology	2001	107
11343904	7157	Ryan KM	Regulation and function of the p53 tumor suppressor protein.	Current opinion in cell biology	2001	127
11830638	7157	Lingle WL	Centrosome amplification drives chromosomal instability in breast tumor development.	Proceedings of the National Academy of Sciences of the United States of America	2002	150
11859195	7157	Yu JL	Effect of p53 status on tumor response to antiangiogenic therapy.	Science	2002	86
11875500	7157	Bykov VJ	Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound.	Nature medicine	2002	198
11900253	7157	Bullock AN	Rescuing the function of mutant p53.	Nature reviews. Cancer	2001	112
11902578	7157	Soussi T	Assessing TP53 status in human tumours to evaluate clinical outcome.	Nature reviews. Cancer	2001	128
11965534	7157	Mirza A	Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway.	Oncogene	2002	130
12007217	7157	Olivier M	The IARC TP53 database: new online mutation analysis and recommendations to users.	Human mutation	2002	267
12379884	7157	Pfeifer GP	Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers.	Oncogene	2002	203
12649205	7157	Pihan GA	Centrosome abnormalities and chromosome instability occur together in pre-invasive carcinomas.	Cancer research	2003	102
12826609	7157	Kato S	Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis.	Proceedings of the National Academy of Sciences of the United States of America	2003	156
14612504	7157	Massion PP	Significance of p63 amplification and overexpression in lung cancer development and prognosis.	Cancer research	2003	77
15282313	7157	Zhu W	Rereplication by depletion of geminin is seen regardless of p53 status and activates a G2/M checkpoint.	Molecular and cellular biology	2004	110
15685439	7157	Ohgaki H	Epidemiology and etiology of gliomas.	Acta neuropathologica	2005	212
16141321	7157	Miller LD	An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival.	Proceedings of the National Academy of Sciences of the United States of America	2005	509
16170357	7157	Bossi G	Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression.	Oncogene	2006	68
16172461	7157	Russo A	The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment.	Journal of clinical oncology 	2005	72
16489069	7157	Olivier M	The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.	Clinical cancer research 	2006	119
16601753	7157	Murray-Zmijewski F	p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress.	Cell death and differentiation	2006	154
16897746	7157	Bergamaschi A	Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer.	Genes, chromosomes and cancer	2006	161
16945824	7157	Houtgraaf JH	A concise review of DNA damage checkpoints and repair in mammalian cells.	Cardiovascular revascularization medicine 	2006	65
16951157	7157	Rodriguez J	Chromosomal instability correlates with genome-wide DNA demethylation in human primary colorectal cancers.	Cancer research	2006	82
17030796	7157	Feng Z	Acrolein is a major cigarette-related lung cancer agent: Preferential binding at p53 mutational hotspots and inhibition of DNA repair.	Proceedings of the National Academy of Sciences of the United States of America	2006	96
17189187	7157	Sykes SM	Acetylation of the p53 DNA-binding domain regulates apoptosis induction.	Molecular cell	2006	234
17255760	7157	Kindelberger DW	Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship.	The American journal of surgical pathology	2007	194
17311302	7157	Petitjean A	Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database.	Human mutation	2007	457
17334395	7157	Deyoung MP	p63 and p73 in human cancer: defining the network.	Oncogene	2007	83
17401423	7157	Soussi T	p53 alterations in human cancer: more questions than answers.	Oncogene	2007	58
17401424	7157	Petitjean A	TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes.	Oncogene	2007	190
17401432	7157	Joerger AC	Structure-function-rescue: the diverse nature of common p53 cancer mutants.	Oncogene	2007	108
17417627	7157	Song H	p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM.	Nature cell biology	2007	112
17468756	7157	Theodorou V	MMTV insertional mutagenesis identifies genes, gene families and pathways involved in mammary cancer.	Nature genetics	2007	69
17504517	7157	LangerÃ¸d A	TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer.	Breast cancer research 	2007	93
17517648	7157	Dahl F	Multigene amplification and massively parallel sequencing for cancer mutation discovery.	Proceedings of the National Academy of Sciences of the United States of America	2007	57
17936556	7157	Soussi T	Shaping genetic alterations in human cancer: the p53 mutation paradigm.	Cancer cell	2007	102
18024870	7157	Tsao MS	Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer.	Journal of clinical oncology 	2007	67
18094375	7157	Patocs A	Breast-cancer stromal cells with TP53 mutations and nodal metastases.	The New England journal of medicine	2007	93
18094376	7157	Poeta ML	TP53 mutations and survival in squamous-cell carcinoma of the head and neck.	The New England journal of medicine	2007	160
18323444	7157	Halazonetis TD	An oncogene-induced DNA damage model for cancer development.	Science	2008	527
18394899	7157	Birkenfeld J	Cellular functions of GEF-H1, a microtubule-regulated Rho-GEF: is altered GEF-H1 activity a crucial determinant of disease pathogenesis?	Trends in cell biology	2008	66
18650397	7157	Boeckler FM	Targeted rescue of a destabilized mutant of p53 by an in silico screened drug.	Proceedings of the National Academy of Sciences of the United States of America	2008	86
18685109	7157	Shlien A	Excessive genomic DNA copy number variation in the Li-Fraumeni cancer predisposition syndrome.	Proceedings of the National Academy of Sciences of the United States of America	2008	51
18689542	7157	Zenz T	Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up.	Blood	2008	76
18757330	7157	Carlson JW	Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention.	Journal of clinical oncology 	2008	70
19081593	7157	Howie HL	Papillomavirus E6 proteins.	Virology	2009	77
19165225	7157	Whibley C	p53 polymorphisms: cancer implications.	Nature reviews. Cancer	2009	125
19188171	7157	Rossi D	The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness.	Clinical cancer research 	2009	48
19204208	7157	Gonzalez KD	Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations.	Journal of clinical oncology 	2009	86
19308457	7157	Pfeifer GP	Mutational spectra of human cancer.	Human genetics	2009	69
19349354	7157	Seligson DB	Global levels of histone modifications predict prognosis in different cancers.	The American journal of pathology	2009	109
19562738	7157	Zuckerman V	Tumour suppression by p53: the importance of apoptosis and cellular senescence.	The Journal of pathology	2009	49
19626115	7157	Suzuki HI	Modulation of microRNA processing by p53.	Nature	2009	393
19701195	7157	Fujita K	p53 isoforms Delta133p53 and p53beta are endogenous regulators of replicative cellular senescence.	Nature cell biology	2009	80
19881536	7157	Liu DP	A common gain of function of p53 cancer mutants in inducing genetic instability.	Oncogene	2010	50
20066118	7157	Zilfou JT	Tumor suppressive functions of p53.	Cold Spring Harbor perspectives in biology	2009	96
20123995	7157	Thompson SL	Proliferation of aneuploid human cells is limited by a p53-dependent mechanism.	The Journal of cell biology	2010	142
20182602	7157	Olivier M	TP53 mutations in human cancers: origins, consequences, and clinical use.	Cold Spring Harbor perspectives in biology	2010	236
20182618	7157	Oren M	Mutant p53 gain-of-function in cancer.	Cold Spring Harbor perspectives in biology	2010	181
20229506	7157	Ahmed AA	Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary.	The Journal of pathology	2010	149
20538793	7157	Lin TT	Telomere dysfunction and fusion during the progression of chronic lymphocytic leukemia: evidence for a telomere crisis.	Blood	2010	42
20697090	7157	Zenz T	TP53 mutation and survival in chronic lymphocytic leukemia.	Journal of clinical oncology 	2010	91
20871609	7157	Swarbrick A	miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma.	Nature medicine	2010	52
20952405	7157	Forbes SA	COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer.	Nucleic acids research	2011	834
20974671	7157	Martinez-Garcia E	The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells.	Blood	2011	94
21205967	7157	Fabbri M	Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia.	JAMA	2011	72
21331359	7157	Mogi A	TP53 mutations in nonsmall cell lung cancer.	Journal of biomedicine and biotechnology	2011	45
21364938	7157	Enerly E	miRNA-mRNA integrated analysis reveals roles for miRNAs in primary breast tumors.	PloS one	2011	115
21389100	7157	Rajeshkumar NV	MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts.	Clinical cancer research 	2011	63
21483000	7157	Gonzalez D	Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial.	Journal of clinical oncology 	2011	47
21519010	7157	JÃ¤dersten M	TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression.	Journal of clinical oncology 	2011	69
21601526	7157	Villani A	Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study.	The Lancet. Oncology	2011	46
21747090	7157	Hof J	Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia.	Journal of clinical oncology 	2011	41
21765642	7157	Suzuki K	Recent advances in p53 research and cancer treatment.	Journal of biomedicine and biotechnology	2011	40
21779513	7157	Khoury MP	p53 Isoforms: An Intracellular Microprocessor?	Genes and cancer	2011	44
21941372	7157	Marcel V	Biological functions of p53 isoforms through evolution: lessons from animal and cellular models.	Cell death and differentiation	2011	65
22084170	7157	Kreahling JM	MK1775, a selective Wee1 inhibitor, shows single-agent antitumor activity against sarcoma cells.	Molecular cancer therapeutics	2012	39
22090360	7157	Skinner HD	TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence.	Clinical cancer research 	2012	58
22186996	7157	RÃ¼cker FG	TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome.	Blood	2012	69
22265402	7157	Rausch T	Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations.	Cell	2012	175
22265415	7157	Freed-Pastor WA	Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway.	Cell	2012	163
22297721	7157	Pospisilova S	ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia.	Leukemia	2012	38
22549840	7157	Gerstung M	Reliable detection of subclonal single-nucleotide variants in tumour cell populations.	Nature communications	2012	55
22698402	7157	Davoli T	Telomere-driven tetraploidization occurs in human cells undergoing crisis and promotes transformation of mouse cells.	Cancer cell	2012	58
22715097	7157	Ano Bom AP	Mutant p53 aggregates into prion-like amyloid oligomers and fibrils: implications for cancer.	The Journal of biological chemistry	2012	41
22822097	7157	Walerych D	The rebel angel: mutant p53 as the driving oncogene in breast cancer.	Carcinogenesis	2012	61
22911014	7157	Mirzayans R	New insights into p53 signaling and cancer cell response to DNA damage: implications for cancer therapy.	Journal of biomedicine and biotechnology	2012	55
22955915	7157	Xu-Monette ZY	Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study.	Blood	2012	42
22965953	7157	Lehmann S	Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer.	Journal of clinical oncology 	2012	58
23150340	7157	Menendez D	Interactions between the tumor suppressor p53 and immune responses.	Current opinion in oncology	2013	31
23151455	7157	Rodriguez OC	Dietary downregulation of mutant p53 levels via glucose restriction: mechanisms and implications for tumor therapy.	Cell cycle	2012	33
23297687	7157	Kulasekararaj AG	TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis.	British journal of haematology	2013	44
23360998	7157	Wassman CD	Computational identification of a transiently open L1/S3 pocket for reactivation of mutant p53.	Nature communications	2013	35
23630207	7157	Vignot S	Next-generation sequencing reveals high concordance of recurrent somatic alterations between primary tumor and metastases from patients with non-small-cell lung cancer.	Journal of clinical oncology 	2013	38
23644491	7157	Kadoch C	Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy.	Nature genetics	2013	169
23649806	7157	Kleiblova P	Gain-of-function mutations of PPM1D/Wip1 impair the p53-dependent G1 checkpoint.	The Journal of cell biology	2013	33
23835706	7157	Zhukova N	Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma.	Journal of clinical oncology 	2013	43
23913924	7157	Vakifahmetoglu-Norberg H	Chaperone-mediated autophagy degrades mutant p53.	Genes and development	2013	30
24138928	7157	Horvath S	DNA methylation age of human tissues and cell types.	Genome biology	2013	377
24296170	7157	Mellman I	Endocytosis and cancer.	Cold Spring Harbor perspectives in biology	2013	51
24374014	7157	Liu J	Tumor suppressor p53 and its mutants in cancer metabolism.	Cancer letters	2015	24
24379683	7157	Surget S	Uncovering the role of p53 splice variants in human malignancy: a clinical perspective.	OncoTargets and therapy	2013	39
24469795	7157	Morrison CD	Whole-genome sequencing identifies genomic heterogeneity at a nucleotide and chromosomal level in bladder cancer.	Proceedings of the National Academy of Sciences of the United States of America	2014	24
24487586	7157	Arjonen A	Mutant p53-associated myosin-X upregulation promotes breast cancer invasion and metastasis.	The Journal of clinical investigation	2014	36
24501221	7157	Rossi D	Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia.	Blood	2014	50
24630730	7157	Supek F	Synonymous mutations frequently act as driver mutations in human cancers.	Cell	2014	76
24642672	7157	McBride KA	Li-Fraumeni syndrome: cancer risk assessment and clinical management.	Nature reviews. Clinical oncology	2014	25
24658082	7157	Powell E	Contribution of p53 to metastasis.	Cancer discovery	2014	38
24665023	7157	Leroy B	TP53 mutations in human cancer: database reassessment and prospects for the next decade.	Human mutation	2014	28
24682512	7157	Saft L	p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q).	Haematologica	2014	22
24768524	7157	Bykov VJ	Mutant p53 reactivation by small molecules makes its way to the clinic.	FEBS letters	2014	32
25086664	7157	Gross AM	Multi-tiered genomic analysis of head and neck cancer ties TP53 mutation to 3p loss.	Nature genetics	2014	32
25287991	7157	Malcikova J	Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia.	Leukemia	2015	18
25368020	7157	Park EY	Targeting of miR34a-NOTCH1 axis reduced breast cancer stemness and chemoresistance.	Cancer research	2014	30
25482194	7157	James A	Nucleolar stress with and without p53.	Nucleus	2014	41
25538195	7157	Vieira VC	Human papillomavirus E6 triggers upregulation of the antiviral and cancer genomic DNA deaminase APOBEC3B.	mBio	2014	33
25555420	7157	Farooqui MZ	Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.	The Lancet. Oncology	2015	51
25634208	7157	Neskey DM	Evolutionary Action Score of TP53 Identifies High-Risk Mutations Associated with Decreased Survival and Increased Distant Metastases in Head and Neck Cancer.	Cancer research	2015	19
25827447	7157	Hong MK	Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer.	Nature communications	2015	39
25894828	7157	Cristescu R	Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes.	Nature medicine	2015	84
26014290	7157	Bougeard G	Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers.	Journal of clinical oncology 	2015	20
26024390	7157	Soussi T	TP53: an oncogene in disguise.	Cell death and differentiation	2015	26
26398160	7157	Danilova N	Ribosomopathies: how a common root can cause a tree of pathologies.	Disease models and mechanisms	2015	20
26605532	7157	Jin W	Genome-wide detection of DNase I hypersensitive sites in single cells and FFPE tissue samples.	Nature	2015	31
27009395	7157	Stracquadanio G	The importance of p53 pathway genetics in inherited and somatic cancer genomes.	Nature reviews. Cancer	2016	19
27328919	7157	Bouaoun L	TP53 Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data.	Human mutation	2016	12
27377626	7157	Fernandez-Cuesta L	Identification of Circulating Tumor DNA for the Early Detection of Small-cell Lung Cancer.	EBioMedicine	2016	13
9242607	7248	van Slegtenhorst M	Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34.	Science	1997	235
11112665	7248	Dabora SL	Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs.	American journal of human genetics	2001	126
15798777	7248	Sancak O	Mutational analysis of the TSC1 and TSC2 genes in a diagnostic setting: genotype--phenotype correlations and comparison of diagnostic DNA techniques in Tuberous Sclerosis Complex.	European journal of human genetics 	2005	71
17304050	7248	Au KS	Genotype/phenotype correlation in 325 individuals referred for a diagnosis of tuberous sclerosis complex in the United States.	Genetics in medicine 	2007	61
17386056	7248	Holmes GL	Tuberous sclerosis complex and epilepsy: recent developments and future challenges.	Epilepsia	2007	62
22923433	7248	Iyer G	Genome sequencing identifies a basis for everolimus sensitivity.	Science	2012	158
7915601	7428	Gnarra JR	Mutations of the VHL tumour suppressor gene in renal carcinoma.	Nature genetics	1994	298
7937876	7428	Herman JG	Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma.	Proceedings of the National Academy of Sciences of the United States of America	1994	236
8493574	7428	Latif F	Identification of the von Hippel-Lindau disease tumor suppressor gene.	Science	1993	389
14985465	7428	Zimmer M	Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors.	Molecular cancer research 	2004	80
16488999	7428	Banks RE	Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer.	Cancer research	2006	73
18676741	7428	Nickerson ML	Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors.	Clinical cancer research 	2008	133
21402874	7428	Pease JC	Mitotic spindle misorientation in cancer--out of alignment and into the fire.	Journal of cell science	2011	41
21725364	7428	Niu X	The von Hippel-Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C.	Oncogene	2012	46
8395349	7490	Kreidberg JA	WT-1 is required for early kidney development.	Cell	1993	299
21941004	8314	Abdel-Rahman MH	Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers.	Journal of medical genetics	2011	76
22545102	8314	Njauw CN	Germline BAP1 inactivation is preferentially associated with metastatic ocular melanoma and cutaneous-ocular melanoma families.	PloS one	2012	44
23277170	8314	Murali R	Tumours associated with BAP1 mutations.	Pathology	2013	27
23709298	8314	Farley MN	A novel germline mutation in BAP1 predisposes to familial clear-cell renal cell carcinoma.	Molecular cancer research 	2013	34
25380601	8314	Baumann F	Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival.	Carcinogenesis	2015	23
25658628	8314	Nasu M	High Incidence of Somatic BAP1 alterations in sporadic malignant mesothelioma.	Journal of thoracic oncology 	2015	31
11882383	10000	Nicholson KM	The protein kinase B/Akt signalling pathway in human malignancy.	Cellular signalling	2002	296
18813315	10000	Davies MA	A novel AKT3 mutation in melanoma tumours and cell lines.	British journal of cancer	2008	93
22722202	10000	Banerji S	Sequence analysis of mutations and translocations across breast cancer subtypes.	Nature	2012	320
24608573	10000	Meric-Bernstam F	Concordance of genomic alterations between primary and recurrent breast cancer.	Molecular cancer therapeutics	2014	21
25122428	10000	Umemura S	Therapeutic priority of the PI3K/AKT/mTOR pathway in small cell lung cancers as revealed by a comprehensive genomic analysis.	Journal of thoracic oncology 	2014	21
25722288	10000	Jansen LA	PI3K/AKT pathway mutations cause a spectrum of brain malformations from megalencephaly to focal cortical dysplasia.	Brain 	2015	26
20404132	10019	Oh ST	Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms.	Blood	2010	98
20724988	10019	Pardanani A	LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations.	Leukemia	2010	42
21220604	10019	Tefferi A	Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies.	Journal of clinical oncology 	2011	60
22897847	10019	Roberts KG	Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia.	Cancer cell	2012	141
24056718	10019	Yoshida K	The landscape of somatic mutations in Down syndrome-related myeloid disorders.	Nature genetics	2013	41
25207766	10019	Roberts KG	Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.	The New England journal of medicine	2014	142
10426999	10111	Zhong Q	Association of BRCA1 with the hRad50-hMre11-p95 complex and the DNA damage response.	Science	1999	123
10802669	10111	Gatei M	ATM-dependent phosphorylation of nibrin in response to radiation exposure.	Nature genetics	2000	113
10839544	10111	Zhao S	Functional link between ataxia-telangiectasia and Nijmegen breakage syndrome gene products.	Nature	2000	108
15201865	10111	Lukas C	Mdc1 couples DNA double-strand break recognition by Nbs1 with its H2AX-dependent chromatin retention.	The EMBO journal	2004	124
15279769	10111	Stracker TH	The Mre11 complex and the metabolism of chromosome breaks: the importance of communicating and holding things together.	DNA repair	2004	103
18157161	10111	Shrivastav M	Regulation of DNA double-strand break repair pathway choice.	Cell research	2008	316
19092773	10111	Ripperger T	Breast cancer susceptibility: current knowledge and implications for genetic counselling.	European journal of human genetics 	2009	45
21816818	10111	Della-Maria J	Human Mre11/human Rad50/Nbs1 and DNA ligase IIIalpha/XRCC1 protein complexes act together in an alternative nonhomologous end joining pathway.	The Journal of biological chemistry	2011	42
22006311	10111	Walsh T	Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing.	Proceedings of the National Academy of Sciences of the United States of America	2011	149
22048815	10111	Weigman VJ	Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival.	Breast cancer research and treatment	2012	39
22705791	10111	Schiller CB	Structure of Mre11-Nbs1 complex yields insights into ataxia-telangiectasia-like disease mutations and DNA damage signaling.	Nature structural and molecular biology	2012	43
24934408	10111	Al-Ahmadie H	Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy.	Cancer discovery	2014	26
18768390	10320	Yang JJ	Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia.	Blood	2008	55
19129520	10320	Mullighan CG	Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia.	The New England journal of medicine	2009	274
19589926	10320	Iacobucci I	Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMA AL WP).	Blood	2009	50
19770381	10320	Martinelli G	IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report.	Journal of clinical oncology 	2009	61
20139093	10320	Harvey RC	Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia.	Blood	2010	112
20445578	10320	Kuiper RP	IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL.	Leukemia	2010	57
21531982	10320	Klampfl T	Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression.	Blood	2011	36
22368272	10320	Chen IM	Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group study.	Blood	2012	59
23212523	10320	Loh ML	Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group TARGET Project.	Blood	2013	32
24366361	10320	van der Veer A	IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL.	Blood	2014	25
24740809	10320	Beldjord K	Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia.	Blood	2014	23
26321221	10320	Churchman ML	Efficacy of Retinoids in IKZF1-Mutated BCR-ABL1 Acute Lymphoblastic Leukemia.	Cancer cell	2015	19
16814713	10413	Zender L	Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach.	Cell	2006	374
17889654	10413	Dong J	Elucidation of a universal size-control mechanism in Drosophila and mammals.	Cell	2007	582
20048001	10413	Zhao B	A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(beta-TRCP).	Genes and development	2010	245
20947521	10413	Hall CA	Hippo pathway effector Yap is an ovarian cancer oncogene.	Cancer research	2010	63
21317925	10413	Zhang X	The Hippo pathway transcriptional co-activator, YAP, is an ovarian cancer oncogene.	Oncogene	2011	75
23737213	10413	Antonescu CR	Novel YAP1-TFE3 fusion defines a distinct subset of epithelioid hemangioendothelioma.	Genes, chromosomes and cancer	2013	31
24362629	10413	Mohseni M	A genetic screen identifies an LKB1-MARK signalling axis controlling the Hippo-YAP pathway.	Nature cell biology	2014	59
24803537	10413	Zhang W	Downstream of mutant KRAS, the transcription regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinoma.	Science signaling	2014	58
24882516	10413	Yu FX	Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP.	Cancer cell	2014	66
25388162	10413	Lee KW	Significant association of oncogene YAP1 with poor prognosis and cetuximab resistance in colorectal cancer patients.	Clinical cancer research 	2015	18
25665005	10413	Lin L	The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.	Nature genetics	2015	62
25778702	10413	Porazinski S	YAP is essential for tissue tension to ensure vertebrate 3D body shape.	Nature	2015	26
26058078	10413	Nguyen LT	ERG Activates the YAP1 Transcriptional Program and Induces the Development of Age-Related Prostate Tumors.	Cancer cell	2015	18
26121086	10413	Schramm A	Mutational dynamics between primary and relapse neuroblastomas.	Nature genetics	2015	37
26691213	10413	Di Agostino S	YAP enhances the pro-proliferative transcriptional activity of mutant p53 proteins.	EMBO reports	2016	12
26950094	10413	Bonilla X	Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma.	Nature genetics	2016	19
18657511	10481	Maeder ML	Rapid "open-source" engineering of customized zinc-finger nucleases for highly efficient gene modification.	Molecular cell	2008	229
22236224	10481	Ewing CM	Germline mutations in HOXB13 and prostate-cancer risk.	The New England journal of medicine	2012	112
22841674	10481	Karlsson R	A population-based assessment of germline HOXB13 G84E mutation and prostate cancer risk.	European urology	2014	33
23064873	10481	Xu J	HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG).	Human genetics	2013	40
23104005	10481	Gudmundsson J	A study based on whole-genome sequencing yields a rare variant at 8q24 associated with prostate cancer.	Nature genetics	2012	72
17512414	10664	Barski A	High-resolution profiling of histone methylations in the human genome.	Cell	2007	2338
22976956	10664	Dolnik A	Commonly altered genomic regions in acute myeloid leukemia are enriched for somatic mutations involved in chromatin remodeling and splicing.	Blood	2012	35
23010778	10664	Deng Z	A role for CTCF and cohesin in subtelomere chromatin organization, TERRA transcription, and telomere end protection.	The EMBO journal	2012	39
26700815	10664	Flavahan WA	Insulator dysfunction and oncogene activation in IDH mutant gliomas.	Nature	2016	82
10888881	11186	Dammann R	Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3.	Nature genetics	2000	229
12024041	11186	Shivakumar L	The RASSF1A tumor suppressor blocks cell cycle progression and inhibits cyclin D1 accumulation.	Molecular and cellular biology	2002	81
15867337	11186	Agathanggelou A	Role of the Ras-association domain family 1 tumor suppressor gene in human cancers.	Cancer research	2005	108
16618406	11186	Calvisi DF	Ubiquitous activation of Ras and Jak/Stat pathways in human HCC.	Gastroenterology	2006	150
17878233	11186	Donninger H	The RASSF1A tumor suppressor.	Journal of cell science	2007	128
22195963	11186	Matallanas D	Mutant K-Ras activation of the proapoptotic MST2 pathway is antagonized by wild-type K-Ras.	Molecular cell	2011	43
10617473	11200	Bell DW	Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome.	Science	1999	140
11967536	11200	Meijers-Heijboer H	Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations.	Nature genetics	2002	216
12094328	11200	Vahteristo P	A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer.	American journal of human genetics	2002	86
15122511	11200	CHEK2 Breast Cancer Case-Control Consortium.	CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies.	American journal of human genetics	2004	107
15604286	11200	Hickson I	Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM.	Cancer research	2004	422
15829956	11200	Bartkova J	DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis.	Nature	2005	819
15829965	11200	Gorgoulis VG	Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions.	Nature	2005	644
16551709	11200	Walsh T	Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.	JAMA	2006	143
18004398	11200	Antoni L	CHK2 kinase: cancer susceptibility and cancer therapy - two sides of the same coin?	Nature reviews. Cancer	2007	85
20364141	11200	Stolz A	The CHK2-BRCA1 tumour suppressor pathway ensures chromosomal stability in human somatic cells.	Nature cell biology	2010	52
21960636	11200	Janssen A	Chromosome segregation errors as a cause of DNA damage and structural chromosome aberrations.	Science	2011	143
24549055	11200	CastÃ©ra L	Next-generation sequencing for the diagnosis of hereditary breast and ovarian cancer using genomic capture targeting multiple candidate genes.	European journal of human genetics 	2014	39
24976383	11200	Ertych N	Increased microtubule assembly rates influence chromosomal instability in colorectal cancer cells.	Nature cell biology	2014	30
25186627	11200	Tung N	Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel.	Cancer	2015	49
25288723	11200	Kiiski JI	Exome sequencing identifies FANCM as a susceptibility gene for triple-negative breast cancer.	Proceedings of the National Academy of Sciences of the United States of America	2014	22
25613496	11200	Hu L	Up-regulation of long noncoding RNA MALAT1 contributes to proliferation and metastasis in esophageal squamous cell carcinoma.	Journal of experimental and clinical cancer research 	2015	43
26270727	11200	Desmond A	Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.	JAMA oncology	2015	24
26483394	11200	Hu C	Prevalence of Pathogenic Mutations in Cancer Predisposition Genes among Pancreatic Cancer Patients.	Cancer epidemiology, biomarkers and prevention 	2016	11
26510020	11200	Mateo J	DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.	The New England journal of medicine	2015	128
26976419	11200	Tung N	Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer.	Journal of clinical oncology 	2016	10
27433846	11200	Pritchard CC	Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer.	The New England journal of medicine	2016	29
12438234	22882	Yuen ST	Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia.	Cancer research	2002	95
12692057	22882	Tannapfel A	Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma.	Gut	2003	92
15781657	22882	Sharma A	Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors.	Cancer research	2005	94
16273091	22882	Solit DB	BRAF mutation predicts sensitivity to MEK inhibition.	Nature	2006	370
16364920	22882	Garnett MJ	Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization.	Molecular cell	2005	106
17208430	22882	Dhomen N	New insight into BRAF mutations in cancer.	Current opinion in genetics and development	2007	67
18372904	22882	Haigis KM	Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon.	Nature genetics	2008	193
18390968	22882	Adjei AA	Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.	Journal of clinical oncology 	2008	161
18559533	22882	Montagut C	Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma.	Cancer research	2008	145
19117997	22882	Ihle NT	Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance.	Cancer research	2009	110
19915144	22882	Emery CM	MEK1 mutations confer resistance to MEK and B-RAF inhibition.	Proceedings of the National Academy of Sciences of the United States of America	2009	170
20538618	22882	Whittaker S	Gatekeeper mutations mediate resistance to BRAF-targeted therapies.	Science translational medicine	2010	59
20818433	22882	Kaplan FM	Hyperactivation of MEK-ERK1/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cells.	Oncogene	2011	44
21803746	22882	Shi H	Combinatorial treatments that overcome PDGFRÎ²-driven resistance of melanoma cells to V600EB-RAF inhibition.	Cancer research	2011	64
22113612	22882	Poulikakos PI	RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E).	Nature	2011	347
22402123	22882	Hatzivassiliou G	ERK inhibition overcomes acquired resistance to MEK inhibitors.	Molecular cancer therapeutics	2012	48
23134356	22882	Callahan MK	Progression of RAS-mutant leukemia during RAF inhibitor treatment.	The New England journal of medicine	2012	57
23489023	22882	Kim KB	Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation.	Thyroid 	2013	43
24178622	22882	Jain N	Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial.	Clinical cancer research 	2014	27
24202393	22882	Lito P	Tumor adaptation and resistance to RAF inhibitors.	Nature medicine	2013	130
24265153	22882	Van Allen EM	The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.	Cancer discovery	2014	157
24265154	22882	Wagle N	MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.	Cancer discovery	2014	109
24823863	22882	Levy JM	Autophagy inhibition improves chemosensitivity in BRAF(V600E) brain tumors.	Cancer discovery	2014	31
24957944	22882	Holderfield M	Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond.	Nature reviews. Cancer	2014	110
25324352	22882	Hyman DM	Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders.	Cancer discovery	2015	27
25878360	22882	McCormick F	KRAS as a Therapeutic Target.	Clinical cancer research 	2015	29
26466569	22882	Zhang C	RAF inhibitors that evade paradoxical MAPK pathway activation.	Nature	2015	28
26566875	22882	Diamond EL	Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.	Cancer discovery	2016	21
19092150	23405	Merritt WM	Dicer, Drosha, and outcomes in patients with ovarian cancer.	The New England journal of medicine	2008	252
19219043	23405	Melo SA	A TARBP2 mutation in human cancer impairs microRNA processing and DICER1 function.	Nature genetics	2009	146
19556464	23405	Hill DA	DICER1 mutations in familial pleuropulmonary blastoma.	Science	2009	118
20194440	23405	Klusmann JH	miR-125b-2 is a potential oncomiR on human chromosome 21 in megakaryoblastic leukemia.	Genes and development	2010	77
20962848	23405	Su X	TAp63 suppresses metastasis through coordinate regulation of Dicer and miRNAs.	Nature	2010	157
21205968	23405	Rio Frio T	DICER1 mutations in familial multinodular goiter with and without ovarian Sertoli-Leydig cell tumors.	JAMA	2011	43
21266384	23405	Slade I	DICER1 syndrome: clarifying the diagnosis, clinical features and management implications of a pleiotropic tumour predisposition syndrome.	Journal of medical genetics	2011	59
21882293	23405	Foulkes WD	Extending the phenotypes associated with DICER1 mutations.	Human mutation	2011	37
23325850	23405	Castellano L	Deep sequencing of small RNAs identifies canonical and non-canonical miRNA and endogenous siRNAs in mammalian somatic tissues.	Nucleic acids research	2013	30
23620094	23405	Wu MK	Biallelic DICER1 mutations occur in Wilms tumours.	The Journal of pathology	2013	29
25190313	23405	Rakheja D	Somatic mutations in DROSHA and DICER1 impair microRNA biogenesis through distinct mechanisms in Wilms tumours.	Nature communications	2014	27
26971015	23405	Gurtner A	Dysregulation of microRNA biogenesis in cancer: the impact of mutant p53 on Drosha complex activity.	Journal of experimental and clinical cancer research 	2016	17
21909114	23451	Yoshida K	Frequent pathway mutations of splicing machinery in myelodysplasia.	Nature	2011	365
21995386	23451	Papaemmanuil E	Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts.	The New England journal of medicine	2011	234
21998214	23451	Malcovati L	Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.	Blood	2011	91
22323480	23451	Makishima H	Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis.	Blood	2012	111
22722193	23451	Ellis MJ	Whole-genome analysis informs breast cancer response to aromatase inhibition.	Nature	2012	283
22826563	23451	Visconte V	SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes.	Blood	2012	53
23086750	23451	Oscier DG	The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial.	Blood	2013	51
23160465	23451	Cazzola M	Biologic and clinical significance of somatic mutations of SF3B1 in myeloid and lymphoid neoplasms.	Blood	2013	25
23415222	23451	Landau DA	Evolution and impact of subclonal mutations in chronic lymphocytic leukemia.	Cell	2013	299
23861464	23451	Furney SJ	SF3B1 mutations are associated with alternative splicing in uveal melanoma.	Cancer discovery	2013	56
24113472	23451	Jeromin S	SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients.	Leukemia	2014	37
24652989	23451	Stilgenbauer S	Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial.	Blood	2014	49
24943832	23451	Baliakas P	Recurrent mutations refine prognosis in chronic lymphocytic leukemia.	Leukemia	2015	46
24970933	23451	Malcovati L	Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia.	Blood	2014	27
25957392	23451	Malcovati L	SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts.	Blood	2015	25
26429975	23451	Kwok B	MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance.	Blood	2015	20
26565915	23451	Darman RB	Cancer-Associated SF3B1 Hotspot Mutations Induce Cryptic 3' Splice Site Selection through Use of a Different Branch Point.	Cell reports	2015	34
26675346	23451	LjungstrÃ¶m V	Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations.	Blood	2016	12
26837699	23451	Nadeu F	Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia.	Blood	2016	15
17159987	29126	Parsa AT	Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma.	Nature medicine	2007	281
18268286	29126	Rawstron AC	Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders.	Haematologica	2008	72
25399552	29126	Robert C	Nivolumab in previously untreated melanoma without BRAF mutation.	The New England journal of medicine	2015	461
25736262	29126	Johnson DB	Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies.	Cancer immunology research	2015	21
26181000	29126	Howitt BE	Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1.	JAMA oncology	2015	35
26181250	29126	Larkin J	Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.	JAMA oncology	2015	25
27030389	29126	Georgiou K	Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas.	Blood	2016	11
27069084	29126	Roemer MG	PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome.	Journal of clinical oncology 	2016	25
27196573	29126	Masugi Y	Tumour CD274 (PD-L1) expression and T cells in colorectal cancer.	Gut	2017	8
27269947	29126	Lesokhin AM	Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study.	Journal of clinical oncology 	2016	35
19262599	54790	Tefferi A	Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates.	Leukemia	2009	55
19262601	54790	Tefferi A	TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis.	Leukemia	2009	96
19372255	54790	Jankowska AM	Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms.	Blood	2009	104
19797729	54790	Kosmider O	TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia.	Haematologica	2009	49
20644105	54790	Kohlmann A	Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1.	Journal of clinical oncology 	2010	65
20693430	54790	Smith AE	Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value.	Blood	2010	53
21343549	54790	Metzeler KH	TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.	Journal of clinical oncology 	2011	86
21494260	54790	Itzykson R	Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias.	Leukemia	2011	82
21734233	54790	Pronier E	Inhibition of TET2-mediated conversion of 5-methylcytosine to 5-hydroxymethylcytosine disturbs erythroid and granulomonocytic differentiation of human hematopoietic progenitors.	Blood	2011	47
21828143	54790	Chou WC	TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics.	Blood	2011	50
22116554	54790	Weissmann S	Landscape of TET2 mutations in acute myeloid leukemia.	Leukemia	2012	41
22430270	54790	Gaidzik VI	TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group.	Journal of clinical oncology 	2012	43
22760778	54790	Lemonnier F	Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters.	Blood	2012	55
23319568	54790	Itzykson R	Clonal architecture of chronic myelomonocytic leukemias.	Blood	2013	40
23359070	54790	Lobry C	Notch pathway activation targets AML-initiating cell homeostasis and differentiation.	The Journal of experimental medicine	2013	38
23831920	54790	Asmar F	Genome-wide profiling identifies a DNA methylation signature that associates with TET2 mutations in diffuse large B-cell lymphoma.	Haematologica	2013	27
24373966	54790	Madzo J	Hydroxymethylation at gene regulatory regions directs stem/early progenitor cell commitment during erythropoiesis.	Cell reports	2014	25
22810696	139285	Cancer Genome Atlas Network.	Comprehensive molecular characterization of human colon and rectal cancer.	Nature	2012	1543
19388938	171023	Gelsi-Boyer V	Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia.	British journal of haematology	2009	137
20068184	171023	Abdel-Wahab O	Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias.	Cancer research	2010	68
20693432	171023	Chou WC	Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutations.	Blood	2010	41
20880116	171023	Gelsi-Boyer V	ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia.	British journal of haematology	2010	46
21576631	171023	Thol F	Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes.	Journal of clinical oncology 	2011	59
22031865	171023	Metzeler KH	ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category.	Blood	2011	61
22343920	171023	Damm F	Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes.	Blood	2012	47
22489043	171023	Brecqueville M	Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms.	Genes, chromosomes and cancer	2012	39
22897849	171023	Abdel-Wahab O	ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression.	Cancer cell	2012	95
22898539	171023	Shih AH	The role of mutations in epigenetic regulators in myeloid malignancies.	Nature reviews. Cancer	2012	186
22915647	171023	Grossmann V	A novel hierarchical prognostic model of AML solely based on molecular mutations.	Blood	2012	37
23018865	171023	Schnittger S	ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome.	Leukemia	2013	38
23640996	171023	Abdel-Wahab O	Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia.	Blood	2013	42
23690417	171023	Itzykson R	Prognostic score including gene mutations in chronic myelomonocytic leukemia.	Journal of clinical oncology 	2013	70
23958953	171023	Schwaab J	Comprehensive mutational profiling in advanced systemic mastocytosis.	Blood	2013	28
24045501	171023	Traina F	Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms.	Leukemia	2014	46
24077845	171023	West RR	Acquired ASXL1 mutations are common in patients with inherited GATA2 mutations and correlate with myeloid transformation.	Haematologica	2014	21
24695057	171023	Patnaik MM	ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients.	Leukemia	2014	25
25139356	171023	Kulasekararaj AG	Somatic mutations identify a subgroup of aplastic anemia patients who progress to myelodysplastic syndrome.	Blood	2014	24
25224413	171023	Bejar R	TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients.	Blood	2014	56
25326804	171023	Xie M	Age-related mutations associated with clonal hematopoietic expansion and malignancies.	Nature medicine	2014	168
25426837	171023	Jaiswal S	Age-related clonal hematopoiesis associated with adverse outcomes.	The New England journal of medicine	2014	222
25426838	171023	Genovese G	Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence.	The New England journal of medicine	2014	202
25574665	171023	Gerstung M	Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes.	Nature communications	2015	21
26132940	171023	Yoshizato T	Somatic Mutations and Clonal Hematopoiesis in Aplastic Anemia.	The New England journal of medicine	2015	30
26182311	171023	Tefferi A	Myeloproliferative Neoplasms: A Contemporary Review.	JAMA oncology	2015	21
26332545	171023	Tefferi A	A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis.	The New England journal of medicine	2015	26
15852235	201163	Schmidt LS	Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-DubÃ© syndrome.	American journal of human genetics	2005	80
19959076	201163	Menko FH	Birt-Hogg-DubÃ© syndrome: diagnosis and management.	The Lancet. Oncology	2009	67
22977732	201163	Nookala RK	Crystal structure of folliculin reveals a hidDENN function in genetically inherited renal cancer.	Open biology	2012	31
24763318	201163	Possik E	Folliculin regulates ampk-dependent autophagy and metabolic stress survival.	PLoS genetics	2014	21
